International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 83

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–1117) and Recommended (1–78) International Nonproprietary Names can be found in *Cumulative List No. 17, 2017* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 83

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la *Liste récapitulative No. 17, 2017* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 83

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en *Cumulative List No. 17, 2017* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

acidum arlipoicum

arlipoic acid — 5-[(3*R*)-1,2-dithiolan-3-yl]pentanoic acid

acide arlipoïque — acide 5-[(3*R*)-1,2-dithiolan-3-yl]pentanoïque

ácido arlipóico — ácido 5-[(3*R*)-1,2-ditiolan-3-il]pentanoico

$C_8H_{14}O_2S_2$



actinium (^{225}Ac) lintuzumabum satetraxetanum #

actinium (^{225}Ac) lintuzumab satetraxetan

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], humanized monoclonal antibody, conjugated to satetraxetan (DOTA derivative) and radiolabelled with actinium-225 (^{225}Ac);
gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (213) (117-214), hinge 1-15 (215-229), CH2 (230-339), CH3 D12 (355), L14 (357) (340-444), CHS (445-446)) (117-446)], (219-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.8%) -IGKJ1*01 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (225-225":228-228")-bisdisulfide, produced in SP2/0-Ag14 murine myeloma cell line, glycoform alfa; actinium-225 (^{225}Ac) radiolabelled satetraxetan (DOTA derivative) conjugate, on an average of 1 or 2 lysyl
For the *satetraxetan* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups & others*"*

actinium (^{225}Ac) lintuzumab satétraxétan

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD33 (lectine 3 de type Ig-like liant l'acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal humanisé, conjugué au satétraxétan (dérivé DOTA) et radiomarqué à l'actinium-225 (^{225}Ac);

chaîne lourde gamma1 humanisée (1-446) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (213) (117-214), charnière 1-15 (215-229), CH2 (230-339), CH3 D12 (355), L14 (357) (340-444), CHS (445-446)) (117-446)], (219-218')-disulfure avec la chaîne légère kappa humanisée (1'-218') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.8%) -IGKJ1*01 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (225-225":228-228")-bisdisulfure, produite dans la lignée cellulaire de myélome murin SP2/0-Ag14, glycoforme alfa; conjugué au satétraxétan (dérivé DOTA), sur 1 à 2 lysyl en moyenne, et radiomarqué à l'actinium-225 (^{225}Ac)

Pour la partie *satétraxétan*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups & others*"*.

actinio (^{225}Ac) lintuzumab satetraxetán

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD33 (lectina 3 de tipo Ig-like que se une al ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal humanizado, conjugado con satetraxetán (derivado DOTA) y radiomarcado con actinio-225 (^{225}Ac);

cadena pesada gamma1 humanizada (1-446) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (213) (117-214), bisagra 1-15 (215-229), CH2 (230-339), CH3 D12 (355), L14 (357) (340-444), CHS (445-446)) (117-446)], (219-218')-disulfuro con la cadena ligera kappa humanizada (1'-218') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.8%) -IGKJ1*01 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (225-225":228-228")-bisdisulfuro, producido en la línea celular de mieloma murino SP2/0-Ag14, glicoforma alfa; conjugado con satetraxetán (derivado DOTA), en 1 o 2 restos lisil por término medio, y radiomarcado con actinium-225 (^{225}Ac)

Para la fracción *satetraxetán*, se puede referir al documento "*INN for pharmaceutical substances: Names for radicals, groups & others*"*.

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DYNMHWVRQA PGQGLEWIGY  50
IYPYNGGTGY NQKFKSKATI TADESTNTAY MELSSLRSED TAVYYCARGR 100
PAMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASESVD NYGISFMNWF QQKPGKAPKL  50
LIYAASNQGS GVPSRFSGSG SGTDFTLTIS SLQPDDFATY YCQQSKEVPW 100
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 260-320 366-424
22"-96" 143"-199" 260"-320" 366"-424"

Intra-L (C23-C104) 23'-92' 138'-198'
23'"-92'" 138'"-198'"

Inter-H-L (h 5-CL 126) 219-218' 219"-218'"

Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
296, 296"

Fucosylated complex bi-antennary SP2/0-Ag14-type glycans / glycanes de type SP2/0-Ag14 bi-antennaires complexes fucosylés / glicanos de tipo SP2/0-Ag14 biantenarios complejos fucosilados

C-terminal lysine clipping:

H CHS K2:
446, 446"

Modified residues / Résidus modifiés / Restos modificados

K
An average of 1 to 2 are *N*-substituted by R
Environ 1 à 2 sont *N*-substitués par R
Una media de 1 a 2 están *N*-sustituidos por R



amivantamabum #

amivantamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)] and anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], *Homo sapiens* monoclonal antibody, bispecific; gamma1 heavy chain *Homo sapiens* anti-EGFR (1-455) [VH (*Homo sapiens* IGHV3-33*01 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.18] (1-125) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (222) (126-223), hinge 1-15 (224-238), CH2 (239-348), CH3 E12 (364), M14 (366), F85.1>L (413) (349-453), CHS (454-455)) (126-455)], (228-214')-disulfide with kappa light chain *Homo sapiens* anti-EGFR (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-13*02 (96.8%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-213')]; gamma1 heavy chain *Homo sapiens* anti-MET (1''-449'') [VH (*Homo sapiens* IGHV1-18*01 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1''-119'') -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360), K88>R (411) (343-447), CHS (448-449)) (119''-449'')], (222''-214''')-disulfide with kappa light chain *Homo sapiens* anti-MET (1'''-214''') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (95.8%) -IGKJ5*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimer (234-228'':237-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
amivantamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)] et anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal *Homo sapiens* bispécifique; chaîne lourde gamma1 *Homo sapiens* anti-EGFR (1-455) [VH (*Homo sapiens* IGHV3-33*01 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.18] (1-125) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (222) (126-223), charnière 1-15 (224-238), CH2 (239-348), CH3 E12 (364), M14 (366), F85.1>L (413) (349-453), CHS (454-455)) (126-455)], (228-214')-disulfure avec la chaîne légère kappa *Homo sapiens* anti-EGFR (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-13*02 (96.8%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-213')]; chaîne lourde gamma1 *Homo sapiens* anti-MET (1''-449'') [VH (*Homo sapiens* IGHV1-18*01 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1''-119'') -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360), K88>R (411) (343-447), CHS (448-449)) (119''-449'')], (222''-214''')-disulfure avec la chaîne légère kappa *Homo sapiens* anti-MET(1'''-214''') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (95.8%) -IGKJ5*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimère (234-228'':237-231'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

amivantamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)] y anti-[*Homo sapiens* MET (proto-oncogén met, receptor del factor de crecimiento hepatocitario, HGFR, receptor del factor de dispersión, receptor de l'HGF/SF, receptor proteína-tirosina kinasa c-Met, carcinoma papilar de células renales 2, RCCP2)], anticuerpo monoclonal *Homo sapiens* biespecífico;
cadena pesada gamma1 *Homo sapiens* anti-EGFR (1-455) [VH (*Homo sapiens* IGHV3-33*01 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.18] (1-125) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (222) (126-223), bisagra 1-15 (224-238), CH2 (239-348), CH3 E12 (364), M14 (366), F85.1>L (413) (349-453), CHS (454-455)) (126-455)], (228-214')-disulfuro con la cadena ligera kappa *Homo sapiens* anti-EGFR (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-13*02 (96.8%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-213')];
cadena pesada gamma1 *Homo sapiens* anti-MET (1''-449'') [VH (*Homo sapiens* IGHV1-18*01 (95.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1''-119'') -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360), K88>R (411) (343-447), CHS (448-449)) (119''-449'')], (222''-214''')-disulfuro con la cadena ligera kappa *Homo sapiens* anti-MET(1'''-214''') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (95.8%) -IGKJ5*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'''-214''')];
dímero (234-228'':237-231'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada (anti-EGFR)

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS TYGMHWVRQA PGKGLEWVAV  50
IWDDGSYKYY GDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDG 100
ITMVRGVMKD YFDYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL 250
FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR 300
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ 350
PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400
TTPPVLDSDG SFLLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS 450
LSPGK                                                   455
```

Light chain / Chaîne légère / Cadena ligera (anti-EGFR)

```
AIQLTQSPSS LSASVGDRVT ITCRASQDIS SALVWYQQKP GKAPKLLIYD  50
ASSLESGVPS RFSGSESGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-MET)

```
QVQLVQSGAE VKKPGASVKV SCETSGYTFT SYGISWVRQA PGHGLEWMGW  50
ISAYNGYTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL 100
RGTNYFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera (anti-MET)

```
DIQMTQSPSS VSASVGDRVT ITCRASQGIS NWLAWFQHKP GKAPKLLIYA  50
ASSLLSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPITFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 152-208 269-329 375-433
22''-96'' 146''-202'' 263''-323'' 369''-427''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 228-214' 222''-214'''
Inter-H-H (h 11, h 14) 234-228'' 237-231''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 299''
Low fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes faiblement fucosylés / glicanos de tipo CHO biantenarios complejos bajos fucosilados.

anetumabum corixetanum #

anetumab corixetan

immunoglobulin G1-lambda2, anti-[*Homo sapiens* MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte-potentiating factor, MPF, CAK1)], *Homo sapiens* monoclonal antibody, conjugated to chelator corixetan;
gamma1 heavy chain *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV5-51*01 (94.9%) -(IGHD) -IGHJ4*01 (86.7%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359) L14 (361) (344-448), CHS (449-450)) (121-450)], (223-216')-disulfide with lambda light chain *Homo sapiens* (1'-217') [V-LAMBDA (*Homo sapiens* IGLV2-14*01 (95.6%) -IGKJ2*01 (100%)) [9.3.11] (1'-111') -*Homo sapiens* IGLC2*01 (99.1%) A43>G (155) (112'-217')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-S cell line, glycoform alfa; conjugated to chelator corixetan, with an average of 0.5 chelator per antibody

anétumab corixétan

immunoglobuline G1-lambda2, anti-[*Homo sapiens* MSLN (mésothéline, facteur de potentialisation du pré-pro-mégacaryocyte, facteur de potentialisation des mégacaryocytes, MPF, CAK1)], anticorps monoclonal *Homo sapiens*, conjugué au chélateur corixétan;
chaîne lourde gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV5-51*01 (94.9%) -(IGHD) -IGHJ4*01 (86.7%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-216')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-217') [V-LAMBDA (*Homo sapiens* IGLV2-14*01 (95.6%) -IGKJ2*01 (100%)) [9.3.11] (1'-111') -*Homo sapiens* IGLC2*01 (99.1%) A43>G (155) (112'-217')]; dimère (229-229'':232-232'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire CHO-S, glycoforme alfa; conjugué au chélateur corixétan, avec une moyenne de 0.5 chélateur par anticorps

anetumab corixetán

inmunoglobulina G1-lambda2, anti-[*Homo sapiens* MSLN (mesotelina, factor potenciador de pre-pro-megacariocito, factor potenciador de los megacariocitos, MPF, CAK1)], anticuerpo monoclonal *Homo sapiens*, conjugado con el quelante corixetán;
cadena pesada gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV5-51*01 (94.9%) -(IGHD) -IGHJ4*01 (86.7%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-216')-disulfuro con lacadena ligera lambda *Homo sapiens* (1'-217') [V-LAMBDA (*Homo sapiens* IGLV2-14*01 (95.6%) -IGKJ2*01 (100%)) [9.3.11] (1'-111') -*Homo sapiens* IGLC2*01 (99.1%) A43>G (155) (112'-217')]; dímero (229-229'':232-232'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular CHO-S, glicoforma alfa; conjugado con el quelante corixetán, con una media de 0.5 quelantes por anticuerpo

Heavy chain / Chaîne lourde / Cadena pesada

```
QVELVQSGAE VKKPGESLKI SCKGSGYSFT SYWIGWVRQA PGKGLEWMGI  50
IDPGDSRTRY SPSFQGQVTI SADKSISTAY LQWSSLKASD TAMYYCARGQ 100
LYGGTYMDGW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIALTQPASV SGSPGQSITI SCTGTSSDIG GYNSVSWYQQ HPGKAPKLMI  50
YGVNNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYDIESATP 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKGDSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 22'-90' 139'-198'
22'"-90'" 139'"-198'"

Inter-H-L (h 5-CL 126) 223-216' 223"-216'"

Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales



arpraziquantelum

arpraziquantel — (11b*R*)-2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4*H*-pyrazino[2,1-*a*]isoquinolin-4-one

arpraziquantel — (11b*R*)-2-(cyclohexanecarbonyl)-1,2,3,6,7,11*b*-hexahydro-4*H*-pyrazino[2,1-*a*]isoquinoléin-4-one

arprazicuantel — (11b*R*)-2-(ciclohexanocarbonil)-1,2,3,6,7,11b-hexahidro-4*H*-pirazino[2,1-*a*]isoquinolein-4-ona



astegolimabum #

astegolimab — immunoglobulin G2-kappa, anti-[*Homo sapiens* IL1RL1 (interleukin 1 receptor like 1, DER4, FIT-1, growth stimulation expressed 2 gene, ST2, IL33R)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV5-51*01 (95.9%) -(IGHD) -IGHJ6*01(94.1%)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (100%) (CH1 (122-219), hinge 1-12 (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (223-214')-disulfide with kappa light chain

Homo sapiens (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (97.9%) - IGKJ4*01 (100.0%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (223-223":224-224":227-227":230-230")-tetrakisdisulfide, produced in Chinese Hamster Ovary (CHO) cells, glycoform alfa

astégolimab — immunoglobuline G2-kappa, anti-[*Homo sapiens* IL1RL1 (récepteur like 1 de l'interleukine 1, DER4, FIT-1, gène 2 exprimé lors de la stimulation de la croissance, ST2, IL33R)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma2 *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV5-51*01 (95.9%) -(IGHD) -IGHJ6*01(94.1%)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (100%) (CH1 (122-219), charnière 1-12 (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (223-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (97.9%) -IGKJ4*01 (100.0%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (223-223":224-224":227-227":230-230")-tétrakisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

astegolimab — inmunoglobulina G2-kappa, anti-[*Homo sapiens* IL1RL1 (receptor like 1 de la interleukina 1, DER4, FIT-1, gen 2 expresado en la estimulación del crecimiento, ST2, IL33R)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma2 *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV5-51*01 (95.9%) -(IGHD) -IGHJ6*01(94.1%)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (100%) (CH1 (122-219), bisagra 1-12 (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (223-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (97.9%) -IGKJ4*01 (100.0%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (223-223":224-224":227-227":230-230")-tetrakisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCKGSGYSFT NYWIGWVRQM PGKGLEWMGI  50
IYPGNSDTRF SPSFQGQVTI SADKSITTAY LQWSSLKASD TAMYYCARHG 100
TSSDYYGLDV WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD  50
ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ DDNFPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	261-321	367-425
	22"-96"	148"-204"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)*	135-214'	135"-214'"		
Inter-H-H (h4, h5, h8, h11)*	223-223"	224-224"	227-227"	230-230"

*In addition to the isoform A, isoform A/B characterized by an inter-H-H (h 4 - CH1 10) 223-135" and an inter-H-L (h 4- CL 126) 223"-214'", instead of the inter-H-H (h 4 - h 4) 223-223" and of one of the two inter-H-L (CH1 10-CL 126) 135"-214'"; isoform B characterized by an inter-H-H (h 5 - CH1 10) 224-135 and an inter-H-L (h 5- CL 126) 224"-214', instead of the inter-H-H (h 5 - h 5) 224-224" and of the inter-H-L (CH1 10-CL 126) 135-214'.
*En plus de l'isoforme A, isoforme A/B caractérisée par un inter-H-H (h 4 - CH1 10) 223-135" et un inter-H-L (h 4- CL 126) 223"-214'", au lieu de l'inter-H-H (h 4 - h 4) 223-223" et de l'un des deux inter-H-L (CH1 10-CL 126) 135"-214'"; isoforme B caractérisée par un inter-H-H (h 5 - CH1 10) 224-135 et un inter-H-L (h 5- CL 126) 224"-214', au lieu de l'inter-H-H (h 5 - h 5) 224-224" et de l'inter-H-L (CH1 10-CL 126) 135-214'.
*Además de la isoforma A, isoforma A/B caracterizado por un inter-H-H (h4 - CH1 10) 223-135" y un inter-H-L (h4- CL 126) 223"-214'", en lugar del inter-H-H (h 4 - h 4) 223-223" y uno de los dos inter-H-L (CH1 10-CL 126) 135"-214'"; isoforma B caracterizado por un inter-H-H (h 5 - CH1 10) 224-135 y un inter-H-L (h 5- CL 126) 224"-214', en lugar del inter-H-H (h 5 - h 5) 224-224" y del inter-H-L (CH1 10-CL 126) 135-214'.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

atleradstrocelum

atleradstrocel	human culture expanded autologous adipose stromal progenitor cells (ASC) for cell-based therapy. The cells express CD73 and CD90 cell surface markers and are negative for CD31, CD34 and CD45 markers.
atléradstrocel	cellules progénitrices stromales issues du tissu adipeux (ASC), humaines, autologues, en culture d'expansion pour thérapie cellulaire. Les cellules expriment les marqueurs de surface CD73 et CD90 et sont négatives pour les marqueurs de surface CD31, CD34 and CD45.
atleradstrocel	Células progenitoras estromales de tejido adiposo, autólogas, humanas, expandidas en cultivo para terapia celular. Las células expresan los marcadores de superficie CD73 y CD90 y son negativas para los marcadores CD31, CD34 y CD45.

avalotcagenum ontaparvovecum #

avalotcagene ontaparvovec	A recombinant non-replicating adeno-associated virus type 2/8 (rAAV Rep2-Cap8) vector, encoding codon-optimized, wild-type human ornithine transcarbamylase (OTC) under the control of a hybrid human thyroxine-binding globulin (TBG) / human alpha 1-microglobulin/bikunin precursor (AMBP) promoter/enhancer. The vector genome is a head-to-head dimer, with the vector genome cassette located 5' of the mutated internal inverted terminal repeat (ITR) in a reverse orientation and the vector genome cassette located 3' of the mutated internal ITR in a forward orientation.
avalotcagène ontaparvovec	vecteur viral adéno-associé de type 2/8 recombinant non-répliquant (rAAV Rep2-Cap8), codant pour l'ornithine transcarbamylase humaine sauvage (OTC) avec des codons optimisés, sous le contrôle de l'activateur/promoteur hybride de la globuline liant la thyroxine (TBP) humaine /précurseur de microglobuline alpha 1 / bikunine (AMBP). Le génome du vecteur est un dimère en tête à tête avec la cassette contenant le génome du vecteur en position 5´ de la séquence inverse terminale répétée (ITR) interne et mutée dont l'orientation est inverse et la cassette contenant le vecteur du génome en position 3´ de l'ITR interne et mutée dont l'orientation est vers l'avant.
avalotcagén ontaparvovec	Un vector de virus adenoasociado recombinante no replicativo del serotipo 2/8 (rAAV Rep2-Cap8), que codifica para la ornitina transcarbamilasa silvestre humana (OTC) con codones optimizados, bajo el control de un promotor/potenciador híbrido de la globulina fijadora de tiroxina humana (TBG) / precursor de microglobulina alfa 1 humana/bicunina (AMBP). El genoma del vector es un dímero de cabeza con cabeza, con el casete del genoma del vector en posición 5' a la repetición terminal invertida (ITR) interna y mutada localizado en orientación inversa. y el casete del genoma del vector en posición 3' a la ITR localizado en orientación hacia adelante.

avdoralimabum #

avdoralimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* C5AR1 (complement C5a receptor 1, complement C5 anaphylatoxin (C5a, C5 Pr678-751) receptor 1, CD88)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-454) [VH (*Homo sapiens* IGHV3-13*01 (93.8%) -(IGHD) - IGHJ3*02 (100%)) [8.7.18] (1-124) -*Homo sapiens* IGHG1*03 G1m3>G1m17,nG1m1 (CH1 K120 (221) (125-222), hinge 1-15 (223-237), CH2 L1.3>A (241), L1.2>E (242), G1>A (244), A115>S (337), P116>S (338) (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (98.9%) -IGKJ2*01 (100%)) [7.3.8] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-K1SVcell line, glycoform alfa
avdoralimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* C5AR1 (récepteur 1 du complément C5a, récepteur 1 de l'anaphylatoxine du complément C5 (C5a, C5 Pr678-751), CD88)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-454) [VH (*Homo sapiens* IGHV3-13*01 (93.8%) -(IGHD) - IGHJ3*02 (100%)) [8.7.18] (1-124) -*Homo sapiens* IGHG1*03 G1m3>G1m17,nG1m1 (CH1 K120 (221) (125-222), charnière 1-15 (223-237), CH2 L1.3>A (241), L1.2>E (242), G1>A (244), A115>S (337), P116>S (338) (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (98.9%) -IGKJ2*01 (100%)) [7.3.8] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (233-233'':236-236'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire K1SV, glycoforme alfa
avdoralimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* C5AR1 (receptor 1 del complemento C5a, receptor 1 de la anafilatoxina del complemento C5 (C5a, C5 Pr678-751), CD88)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 *Homo sapiens* (1-454) [VH (*Homo sapiens* IGHV3-13*01 (93.8%) -(IGHD) - IGHJ3*02 (100%)) [8.7.18] (1-124) -*Homo sapiens* IGHG1*03 G1m3>G1m17,nG1m1 (CH1 K120 (221) (125-222), bisagra 1-15 (223-237), CH2 L1.3>A (241), L1.2>E (242), G1>A (244), A115>S (337), P116>S (338) (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (98.9%) -IGKJ2*01 (100%)) [7.3.8] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (233-233'':236-236'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular K1SV, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYVMHWVRQA TGKGLEWVSA  50
IDTGGGTYYA DSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARDYY 100
YYASGSYYKA FDIWGQGTMV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE AEGAPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPSSIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SRYLAWYQQK PGQAPRLLIY  50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-95 151-207 268-328 374-432
22"-95" 151"-207" 268"-328" 374"-432"
Intra-L (C23-C104) 23'-89' 134'-194'
23'"-89'" 134'"-194'"
Inter-H-L (h 5-CL 126) 227-214' 227"-214'"
Inter-H-H (h 11, h 14) 233-233" 236-236"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

avizakimabum #

avizakimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL21 (interleukin 21)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-46*01 (88.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (213) (117-214), hinge 1-15 (215-229), CH2 M15.1>Y (251), S16>T (253), T18>E (255) (IGHG1v21) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-NL1*01 (86.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (225-225":228-228")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

avizakimab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL21 (interleukine 21)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH (*Homo sapiens* IGHV1-46*01 (88.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (213) (117-214), charnière 1-15 (215-229), CH2 M15.1>Y (251), S16>T (253), T18>E (255) (IGHG1v21) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-NL1*01 (86.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (225-225":228-228")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

avizakimab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL21 (interleukina 21)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH (*Homo sapiens* IGHV1-46*01 (88.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (213) (117-214), bisagra 1-15 (215-229), CH2 M15.1>Y (251), S16>T (253), T18>E (255) (IGHG1v21) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-NL1*01 (86.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (225-225":228-228")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYWMHWVRQA PGQGLEWMGT  50
IDPSDQYTIY SQNFKGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYG 100
FAMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
YITREPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVT ITCRASQDIS NFLNWYQQKP GKAVKLLIYY  50
TSRLHSGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCQQ GHTLPRTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 143-199 260-320 366-424
22"-96" 143"-199" 260"-320" 366"-424"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 219-214' 219"-214'"
Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

axatilimabum #
axatilimab

immunoglobulin G4-kappa, anti-[*Homo sapiens* CSF1R (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R, macrophage colony-stimulating factor 1 receptor, c-fms, FMS, CD115)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-453) [VH (*Homo sapiens* IGHV2-70*11 (89.9%) -(IGHD) -IGHJ3*01 (92.9%)) [10.7.18] (1-126) -*Homo sapiens* IGHG4*01 (CH1 (127-224), hinge S10>P (234)(225-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (127-443)], (140-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (87.2%) -IGKJ4*01 (100.0%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (232-232":235-235")-bisdisulfide, produced in Chinese Hamster Ovary (CHO) DG44 cell line, glycoform alfa

axatilimab

immunoglobuline G4-kappa, anti-[*Homo sapiens* CSF1R (récepteur du facteur 1 stimulant de colonies, CSF-1R, CSF-1-R, récepteur du facteur 1 stimulant des colonies de macrophages, c-fms, FMS, CD115)], anticorps monoclonal humanisé;
chaîne lourde gamma4 humanisée (1-453) [VH (Homo sapiens IGHV2-70*11 (89.9%) -(IGHD) -IGHJ3*01 (92.9%)) [10.7.18] (1-126) -*Homo sapiens* IGHG4*01 (CH1 (127-224), charnière S10>P (234)(225-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (127-443)], (140-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (87.2%) -IGKJ4*01 (100.0%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (232-232":235-235")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire DG44, glycoforme alfa

axatilimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* CSF1R (receptor del factor 1 estimulante de colonias, CSF-1R, CSF-1-R, receptor del factor 1 estimulante de las colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 humanizada (1-453) [VH (Homo sapiens IGHV2-70*11 (89.9%) -(IGHD) -IGHJ3*01 (92.9%)) [10.7.18] (1-126) -*Homo sapiens* IGHG4*01 (CH1 (127-224), bisagra S10>P (234)(225-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (127-443)], (140-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (87.2%) -IGKJ4*01 (100.0%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (232-232":235-235")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular DG44, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVTLKESGPA LVKPTQTLTL TCTFSGFSLT TYGMGVGWIR QPPGKALEWL  50
ANIWWDDDKY YNPSLKNRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100
GPIKYPTAPY RYFDFWGQGT MVTVSSASTK GPSVFPLAPC SRSTSESTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTKTYTCN VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE 300
QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR 350
EPQVYTLPPS QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS 450
LGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCLASEDIY DNLAWYQQKP GKAPKLLIYY  50
ASSLQDGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCLQ DSEYPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 153-209 267-327 373-431
22"-97" 153"-209" 267"-327" 373"-431"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (CH1 10-CL 126) 140-214' 140"-214'"
Inter-H-H (h 8, h 11) 232-232" 235-235"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
303, 303"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
453, 453"

bamocaftorum

bamocaftor — (1^4S)-*N*-(benzenesulfonyl)-1^2,1^2,1^4-trimethyl-7^1-(trifluoromethyl)-4-oxa-2(2,6)-pyridina-3(1,3)-pyrazola-1(1)-pyrrolidina-7(1)-cyclopropanaheptaphane-2^3-carboxamide

bamocaftor — (1^4S)-*N*-(benzènesulfonyl)-1^2,1^2,1^4-triméthyl-7^1-(trifluorométhyl)-4-oxa-2(2,6)-pyridina-3(1,3)-pyrazola-1(1)-pyrrolidina-7(1)-cyclopropanaheptaphane-2^3-carboxamide

bamocaftor — (1^4S)-*N*-(bencenosulfonil)-1^2,1^2,1^4-trimetil-7^1-(trifluorometil)-4-oxa-2(2,6)-piridina-3(1,3)-pirazola-1(1)-pirrolidina-7(1)-ciclopropanaheptafano-2^3-carboxamida

$C_{28}H_{32}F_3N_5O_4S$



batoclimabum #

batoclimab — immunoglobulin G1-lambda, anti-[*Homo sapiens* FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV4-39*02 (91.9%) -(IGHD) -IGHJ4*01 (86.7%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 L1.3>A (238), L1.2>A (239) (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-213')-disulfide with lambda light chain *Homo sapiens* (1'-214') [V-LAMBDA (*Homo sapiens* IGLV3-21*02 (97.9%) -IGLJ2*01 (100%)) [6.3.11] (1'-108') -*Homo sapiens* IGLC2*01 (100%) (109'-214')]; dimer (230-230":233-233")-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-S cell line, glycoform alfa

batoclimab — immunoglobuline G1-lambda, anti-[*Homo sapiens* FCGRT (transporteur et récepteur du fragment Fc des IgG, récepteur Fc néonatal, FcRn, chaîne alpha transmembranaire du récepteur néonatal)], anticorps monoclonal *Homo sapiens*;
chaîne lourde gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV4-39*02 (91.9%) -(IGHD) - IGHJ4*01 (86.7%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03 G1m3,nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220-234), CH2 L1.3>A (238), L1.2>A (239) (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-213')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-214') [V-LAMBDA (*Homo sapiens* IGLV3-21*02 (97.9%) -IGLJ2*01 (100%)) [6.3.11] (1'-108') -*Homo sapiens* IGLC2*01 (100%) (109'-214')]; dimère (230-230":233-233")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire CHO-S, glycoforme alfa

batoclimab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* FCGRT (transportador y receptor del fragmento Fc de las IgG, receptor Fc neonatal, FcRn, cadena alfa transmembranaria del receptor neonatal)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV4-39*02 (91.9%) -(IGHD) - IGHJ4*01 (86.7%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03 G1m3,nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2 L1.3>A (238), L1.2>A (239) (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-213')-disulfuro con la cadena ligera lambda *Homo sapiens* (1'-214') [V-LAMBDA (*Homo sapiens* IGLV3-21*02 (97.9%) -IGLJ2*01 (100%)) [6.3.11] (1'-108') -*Homo sapiens* IGLC2*01 (100%) (109'-214')]; dímero (230-230":233-233")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular CHO-S, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QLLLQESGPG LVKPSETLSL TCTVSGGSLS SSFSYWVWIR QPPGKGLEWI  50
GTIYYSGNTY YNPSLKSRLT ISVDTSKNHF SLKLSSVTAA DTAVYYCARR 100
AGILTGYLDS WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPEAAG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
```

Light chain / Chaîne légère / Cadena ligera

```
SYVLTQSPSV SVAPGQTARI TCGGNNIGSK SVHWYQQKPG QAPVLVVYDD  50
SDRPSGIPER FSASNSGNTA TLTISRVEAG DEADYYCQVW DSSSDHVVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 148-204 265-325 371-429
22"-97" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 22'-87' 136'-195'
22'"-87'" 136'"-195'"
Inter-H-L (h 5-CL 126) 224-213' 224"-213"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

befovacimabum #

befovacimab

immunoglobulin G2-lambda, anti-[*Homo sapiens* TFPI (tissue factor pathway inhibitor, lipoprotein-associated coagulation inhibitor)], monoclonal antibody;
gamma2 heavy chain *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV3-23*04 (93.9%) -(IGHD) -IGHJ4*01(93.3%)) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 (CH1 (118-215), hinge 1-12 (216-227), CH2 (228-336), CH3 (337-441), CHS K2>del (442)) (118-442)], (131-211')-disulfide with lambda light chain humanized (1'-212') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (86.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-106') -*Homo sapiens* IGLC2*01 (100%) (107'-212')]; dimer (131-219":220-220":223-223":226-226")-tetrakisdisulfide, produced in Chinese hamster ovary (CHO)-K1SV cell line, glycoform alfa

béfovacimab

immunoglobuline G2-lambda, anti-[*Homo sapiens* TFPI (inhibiteur de la voie du facteur tissulaire, inhibiteur de la coagulation associée aux lipoprotéines)], anticorps monoclonal;

chaîne lourde gamma2 *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV3-23*04 (93.9%) -(IGHD) - IGHJ4*01(93.3%)) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 (CH1 (118-215), charnière 1-12 (216-227), CH2 (228-336), CH3 (337-441), CHS K2>del (442)) (118-442)], (131-211')-disulfure avec la chaîne légère lambda humanisée (1'-212') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (86.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-106') -*Homo sapiens* IGLC2*01 (100%) (107'-212')]; dimère (131-219":220-220":223-223":226-226")-tétrakisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire K1SV, glycoforme alfa

befovacimab

inmunoglobulina G2-lambda, anti-[*Homo sapiens* TFPI (inhibidor de la vía del factor tisular, inhibidor de la coagulación asociada con las lipoproteínas)], anticuerpo humanizado;
cadena pesada gamma2 *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV3-23*04 (93.9%) -(IGHD) - IGHJ4*01(93.3%)) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 (CH1 (118-215), bisagra 1-12 (216-227), CH2 (228-336), CH3 (337-441), CHS K2>del (442)) (118-442)], (131-211')-disulfuro con la cadena ligera lambda humanizada (1'-212') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (86.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-106') -*Homo sapiens* IGLC2*01 (100%) (107'-212')]; dímero (131-219":220-220":223-223":226-226")-tetrakisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular K1SV, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYGMDWVRQA PGKGLEWVSS  50
IRGSRGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARLY 100
RYWFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SNFGTQTYTC 200
NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTFRVVS 300
VLTVVHQDWL NGKEYKCKVS NKGLPAPIEK TISKTKGQPR EPQVYTLPPS 350
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPMLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PG          442
```

Light chain / Chaîne légère / Cadena ligera

```
SYELTQPPSV SVSPGQTARI TCSGDNLPKY YAHWYQQKPG QAPVVVIFYD  50
VNRPSGIPER FSGSNSGNTA TLTISGTQAM DEADYYCQAW WSSTPVFGGG 100
TKLTVLGQPK AAPSVTLFPP SSEELQANKA TLVCLISDFY PGAVTVAWKA 150
DSSPVKAGVE TTTPSKQSNN KYAASSYLSL TPEQWKSHRS YSCQVTHEGS 200
TVEKTVAPTE CS                                          212
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 144-200 257-317 363-421
22"-96" 144"-200" 257"-317" 363'-421"
Intra-L (C23-C104) 22'-87' 134'-193'
22'"-87'" 134'"-193'"
Inter-H-L (CH1 10-CL 126) 131-211' 131"-211'"
Inter-H-H (h 4, h 5, h 8, h 11) 219-219" 220-220" 223-223" 226-226"

*In addition to the isoform A, isoform A/B characterized by an inter-H-H (h 4 - CH1 10) 219-131" and an inter-H-L (h 4- CL 126) 219"-211'", instead of the inter-H-H (h 4 - h 4) 219-219" and of one of the two inter-H-L (CH1 10-CL 126) 131"-211'";
*En plus de l'isoforme A, isoforme A/B caractérisée par un inter-H-H (h 4 - CH1 10) 219-131" et un inter-H-L (h 4- CL 126) 219"-211'", au lieu de l'inter-H-H (h 4 - h 4) 219-219" et de l'un des deux inter-H-L (CH1 10-CL 126) 131"-211'";
*Además de la isoforma A, isoforma A/B caracterizado por un inter-H-H (h4 - CH1 10) 219-131" y un inter-H-L (h 4- CL 126) 219"-211'", en lugar del inter-H-H (h 4 - h 4) 219-219" y uno de los dos inter-H-L (CH1 10-CL 126) 131"-211'";

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
293, 293"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

benufutamabum #

benufutamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, TR-2, CD262)], monoclonal antibody; gamma1 heavy chain chimeric (1-447) [VH (*Mus musculus* IGHV14-3*02 G63>T (56) (87.8%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens*IGHV1-3*01 G63>T (56) (71.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03,G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), E109>G (431) (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (89.5%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-DG44 cell line, glycoform alfa
bénufutamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF10B (membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale, récepteur de mort 5, DR5, récepteur 2 de TRAIL, TRAIL-R2, TR-2, CD262)], anticorps monoclonal; chaîne lourde gamma1 chimérique (1-447) [VH (*Mus musculus* IGHV14-3*02 G63>T (56) (87.8%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens*IGHV1-3*01 G63>T (56) (71.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) E109>G (431) (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (89.5%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire DG44, glycoforme alfa
benufutamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF10B (miembro 10B de la superfamilia de los receptores del factor de necrosis tumoral, receptor de muerte 5, DR5, receptor 2 de TRAIL, TRAIL-R2, TR-2, CD262)], anticuerpo monoclonal; cadena pesada gamma1 quimérica (1-447) [VH (*Mus musculus* IGHV14-3*02 G63>T (56) (87.8%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens* IGHV1-3*01 G63>T (56) (71.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (215) (119-216), bisagra 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) E109>G (431) (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfuro con lacadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (89.5%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (227-227'':230-230'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular DG44, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQQSGAE VVKPGASVKL SCKASGFNIK DTFIHWVKQA PGQGLEWIGR  50
IDPANTNTKY DPKFQGKATI TTDTSSNTAY MELSSLRSED TAVYYCVRGL 100
YTYYFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH GALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSIS NNLHWYQQKP GQAPRLLIKF  50
ASQSITGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ GNSWPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 221-214' 221"-214'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

betibeglogenum autotemcelum

betibeglogene autotemcel

Autologous CD34+ hematopoietic stem cells transduced *ex vivo* with *betibeglogene darolentivec (116)(78)*, a self-inactivating human immunodeficiency virus-1 (HIV-1)-derived lentiviral vector encoding a T87Q-mutated form of the human hemoglobin subunit beta (HBB, beta-globin) gene under the control of a human β-globin promoter and a 3' β-globin enhancer.

bétibéglogène autotemcel

Cellules souches hématopoïétiques CD34+ autologues transduites *ex vivo* avec le *bétibéglogène darolentivec (116)(78)*, vecteur lentiviral auto-inactivant dérivé du virus de l'immunodéficience humaine-1 (HIV-1) codant pour une forme mutée (T87Q) du gène de la sous-unité bêta de l'hémoglobine humaine (HBB, bêta-globine) sous le contrôle d'un promoteur de la β-globine humaine et un activateur de la β-globine en position 3'.

betibeglogén autotemcel

Células madre hematopoyéticas CD34+ autólogas transducidas *ex vivo* con *betibeglogeéne darolentivec (116)(78)*, un vector lentiviral, auto-inactivante, derivado del virus de la inmunodeficiencia humana-1 (VIH-1) que codifica para una forma mutada T87Q del gen de la subunidad beta de la hemoglobina humana (HBB, beta globina) bajo el control del promotor de la β-globina humana y un potenciador de la β-globina localizado en posición 3'.

branebrutinibum

branebrutinib

4-[(3*S*)-3-(but-2-ynamido)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide

branébrutinib

4-[(3*S*)-3-(but-2-ynamido)pipéridin-1-yl]-5-fluoro-2,3-diméthyl-1*H*-indole-7-carboxamide

branebrutinib

4-[(3*S*)-3-(but-2-inamido)piperidin-1-il]-5-fluoro-2,3-dimetil-1*H*-indol-7-carboxamida

$C_{20}H_{23}FN_4O_2$



brensocatibum

brensocatib

(2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide

brensocatib

(2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phényl]éthyl}-1,4-oxazépane-2-carboxamide

brensocatib

(2*S*)-*N*-{(1*S*)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida

$C_{23}H_{24}N_4O_4$



brepocitinibum

brepocitinib

[(1*S*)-2,2-difluorocyclopropyl](3-{2-[(1-methyl-1*H*-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone

brépocitinib

[(1*S*)-2,2-difluorocyclopropyl](3-{2-[(1-méthyl-1*H*-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl)méthanone

brepocitinib

[(1*S*)-2,2-difluorociclopropil](3-{2-[(1-metil-1*H*-pirazol-4-il)amino]pirimidin-4-il}-3,8-diazabiciclo[3.2.1]octan-8-il)metanona

$C_{18}H_{21}F_2N_7O$



catequentinibum

catequentinib 1-[({4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine

catéquentinib 1-[({4-[(4-fluoro-2-méthyl-1*H*-indol-5-yl)oxy]-6-méthoxyquinoléin-7-yl}oxy)méthyl]cyclopropan-1-amine

catequentinib 1-[({4-[(4-fluoro-2-metil-1*H*-indol-5-il)oxo]-6-metoxiquinolein-7-il}oxi)metil]ciclopropan-1-amina

$C_{23}H_{22}FN_3O_3$



centhaquinum

centhaquine 2-{2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]quinoline

centhaquine 2-{2-[4-(3-méthylphényl)pipérazin-1-yl]éthyl]quinoléine

centhaquina 2-{2-[4-(3-metilfenil)piperazin-1-il]etil]quinoleina

$C_{22}H_{25}N_3$



cinrebafuspum alfa #

cinrebafusp alfa [S^{228}>P,F^{234}>A,L^{235}>A] immunoglobulin G4-kappa (chimeric human-*Mus musculus*, anti-(receptor tyrosine-protein kinase erbB-2, ERBB2, HER2)) fused on both heavy chains (1-447, 1''-447'') via a $(G_4S)_3$ linker (448-462, 448''-462'') to a CD137 (tumor necrosis factor receptor superfamily member 9, TNFRSF9, 4-1BB)-targeting mutant (23 exchanged residues) of human lipocalin-2 (neutrophil gelatinase-associated lipocalin, NGAL, oncogene 24p3, siderocalin) (463-640, 463''-640''):
gamma4 heavy chain fused to lipocalin-2 mutein (1-640) [*Homo sapiens* VH CH1 CH2 CH3 (*Homo sapiens* IGHV3-66*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: DTYIH (31-35); CDRKabatH2: RIYPTNGYTRYADSVKG (50-66); CDRKabatH3: WGGDGFYAMDY (99-109)] (1-120) - *Homo sapiens* IGHG4*01 (CH1 (121-218), hinge (S^{228}>P) (219-230), CH2 (F^{234}>A, L^{235}>A) (231-340), CH3 (341-445), CHS (446-447)) (1-447) - $(G_4S)_3$ linker (448-462) -human lipocalin-2 [mutant Q^{28}>H, L^{36}>Q, A^{40}>I, I^{41}>R, Q^{49}>I, Y^{52}>M, N^{65}>D, S^{68}>M, L^{70}>K, R^{72}>D, K^{73}>D, D^{77}>M, W^{79}>D, R^{81}>W, C^{87}>S, N^{96}>K, Y^{100}>F, L^{103}>H, Y^{106}>S, K^{125}>F, S^{127}>F, Y^{132}>E, K^{134}>Y (1-178)] (463-640)], (134-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* VL CL (*Homo sapiens* IGKV1-39*01 -IGKJ1*01 [CDRKabatL1: RASQDVNTAVA (24'-34'); CDRKabatL2: SASFLYS (50'-56'); CDRKabatL3: QQHYTTPPT (89'-97')] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

cinrébafusp alfa	[S^{228}>P,F^{234}>A,L^{235}>A]immunoglobuline G4-kappa (chimérique humaine-*Mus musculus*, anti-(récepteur tyrosine-protéine kinase erbB-2, ERBB2, HER2)) fusionnée sur les deux chaînes lourdes (1-447, 1''-447'') via un linker $(G_4S)_3$ (448-462, 448''-462'') à un mutant de la lipocaline-2 humaine (lipocaline associée à la gélatinase neutrophile, NGAL, oncogène 24p3, sidérocaline) ciblant le CD137 (membre 9 de la superfamille des récepteurs du facteur de nécrose tumorale, TNFRSF9, 4-1BB) (23 résidus échangés) (463-640, 463''-640''): chaîne lourde gamma4 fusionnée à une mutéine de la lipocaline-2 (1-640) [*Homo sapiens* VH CH1 CH2 CH3 (*Homo sapiens* IGHV3-66*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: DTYIH (31-35); CDRKabatH2: RIYPTNGYTRYADSVKG (50-66); CDRKabatH3: WGGDGFYAMDY (99-109)] (1-120) - *Homo sapiens* IGHG4*01 (CH1 (121-218), charnière (S^{228}>P) (219-230), CH2 (F^{234}>A, L^{235}>A) (231-340), CH3 (341-445), CHS (446-447)) (1-447) -$(G_4S)_3$ linker (448-462) - lipocaline-2 humaine [mutant Q^{28}>H, L^{36}>Q, A^{40}>I, I^{41}>R, Q^{49}>I, Y^{52}>M, N^{65}>D, S^{68}>M, L^{70}>K, R^{72}>D, K^{73}>D, D^{77}>M, W^{79}>D, R^{81}>W, C^{87}>S, N^{96}>K, Y^{100}>F, L^{103}>H, Y^{106}>S, K^{125}>F, S^{127}>F, Y^{132}>E, K^{134}>Y (1-178)] (463-640)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* VL CL (*Homo sapiens* IGKV1-39*01 -IGKJ1*01 [CDRKabatL1: RASQDVNTAVA (24'-34'); CDRKabatL2: SASFLYS (50'-56'); CDRKabatL3: QQHYTTPPT (89'-97')] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dimère (226-226'':229-229'')-bisdisulfure, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
cinrebafusp alfa	[S^{228}>P,F^{234}>A,L^{235}>A] inmunoglobulina G4-kappa (quimérica humana-*Mus musculus*, anti-(receptor tirosina-proteína kinasa erbB-2, ERBB2, HER2)) fusionada a las dos cadenas pesadas (1-447, 1''-447'') a través de un conector $(G_4S)_3$ (448-462, 448''-462'') con un mutante de la lipocalina-2 humana (lipocalina asociada con la gelatinasa neutrófila, NGAL, oncogen 24p3, siderocalina) dirigidos al CD137 (miembro 9 de la superfamilia de los receptores del factor de necrosis tumoral, TNFRSF9, 4-1BB) (23 residuos intercambiados) (463-640, 463''-640''): cadena pesada gamma4 fusionada con une muteína de la lipocalina-2 (1-640) [*Homo sapiens* VH CH1 CH2 CH3 (*Homo sapiens* IGHV3-66*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: DTYIH (31-35); CDRKabatH2: RIYPTNGYTRYADSVKG (50-66); CDRKabatH3: WGGDGFYAMDY (99-109)] (1-120) - *Homo sapiens* IGHG4*01 (CH1 (121-218), bisagra (S^{228}>P) (219-230), CH2 (F^{234}>A, L^{235}>A) (231-340), CH3 (341-445), CHS (446-447)) (1-447) -$(G_4S)_3$ conector (448-462) - lipocalina-2 humana [mutante Q^{28}>H, L^{36}>Q, A^{40}>I, I^{41}>R, Q^{49}>I, Y^{52}>M, N^{65}>D, S^{68}>M, L^{70}>K, R^{72}>D, K^{73}>D, D^{77}>M, W^{79}>D, R^{81}>W, C^{87}>S, N^{96}>K, Y^{100}>F, L^{103}>H, Y^{106}>S, K^{125}>F, S^{127}>F, Y^{132}>E, K^{134}>Y (1-178)] (463-640)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* VL CL (*Homo sapiens* IGKV1-39*01 -IGKJ1*01 [CDRKabatL1: RASQDVNTAVA (24'-34'); CDRKabatL2: SASFLYS (50'-56'); CDRKabatL3: QQHYTTPPT (89'-97')] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro, producido por de las celúlas ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia:
Heavy chain / Chaîne lourde / Cadena pesada:

```
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR  50
IYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG 100
GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEAAGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGKGGG 450
GSGGGGSGGG GSQDSTSDLI PAPPLSKVPL QQNFQDNQFH GKWYVVGQAG 500
NIRLREDKDP IKMMATIYEL KEDKSYDVTM VKFDDKKCMY DIWTFVPGSQ 550
PGEFTLGKIK SFPGHTSSLV RVVSTNYNQH AMVFFKFVFQ NREEFYITLY 600
GRTKELTSEL KENFIRFSKS LGLPENHIVF PVPIDQCIDG             640
```

Light chain / Chaîne légère / Cadena ligera:

```
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS  50
ASFLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posición de los puentes disulfuro:

intra-H: IgG4:	22-96, 147-203, 261-321, 367-425, 22"-96", 147"-203", 261"-321", 367"-425"
lipocalin-2:	538-637, 538"-637"
intra-L:	23'-88', 134'-194', 23'"-88'", 134'"-194'"
inter-H-L:	134-214', 134"-214'"
inter-H-H:	226-226", 229-229"

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N297, N297"

cosibelimabum #

cosibelimab

immunoglobulin G1-lambda, anti-[*Homo sapiens* CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV1-69*01 (93.9%) -(IGHD) - IGHJ1*01(100%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359) L14 (361) (344-448), CHS (449-450)) (121-450)], (223-217')-disulfide with lambda light chain *Homo sapiens* (1'-218') [V-LAMBDA (*Homo sapiens* IGLV6-57*01 (96.9%) -IGLJ2*01 (91.7%)) [8.3.11] (1'-112') - *Homo sapiens* IGLC2*01 (100%) (113'-218')]; dimer (229-229":232-232")-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cells, glycoform alfa

cosibélimab

immunoglobuline G1-lambda, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal *Homo sapiens*;
chaîne lourde gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV1-69*01 (93.9%) -(IGHD) - IGHJ1*01(100%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-217')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-218') [V-LAMBDA (*Homo sapiens* IGLV6-57*01 (96.9%) -IGLJ2*01 (91.7%)) [8.3.11] (1'-112') -*Homo sapiens* IGLC2*01 (100%) (113'-218')]; dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

cosibelimab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV1-69*01 (93.9%) -(IGHD) - IGHJ1*01(100%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-217')-disulfuro con la cadena ligera lambda *Homo sapiens* (1'-218') [V-LAMBDA (*Homo sapiens* IGLV6-57*01 (96.9%) -IGLJ2*01 (91.7%)) [8.3.11] (1'-112') -*Homo sapiens* IGLC2*01 (100%) (113'-218')];
dímero (229-229":232-232")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGSSVKV SCKASGGTFS RSAISWVRQA PGQGLEWMGV  50
IIPAFGEANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGR 100
QMFGAGIDFW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
NFMLTQPHSV SESPGKTVTI SCTRSSGSID SNYVQWYQQR PGSAPTTVIY  50
EDNQRPSGVP DRFSGSIDSS SNSASLTISG LKTEDEADYY CQSYDSNNRH 100
VIFGGGTKLT VLGQPKAAPS VTLFPPSSEE LQANKATLVC LISDFYPGAV 150
TVAWKADSSP VKAGVETTTP SKQSNNKYAA SSYLSLTPEQ WKSHRSYSCQ 200
VTHEGSTVEK TVAPTECS                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 22'-91' 140'-199'
22'"-91'" 140'"-199'"
Inter-H-L (h 5-CL 126) 223-217' 223"-217'"
Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

dirloctocogenum samoparvovecum #

dirloctocogene samoparvovec

A recombinant non-replicating adeno-associated virus vector with a bio-engineered capsid derived by DNA shuffling of 10 AAV capsid sequences (AAV1, 2, 3B, 4, 5, 6 8, 9, avian and bovine AAV) followed by *in vivo* selection in Fah−/−/Rag2−/−/Il2rg−/− (FRG) mice partially repopulated with human hepatocytes. The vector has AAV2 genomic inverted terminal repeats (ITR) and encodes a human B-domain-deleted blood coagulation factor VIII (hF8, FVIII) under the control of a modified transthyretin (TTRm) promoter.
Note: the nucleotide sequence of the vector is a modification of the one of the vector of *rovoctocogene durparvovec (Prop. INN List 120, Rec. INN List 82).*

dirloctocogène samoparvovec	Vecteur viral adéno-associé recombinant non-répliquant avec une capside obtenue par bio-ingénierie dérivée du mélange des séquences de l'ADN de 10 capsides de AAV (AAV1, 2, 3B, 4, 5, 6, 8, 9, AAV aviaire et AAV bovin) suivi de la sélection *in vivo* chez des souris Fah−/−/Rag2−/−/Il2rg−/− (FRG) partiellement repeuplés avec des hépatocytes humains. Le vecteur contient les séquences inverses terminales répétées (ITR) de AAV2 et code pour le facteur de coagulation sanguine VIII humain (hF8, FVIII), dont le domaine B a été supprimé, sous le contrôle d'un promoteur modifié de la transthyrétine (TTRm). Note: la séquence de nucléotides du vecteur est une modification de celle du vecteur du *rovoctocogène durparvovec (DCI Prop. Liste 120, DCI Rec. Liste 82)*.
dirloctocogén samoparvovec	Un vector de virus adenoasociado recombinante no replicativo con una cápsida bioingenierizada mediante la mezcla de secuencias de DNA de 10 cápsidas de AAV (AAV1, 2, 3B, 4, 5, 6, 8, 9, AAV aviar y AAV bovino) seguido de selección in vivo en ratones Fah−/−/Rag2−/−/Il2rg−/− (FRG) parcialmente repoblados con hepatocitos humanos. El vector tiene repeticiones terminales invertidas (ITR) genómicas de AAV2 y codifica para un factor de coagulación sanguíneo VIII humano (hF8, FVIII) con el dominio B delecionado, bajo el control de un promotor de transtiretina modificado (TTRm). Nota: la secuencia de nucleótidos del vector es una modificación de la del vector de *rovoctocogén durparvovec (DCI Prop. Lista 120, DCI Rec. Lista 82).*

dovanvetmabum #

dovanvetmab	immunoglobulin G1-kappa, anti-[*Felis catus* IL31 (interleukin 31)], felinized monoclonal antibody; gamma1 heavy chain felinized (1-457) [VH (*Homo sapiens* IGHV1-46*01 (72.4%) -(IGHD) -IGHJ3*01(80.0%)) [8.8.15] (1-122) -*Felis catus* IGHG1*01 (CH1 (123-220), hinge 1-18 (221-238), CH2 ML1.4-1.3>AA (242-243), G1.1>A (245) (239-348), CH3 (349-455), CHS (456-457)) (123-457)], (137-214')-disulfide with kappa light chain felinized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (80.9%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') -*Felis catus* IGKC*01 (99.1%) N122>Q (210) (108'-214')]; dimer (232-232":234-234":237-237")-trisdisulfide, produced in Chinese Hamster Ovary (CHO)-GS cell line, glycoform alfa
dovanvetmab	immunoglobuline G1-kappa, anti-[*Felis catus* IL31 (interleukine 31)], anticorps monoclonal félinisé;

chaîne lourde gamma1 félinisée (1-457) [VH (*Homo sapiens* IGHV1-46*01 (72.4%) -(IGHD) - IGHJ3*01(80.0%)) [8.8.15] (1-122) -*Felis catus* IGHG1*01 (CH1 (123-220), charnière 1-18 (221-238), CH2 ML1.4-1.3>AA (242-243), G1.1>A (245) (239-348), CH3 (349-455), CHS (456-457)) (123-457)], (137-214')-disulfure avec la chaîne légère kappa félinisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (80.9%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') - *Felis catus* IGKC*01 (99.1%) N122>Q (210) (108'-214')]; dimère (232-232":234-234":237-237")-trisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire GS, glycoforme alfa

dovanvetmab

inmunoglobulina G1-kappa, anti-[*Felis catus* IL31 (interleukina 31)], anticuerpo monoclonal felinizado; cadena pesada gamma1 felinizada (1-457) [VH (*Homo sapiens* IGHV1-46*01 (72.4%) -(IGHD) - IGHJ3*01(80.0%)) [8.8.15] (1-122) -*Felis catus* IGHG1*01 (CH1 (123-220), bisagra 1-18 (221-238), CH2 ML1.4-1.3>AA (242-243), G1.1>A (245) (239-348), CH3 (349-455), CHS (456-457)) (123-457)], (137-214')-disulfuro con la cadena ligera kappa felinizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (80.9%) -IGKJ4*01 (91.7%)) [6.3.9] (1'-107') - *Felis catus* IGKC*01 (99.1%) N122>Q (210) (108'-214')]; dímero (232-232":234-234":237-237")-trisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular GS, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVLLVQSGAE VRTPGASVKI FCKASGYSFT SYTIHWLRQA PAQGLEWMGN  50
INPTSGYTEN NQRFKDRLTL TADTSTNTAY MELSSLRSAD TAMYYCARWG 100
FKYDGEWSFD VWGAGTTVTV SSASTTAPSV FPLAPSCGTT SGATVALACL 150
VLGYFPEPVT VSWNSGALTS GVHTFPAVLQ ASGLYSLSSM VTVPSSRWLS 200
DTFTCNVAHP PSNTKVDKTV RKTDHPPGPK PCDCPKCPPP EAAGAPSIFI 250
FPPKPKDTLS ISRTPEVTCL VVDLGPDDSD VQITWFVDNT QVYTAKTSPR 300
EEQFNSTYRV VSVLPILHQD WLKGKEFKCK VNSKSLPSPI ERTISKAKGQ 350
PHEPQVYVLP PAQEELSRNK VSVTCLIKSF HPPDIAVEWE ITGQPEPENN 400
YRTTPPQLDS DGTYFVYSKL SVDRSHWQRG NTYTCSVSHE ALHSHHTQKS 450
LTQSPGK                                                 457
```

Light chain / Chaîne légère / Cadena ligera

```
EIQMTQSPSS LSASPGDRVT ITCRASQGIS IWLSWYQQKP GNIPKVLINK  50
ASNLHIGVPS RFSGSGSGTD FTLTISSLEP EDAATYYCLQ SQTYPLTFGG 100
GTKLEIKRSD AQPSVFLFQP SLDELHTGSA SIVCILNDFY PKEVNVKWKV 150
DGVVQNKGIQ ESTTEQNSKD STYSLSSTLT MSSTEYQSHE KFSCEVTHKS 200
LASTLVKSFQ RSEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 149-205 269-329 375-435
22"-96" 149"-205" 269"-329" 375"-435"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (CH1 11-CL 126) 137-214' 137"-214'"
Inter-H-H (h 12, h14, h 17) 232-232" 234-234" 237-237"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 305'
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

efbemalenograstimum alfa #

efbemalenograstim alfa

human granulocyte colony-stimulating factor (G-CSF) fragment fused via a peptidyl linker to a human immunoglobulin G2 Fc fragment variant, dimer:

[human granulocyte colony-stimulating factor (G-CSF, pluripoietin) short [A[1],V[37],S[38],E[39]>del] isoform (1-174)]-[$GSG_3S(G_4S)_2$ linker (175-190)]-[human immunoglobulin G2 Fc fragment (223 C-terminal residues) (*Homo sapiens* IGHG2*01 (natural S^{344}>A variant); hinge (191-197), CH2 (P^{297}>S) (198-306), CH3 (307-411), CHS (412-413)(191-413)] fusion protein, dimer (193-193':196-196')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

efbémalénograstim alfa

fragment du facteur de stimulation des colonies de granulocytes humain (G-CSF) lié par un peptide à un variant du fragment Fc de l'immunoglobuline humaine G2, dimère:
[facteur humain de stimulation des colonies de granulocytes (G-CSF, pluripoïétine) [A[1],V[37],S[38],E[39]>del] isoforme courte (1-174)]-[$GSG_3S(G_4S)_2$ linker (175-190)]-[fragment Fc de l'immunoglobuline humaine G2 (résidus 223 C-terminaux) (*Homo sapiens* IGHG2*01 (variant natural S^{344}>A); charnière (191-197), CH2 (P^{297}>S) (198-306), CH3 (307-411), CHS (412-413)(191-413)] protéine de fusion, dimère (193-193':196-196')-bisdisulfure, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

efbemalenograstim alfa

fragmento del factor de estimulación de las colonias de granulocitos humano (G-CSF) que se une por un péptido a una variante del fragment Fc de la inmunoglobulina humana G2, dímero:
[factor humano de estimulación de las colonias de granulocitos (G-CSF, pluripoyetina) [A[1],V[37],S[38],E[39]>del] isoforma corta (1-174)]-[$GSG_3S(G_4S)_2$ conector (175-190)]-[fragmento Fc de la inmunoglobulina humana G2 (residuo 223 C-terminal) (*Homo sapiens* IGHG2*01 (variante natural S^{344}>A); bisagra (191-197), CH2 (P^{297}>S) (198-306), CH3 (307-411), CHS (412-413)(191-413)] proteína de fusión, dímero (193-193':196-196')-bisdisulfuro, producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia:

```
TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL  50
GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG 150
VLVASHLQSF LEVSYRVLRH LAQPGSGGGS GGGGSGGGGS VECPPCPAPP 200
VAGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVQ FNWYVDGVEV 250
HNAKTKPREE QFNSTFRVVS VLTVVHQDWL NGKEYKCKVS NKGLPASIEK 300
TISKTKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN 350
GQPENNYKTT PPMLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN 400
HYTQKSLSLS PGK                                         413
```

Disulfide bridge location / Position des ponts disulfure / Posición de los puentes disulfuro
intra-G-CSF: 36-42, 64-74, 36'-42', 64'-74'
intra-IgG2 Fc: 227-287, 333-391, 227'-287', 333'-391'
inter-IgG2 Fc: 193-193', 196-196'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N-linked glycans: Asn263, Asn263"
O-linked glycans: Thr133, Thr133'

efmitermantum alfa #

efmitermant alfa

human follistatin fragment fused via a peptidyl linker to a human immunoglobulin G2 Fc fragment, dimer:

[human follistatin (FST, FS, activin-binding protein) (1-291)-peptide]-[TG_3 linker (292-295)]-[human immunoglobulin G2 Fc fragment (223 C-terminal residues) [*Homo sapiens* IGHG2*01; hinge (296-302), CH2 (303-411), CH3 (412-516), CHS (517-518)] (296-518) (natural S^{449}>A variant)] fusion protein, dimer (198-198':201-201')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

efmitermant alfa

fragment de la follistatine humaine fusionnée via un peptide à un fragment Fc de l'immunolgobuline humaine G2, dimère:
[follistatine humaine (FST, FS, protéine liant l'activine) (1-291)-peptide]-[TG_3 linker (292-295)]-[fragment Fc de l'immunoglobuline G2 humaine (223 résidus C-terminaux) [*Homo sapiens* IGHG2*01; charnière (296-302), CH2 (303-411), CH3 (412-516), CHS (517-518)] (296-518) (variant naturel S^{449}>A)] protéine de fusion, dimère (198-198':201-201')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

efmitermant alfa

fragmento de la folistatina humana fusionada a través de un péptido con un fragmento Fc de la inmunolgobulina humana G2, dímero:
[folistatina humana (FST, FS, proteína que se una a la activina) (1-291)-péptido]-[TG_3 conector (292-295)]-[fragmento Fc de la inmunoglobulina G2 humana (residuo 223 C-terminal) [*Homo sapiens* IGHG2*01; bisagra (296-302), CH2 (303-411), CH3 (412-516), CHS (517-518)] (296-518) (variante naturel S^{449}>A)] proteína de fusión, dímero (198-198':201-201')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
GNCWLRQAKN GRCQVLYKTE LSKEECCSTG RLSTSWTEED VNDNTLFKWM  50
IFNGGAPNCI PCKETCENVD CGPGKKCRMN KKNKPRCVCA PDCSNITWKG 100
PVCGLDGKTY RNECALLKAR CKEQPELEVQ YQGRCKKTCR DVFCPGSSTC 150
VVDQTNNAYC VTCNRICPEP ASSEQYLCGN DGVTYSSACH LRKATCLLGR 200
SIGLAYEGKC IKAKSCEDIQ CTGGKKCLWD FKVGRGRCSL CDELCPDSKS 250
DEPVCASDNA TYASECAMKE AACSSGVLLE VKHSGSCNSI STGGGVECPP 300
CPAPPVAGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV 350
DGVEVHNAKT KPREEQFNST FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP 400
APIEKTISKT KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV 450
EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH 500
EALHNHYTQK SLSLSPGK                                    518
```

Disulfide bridge location / Position des ponts disulfure / Posiciones de los puentes disulfuro

intra-H, intra-H':	FST:	3-26, 13-59, 27-62, 66-77, 71-87, 89-121, 93-114, 103-135, 139-150, 144-160, 163-196, 167-189, 178-210, 216-227, 221-238, 241-273, 245-266, 255-287
	IgG2:	332-392, 438-496
inter-H-H':		298-298', 301-301'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn95, Asn259, Asn368

elexacaftorum

elexacaftor

N-(1,3-dimethyl-1*H*-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1*H*-pyrazol-1-yl]-2-[(4*S*)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide

élexacaftor

N-(1,3-diméthyl-1*H*-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-diméthylpropoxy)-1*H*-pyrazol-1-yl]-2-[(4*S*)-2,2,4-triméthylpyrrolidin-1-yl]pyridine-3-carboxamide

elexacaftor

N-(1,3-dimetil-1*H*-pirazol-4-sulfonil)-6-[3-(3,3,3-trifluoro-2,2-dimetilpropoxi)-1*H*-pirazol-1-il]-2-[(4*S*)-2,2,4-trimetilpirrolidin-1-il]piridina-3-carboxamida

$C_{26}H_{34}F_3N_7O_4S$



elivaldogenum autotemcelum #

elivaldogene autotemcel

Autologous CD34+ hematopoietic stem cells transduced *ex vivo* with *elivaldogene tavalentivec (115)(77)*, a VSV-G*-pseudotyped self-inactivating HIV-1-derived lentiviral vector (pLBP100 hALD) encoding human adrenoleukodystrophy (ALD) protein (ABCD1 gene) under the control of a modified myeloproliferative sarcoma virus promoter (MND**)
* VSV-G = vesicular stomatitis virus G envelope protein
** MND = myeloproliferative sarcoma virus enhancer with negative control region deleted, dl587rev primer-binding site substituted

élivaldogène autotemcel

Cellules souches hématopoïétiques CD34+ autologues transduites *ex vivo* avec l'*élivaldogène tavalentivec*, vecteur lentiviral dérivé du VIH-1 auto-inactivant (pLBP100 hALD) pseudotypé VSV-G*, codant pour la protéine humaine de l'adrénoleucodystrophie (ALD) (gène ABCD1), sous le contrôle d'un promoteur du virus du sarcome myéloprolifératif modifié (MND**)
* VSV-G = glycoprotéine G de l'enveloppe du virus de la stomatite vésiculaire
** MND = activateur du virus du sarcome myéloprolifératif dont la région de contrôle négatif a été supprimée, le site de liaison de l'amorce substitué par dl587rev

elivaldogén autotemcel

Células madre hematopoyéticas CD34+ autólogas transducidas *ex vivo* con *elivaldogéne tavalentivec (115)(77)*, un vector lentiviral, auto-inactivante, derivado del VIH-1 y seudotipado con VSV-G* (pLBP100 hALD), que codifica para la proteína de la adrenoleucodistrofia (ALD) humana (gen ABCD1), bajo el control de un promotor modificado del virus del sarcoma mieloproliferativo (MND**)
* VSV-G = proteína G de la envuelta del virus de la estomatitis vesicular
** MND = activator del virus del sarcoma mieloproliferativo con la región de control negativo delecionada y, el sitio de unión del primer dl587rev substituído

elsubrutinibum

elsubrutinib — 4-[(3*S*)-1-(prop-2-enoyl)piperidin-3-yl]-1*H*-indole-7-carboxamide

elsubrutinib — 4-[(3*S*)-1-(prop-2-énoyl)pipéridin-3-yl]-1*H*-indole-7-carboxamide

elsubrutinib — 4-[(3*S*)-1-(prop-2-enoil)piperidin-3-il]-1*H*-indol-7-carboxamida

$C_{17}H_{19}N_3O_2$



enavogliflozinum

enavogliflozin — (1*S*)-1,5-anhydro-1-*C*-{7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl}-D-glucitol

énavogliflozine — (1*S*)-1,5-anhydro-1-*C*-{7-chloro-6-[(4-cyclopropylphényl)méthyl]-2,3-dihydro-1-benzofuran-4-yl}-D-glucitol

enavogliflozina — (1*S*)-1,5-anhidro-1-*C*-{7-cloro-6-[(4-ciclopropilfenil)metil]-2,3-dihidro-1-benzofuran-4-il}-D-glucitol

$C_{24}H_{27}ClO_6$



encelimabum #

encelimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-441) [VH (*Homo sapiens* IGHV1-69-2*01 (78.1%) -(IGHD) -IGHJ4*01 (91.7%)) [8.8.7] (1-114)-*Homo sapiens* IGHG4*01 (CH1 (115-212), hinge 1-12 S10>P (222) (213-224), CH2 (225-334), CH3 (335-439), CHS (440-441)) (115-441)], (128-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (*Homo sapiens* IGKV2D-29*02 (89.0%) -IGKJ4*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')];
dimer (220-220":223-223")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

encelimab

immunoglobuline G4-kappa, anti-[*Homo sapiens* LAG3 (activateur 3 des lymphocytes, lymphocyte-activation 3, CD223)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-441) [VH (*Homo sapiens* IGHV1-69-2*01 (78.1%) -(IGHD) -IGHJ4*01 (91.7%)) [8.8.7] (1-114)-*Homo sapiens* IGHG4*01 (CH1 (115-212), charnière 1-12 S10>P (222) (213-224), CH2 (225-334), CH3 (335-439), CHS (440-441)) (115-441)], (128-219')-disulfure avec la chaîne légère kappa humanisée (1'-219') [V-KAPPA (*Homo sapiens* IGKV2D-29*02 (89.0%) -IGKJ4*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (220-220":223-223")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

encelimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* LAG3 (activador 3 de los linfocitos, activación de linfocito 3, CD223)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-441) [VH (*Homo sapiens* IGHV1-69-2*01 (78.1%) -(IGHD) -IGHJ4*01 (91.7%)) [8.8.7] (1-114)-*Homo sapiens* IGHG4*01 (CH1 (115-212), bisagra 1-12 S10>P (222) (213-224), CH2 (225-334), CH3 (335-439), CHS (440-441)) (115-441)], (128-219')-disulfuro con la cadena ligera kappa humanizada (1'-219') [V-KAPPA (*Homo sapiens* IGKV2D-29*02 (89.0%) -IGKJ4*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (220-220":223-223")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGATVKI SCKASGFSIK DDYIHWVQQA PGKGLEWMGW  50
IDAMNDDSQY SSKFQGRVTI TVDTSTNTAY MKLSSLRSED TAVYYCTYAF 100
GGYWGQGTTV TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP 150
VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL GTKTYTCNVD 200
HKPSNTKVDK RVESKYGPPC PPCPAPEFLG GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTYRVVSVL 300
TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP QVYTLPPSQE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 400
YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG K          441
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSQSLV HSDSNTYLHW YLQKPGQSPQ  50
LLIYLVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YFCGQSTHVP 100
YAFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 141-197 255-315 361-419
22"-96" 141"-197" 255"-315" 361"-419"

Intra-L (C23-C104) 23'-93' 139'-199'
23'"-93'" 139'"-199'"

Inter-H-L (CH1 10-CL 126) 128-219' 128"-219'"

Inter-H-H (h 8, h 11) 220-220" 223-223"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
291, 291"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:

H CHS K2:
441, 441"

enmetazobactamum

enmetazobactam (2*S*,3*S*,5*R*)-3-methyl-3-[(3-methyl-1*H*-1,2,3-triazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4λ^6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

enmétazobactam (2*S*,3*S*,5*R*)-3-méthyl-3-[(3-méthyl-1*H*-1,2,3-triazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4λ^6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

enmetazobactam (2*S*,3*S*,5*R*)-3-metil-3-[(3-metil-1*H*-1,2,3-triazol-3-ium-1-il)metil]-4,4,7-trioxo-4λ^6-tia-1-azabiciclo[3.2.0]heptano-2-carboxilato

$C_{11}H_{14}N_4O_5S$



epcoritamabum #

epcoritamab immunoglobulin G1-lambda/kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)] and anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], monoclonal antibody, bispecific;
gamma1 heavy chain chimeric anti-CD3E (1-454) [VH (*Mus musculus* IGHV10-1*02 (93.9%) -(IGHD) -IGHJ3*01 (93.3%)/*Homo sapiens* IGHV3-72*01 (81.0%) -(IGHD) -IGHJ6*01 (67.0%)) [8.10.16] (1-125) -*Homo sapiens* IGHG1*03G1m3, nG1m1 (CH1 R120 (222) (126-223), hinge 1-15 (224-238), CH2L1.3>F (242), L1.2>E (243), D27>A (273) (239-348), CH3 E12 (364), M14(366), F85.1>L (413) (349-453), CHS K2>del (454)) (126-454)], (228-214')-disulfide with lambda light chain chimeric (1'-215') [V-LAMBDA (*Mus musculus* IGLV1*01 (83.3%) -IGLJ1*01 (100%)/*Homo sapiens* IGLV8-61*01 (70.8%) -IGLJ3*02 (100%)) [9.3.9] (1'-109') -*Homo sapiens* IGLC2*01 (100%) (110'-215')];
gamma1 heavy chain *Homo sapiens* anti-MS4A1 (1''-451'') [VH (*Homo sapiens* IGHV3-9*01 (96.0%) -(IGHD) -IGHJ6*01 (100%)) [8.8.15] (1''-122'') -*Homo sapiens* IGHG1*03 G1m3, G1m1 (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), D27>A (270) (236-345), CH3E12 (361), M14 (363), K88>R (414) (346-450), CHS K2>del (451)) (123''-451'')], (225''-214''')-disulfide with kappa light chain *Homo sapiens* (1'''-214''') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (100%) -IGKJ5*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimer (234-231'':237-234'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-S cell line, glycoform alfa

épcoritamab immunoglobuline G1-lambda/kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)] et anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal bispécifique;

	chaîne lourde gamma1 chimérique anti-CD3E (1-454) [VH (*Mus musculus* IGHV10-1*02 (93.9%) -(IGHD) -IGHJ3*01 (93.3%)/*Homo sapiens* IGHV3-72*01 (81.0%) -(IGHD) -IGHJ6*01 (67.0%)) [8.10.16] (1-125) -*Homo sapiens* IGHG1*03G1m3, nG1m1 (CH1 R120 (222) (126-223), charnière 1-15 (224-238), CH2 L1.3>F (242), L1.2>E (243), D27>A (273) (239-348), CH3 E12 (364), M14(366), F85.1>L (413) (349-453), CHS K2>del (454)) (126-454)], (228-214')-disulfure avec la chaîne légère lambda chimérique (1'-215') [V-LAMBDA (*Mus musculus* IGLV1*01 (83.3%) -IGLJ1*01 (100%)/*Homo sapiens* IGLV8-61*01 (70.8%) -IGLJ3*02 (100%)) [9.3.9] (1'-109') -*Homo sapiens* IGLC2*01 (100%) (110'-215')]; chaîne lourde gamma1 *Homo sapiens* anti-MS4A1 (1''-451'') [VH (*Homo sapiens* IGHV3-9*01 (96.0%) -(IGHD) -IGHJ6*01 (100%)) [8.8.15] (1''-122'') -*Homo sapiens* IGHG1*03G1m3, nG1m1 (CH1 R120 (219) (123-220), charnière 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), D27>A (270) (236-345), CH3 E12 (361), M14 (363), K88>R (414) (346-450), CHS K2>del (451)) (123''-451'')], (225''-214''')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'''-214''') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (100%) -IGKJ5*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimère (234-231''':237-234'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire CHO-S, glycoforme alfa
epcoritamab	inmunoglobulina G1-lambda/kappa, anti-[*Homo sapiens* CD3E (CD3 épsilon)] y anti-[*Homo sapiens* MS4A1 (miembro 1 de la sub-familia A de 4 dominios transmembranarios, CD20)], anticuerpo monoclonal biespecífico; cadena pesada gamma1 quimérica anti-CD3E (1-454) [VH (*Mus musculus* IGHV10-1*02 (93.9%) -(IGHD) -IGHJ3*01 (93.3%)/*Homo sapiens* IGHV3-72*01 (81.0%) -(IGHD) -IGHJ6*01 (67.0%)) [8.10.16] (1-125) -*Homo sapiens* IGHG1*03G1m3, nG1m1 (CH1 R120 (222) (126-223), bisagra 1-15 (224-238), CH2 L1.3>F (242), L1.2>E (243), D27>A (273) (239-348), CH3 E12 (364), M14(366), F85.1>L (413) (349-453), CHS K2>del (454)) (126-454)], (228-214')-disulfuro con la cadena ligera lambda quimérica (1'-215') [V-LAMBDA (*Mus musculus* IGLV1*01 (83.3%) -IGLJ1*01 (100%)/*Homo sapiens* IGLV8-61*01 (70.8%) -IGLJ3*02 (100%)) [9.3.9] (1'-109') -*Homo sapiens* IGLC2*01 (100%) (110'-215')]; cadena pesada gamma1 *Homo sapiens* anti-MS4A1 (1''-451'') [VH (*Homo sapiens* IGHV3-9*01 (96.0%) -(IGHD) -IGHJ6*01 (100%)) [8.8.15] (1''-122'') -*Homo sapiens* IGHG1*03G1m3, nG1m1 (CH1 R120 (219) (123-220), bisagra 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), D27>A (270) (236-345), CH3 E12 (361), M14 (363), K88>R (414) (346-450), CHS K2>del (451)) (123''-451'')], (225''-214''')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'''-214''') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (100%) -IGKJ5*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'''-214''')]; dímero (234-231''':237-234'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular CHO-S, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3E)

```
EVKLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR  50
IRSKYNNYAT YYADSVKDRF TISRDDSKSS LYLQMNNLKT EDTAMYYCVR 100
HGNFGNSYVS WFAYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP EFEGGPSVFL 250
FPPKPKDTLM ISRTPEVTCV VVAVSHEDPE VKFNWYVDGV EVHNAKTKPR 300
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ 350
PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400
TTPPVLDSDG SFLLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS 450
LSPG                                                    454
```

Light chain / Chaîne légère / Cadena ligera (anti-CD2E)

```
QAVVTQEPSF SVSPGGTVTL TCRSSTGAVT TSNYANWVQQ TPGQAFRGLI  50
GGTNKRAPGV PARFSGSLIG DKAALTITGA QADDESIYFC ALWYSNLWVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS                                        215
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD20)

```
EVQLVESGGG LVQPDRSLRL SCAASGFTFH DYAMHWVRQA PGKGLEWVST  50
ISWNSGTIGY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCAKDI 100
QYGNYYYGMD VWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPEFE GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVA VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSRLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera (anti-CD20)

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPITFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-98 152-208 269-329 375-433
22"-96" 149"-205" 266"-326" 372"-430"
Intra-L (C23-C104) 22'-90' 137'-196'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 228-214' 225"-214'"
Inter-H-H (h 11, h 14) 234-231" 237-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

ezaladcigenum resoparvovecum

ezaladcigene resoparvovec	A recombinant non-replicating adeno-associated virus serotype 2 (rAAV2) vector encoding human aromatic-L-amino-acid decarboxylase (AADC, DOPA decarboxylase, DDC) under control of a cytomegalovirus (CMV) promoter.
ézaladcigène résoparvovec	vecteur viral adéno-associé recombinant de sérotype 2 non-répliquant (rAAV2) codant pour la décarboxylase des acides L-aminés aromatiques (AADC, DOPA décarboxylase, DDC) sous le contrôle d'un promoteur de cytomégalovirus (CMV)
ezaladcigén resoparvovec	Un vector de virus adenoasociado recombinante no replicativo del serotipo 2 (rAAV2), que codifica para la L-aminoácido aromático descarboxilasa (AADC, DOPA decarboxilasa, DDC) bajo el control de un promotor de citomegalovirus (CMV).

fadraciclibum

fadraciclib — (2*R*,3*S*)-3-{[6-{[(4,6-dimethylpyridin-3-yl)methyl]amino}-9-(propan-2-yl)-9*H*-purin-2-yl]amino}pentan-2-ol

fadraciclib — (2*R*,3*S*)-3-{[6-{[(4,6-diméthylpyridin-3-yl)méthyl]amino}-9-(propan-2-yl)-9*H*-purin-2-yl]amino}pentan-2-ol

fadraciclib — (2*R*,3*S*)-3-{[6-{[(4,6-dimetilpiridin-3-il)metil]amino}-9-(propan-2-il)-9*H*-purin-2-il]amino}pentan-2-ol

$C_{21}H_{31}N_7O$



felcisetragum

felcisetrag — methyl 4-[(4-{[2-(propan-2-yl)-1*H*-benzimidazole-4-carboxamido]methyl}piperidin-1-yl)methyl]piperidine-1-carboxylate

felcisétrag — 4-[(4-{[2-(propan-2-yl)-1*H*-benzimidazole-4-carboxamido]méthyl}piperidin-1-yl)méthyl]pipéridine-1-carboxylate de méthyle

felcisetrag — 4-[(4-{[2-(propan-2-il)-1*H*-benzimidazol-4-carboxamido]metil}piperidin-1-il)metil]piperidina-1-carboxilato de metilo

$C_{25}H_{37}N_5O_3$



felezonexorum

felezonexor — 1-{[6-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}-3-[(3,3-dimethylbutoxy)methyl]-4-methyl-1*H*-pyrrole-2,5-dione

félézonexor — 1-{[6-chloro-5-(trifluorométhyl)pyridin-2-yl]amino}-3-[(3,3-diméthylbutoxy)méthyl]-4-méthyl-1*H*-pyrrole-2,5-dione

felezonexor — 1-{[6-cloro-5-(trifluorometil)piridin-2-il]amino}-3-[(3,3-dimetilbutoxi)metil]-4-metil-1*H*-pirrol-2,5-diona

$C_{18}H_{21}ClF_3N_3O_3$



ferri bepectas

ferric bepectate

O-(2-hydroxethyl)-substituted (~0.5 per glucose unit) acid-hydrolysed potato starch-(α1→5)-(2*RS*)-D-*gluco*-heptonic acid (~390 glucose units) complexes with iron(III) hydroxide oxide nanoparticles (~13000 Fe per particle) (~20:1)

bépectate ferrique

fécule de pomme de terre-(α1→5)-acide (2*RS*)-D-*gluco*-heptonique (~400 unités de glucose) hydrolysée en milieu acide *O*-(2-hydroxéthyl)-substituée (~0.5 par unité de glucose) complexée avec des nanoparticules d'hydroxyde oxyde de fer(III) (~13000 Fe par particule) (~20:1)

bepectato férrico

almidón de patata-(α1→5)-ácido (2*RS*)-D-*gluco*-heptónico (~400 unidades de glucosa) hidrolizado en medio ácido *O*-(2-hidroxietil)-sustituido (~0.5 por unidad de glucosa) complejo con las nanopartículas de hidróxido de hierro (III) (~13000 Fe por partícula) (~20:1)

$(FeHO_2)_x\{(C_2H_4O)_m(C_6H_{10}O_5)_{m+n}(C_7H_{14}O_8)\}_y$
$m \approx n \approx 200$, $x \approx 13{,}000$, $y \approx 20$



R,R,R = H,H,CH_2-CH_2-OH (*m*) & R,R,R = H,H,H (*n*)

$m \sim n \sim 200$, $x \sim 13000$, $y \sim 20$

fezagepras

fezagepras

(3-pentylphenyl)acetic acid

fézagépras

acide (3-pentylphényl)acétique

fezagepras

ácido (3-pentilfenil)acético

$C_{13}H_{18}O_2$



fianlimabum #

fianlimab

immunoglobulin G4-kappa, anti-[*Homo sapiens* LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], *Homo sapiens* monoclonal antibody;

gamma4 heavy chain *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV3-33*01 (96.9%) -(IGHD) -IGHJ3*01 (92.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), hinge 1-12 S10>P (231) (222-233), CH2 E1.4>P (236), L1.2>V (237), G1.1>A (238) (234-342), CH3 (343-447), CHS (448-449)) (124-449)], (137-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (93.7%) -IGKJ4*01 (100%))[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

fianlimab

immunoglobuline G4-kappa, anti-[*Homo sapiens* LAG3 (activateur 3 des lymhocytes, lymphocyte-activation 3, CD223)], anticorps monoclonal *Homo sapiens*;
chaîne lourde gamma4 *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV3-33*01 (96.9%) -(IGHD) -IGHJ3*01 (92.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), charnière 1-12 S10>P (231) (222-233), CH2 E1.4>P (236), L1.2>V (237), G1.1>A (238) (234-342), CH3 (343-447), CHS (448-449)) (124-449)], (137-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (93.7%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (229-229'':232-232'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

fianlimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma4 *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV3-33*01 (96.9%) -(IGHD) -IGHJ3*01 (92.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), bisagra 1-12 S10>P (231) (222-233), CH2 E1.4>P (236), L1.2>V (237), G1.1>A (238) (234-342), CH3 (343-447), CHS (448-449)) (124-449)], (137-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (93.7%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (229-229'':232-232'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCVASGFTFS SYGMHWVRQA PGKGLEWVAI  50
IWYDGSNKYY ADSVKGRFTI SRDNSKNTQY LQMNSLRAED TAVYYCASVA 100
TSGDFDYYGM DVWGQGTTVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERTT LSCRASQRIS TYLAWYQQKP GQAPRLLIYD  50
ASKRATGIPA RFSGSGSGTG FTLTISSLEP EDFAVYYCQQ RSNWPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 150-206 263-323 369-427
22''-96'' 150''-206'' 263''-323'' 369''-427''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 137-214' 137''-214'''
Inter-H-H (h 11, h 14) 229-229'' 232-232''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299''

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.
C-terminal lysine clipping:
H CHS K2:
449, 449''

firzotemcelum

firzotemcel	allogenic human CD34+ hematopoietic stem/progenitor cells (HSPCs) derived from granulocyte-colony stimulating factor (G-CSF) mobilized peripheral hematopoietic cells from human leukocyte antigen (HLA)-matched prospective transplant organ donors
firzotemcel	cellules souches/cellules progénitrices hématopoïétiques (HSPCs) CD34+, humaines, allogéniques, dérivées de cellules hématopoïétiques périphériques mobilisées par le facteur stimulant les colonies de granulocytes (G-CSF) de donneurs prospectifs pour transplantation d'organes, compatibles vis-à-vis de l'antigène leucocytaire humain (HLA).
firzotemcel	células troncales/precursoras hematopoyéticas CD34+, humanas, alogénicas, derivadas de células hematopoyéticas periféricas movilizadas con el factor estimulador de colonias de granulocitos (G-CSF) de donantes prospectivos para trasplante de órganos, compatibles para el antígeno leucocitario humano (HLA).

flubrobenguanum (^{18}F)

flubrobenguane (^{18}F)	*N*-{[3-bromo-4-(3-(^{18}F)fluoropropoxy)phenyl]methyl}guanidine
flubrobenguane (^{18}F)	*N*-{[3-bromo-4-(3-(^{18}F)fluoropropoxy)phényl]méthyl}guanidine
flubrobenguano (^{18}F)	*N*-{[3-bromo-4-(3-(^{18}F)fluoropropoxi)fenil]metil}guanidine

$C_{11}H_{15}Br^{18}FN_3O$



fosdenopterinum

fosdenopterin	(4a*R*,5a*R*,11a*R*,12a*S*)-8-amino-2,12,12-trihydroxy-4a,5a,6,7,11,11a,12,12a-octahydro-2*H*-2λ^5-[1,3,2]dioxaphosphinino[4',5':5,6]pyrano[3,2-*g*]pteridine-2,10(4*H*)-dione
fosdénoptérine	(4a*R*,5a*R*,11a*R*,12a*S*)-8-amino-2,12,12-trihydroxy-4a,5a,6,7,11,11a,12,12a-octahydro-2*H*-2λ^5-[1,3,2]dioxaphosphinino[4',5':5,6]pyrano[3,2-*g*]ptéridine-2,10(4*H*)-dione
fosdenopterina	(4a*R*,5a*R*,11a*R*,12a*S*)-8-amino-2,12,12-trihidroxi-4a,5a,6,7,11,11a,12,12a-octahidro-2*H*-2λ^5-[1,3,2]dioxafosfinino[4',5':5,6]pirano[3,2-*g*]pteridina-2,10(4*H*)-diona

$C_{10}H_{14}N_5O_8P$



gatralimabum #

gatralimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CD52 (CD52 antigen, CAMPATH-1 antigen, CDW52)], monoclonal antibody; gamma1 heavy chain humanized (1-444) [VH (*Homo sapiens* IGHV3-72*01 (86.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.10.5] (1-114) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (211) (115-212), hinge 1-15 (213-227), CH2 (228-337), CH3 D12 (353), L14 (355) (338-442), CHS (443-444)) (115-444)], (217-218')-disulfide with kappa light chain chimeric (1'-218') [V-KAPPA (*Mus musculus* IGKV1-133*01 (90.9%) -IGKJ4*01(90.9 %)/*Homo sapiens* IGKV2-4*01 (89.5%) -IGKJ2*02 (100%)) [11.3.8] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (223-223'':226-226'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cells, glycoform alfa
gatralimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD52 (CD52 antigène, CAMPATH-1 antigène, CDW52)], anticorps monoclonal; chaîne lourde gamma1 humanisée (1-444) [VH (*Homo sapiens* IGHV3-72*01 (86.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.10.5] (1-114) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (211) (115-212), charnière 1-15 (213-227), CH2 (228-337), CH3 D12 (353), L14 (355) (338-442), CHS (443-444)) (115-444)], (217-218')-disulfure avec la chaîne légère kappa chimérique (1'-218') [V-KAPPA (*Mus musculus* IGKV1-133*01 (90.9%) -IGKJ4*01(90.9 %)/*Homo sapiens* IGKV2-4*01 (89.5%) -IGKJ2*02 (100%)) [11.3.8] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (223-223'':226-226'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
gatralimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD52 (CD52 antígeno, CAMPATH-1 antígeno, CDW52)], anticuerpo monoclonal; cadena pesada gamma1 humanizada (1-444) [VH (*Homo sapiens* IGHV3-72*01 (86.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.10.5] (1-114) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (211) (115-212), bisagra 1-15 (213-227), CH2 (228-337), CH3 D12 (353), L14 (355) (338-442), CHS (443-444)) (115-444)], (217-218')-disulfuro con la cadena ligera kappa quimérica (1'-218') [V-KAPPA (*Mus musculus* IGKV1-133*01 (90.9%) -IGKJ4*01(90.9 %)/*Homo sapiens* IGKV2-4*01 (89.5%) -IGKJ2*02 (100%)) [11.3.8] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (223-223'':226-226'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFPFS NYWMNWVRQA PGKGLEWVGQ  50
IRLKSNNYAT HYAESVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCTP 100
IDYWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP 150
VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL GTQTYICNVN 200
HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP 350
SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL YSNGKTYLNW VLQKPGQSPQ  50
RLIYLVSKLD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCVQGSHFH 100
TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 141-197 258-318 364-422
22"-96" 141"-197" 258"-318" 364"-422"
Intra-L (C23-C104) 23'-93' 138'-198'
23'"-93'" 138'"-198'"
Inter-H-L (h5-CL 126) 217-218' 217"-218"
Inter-H-H (h11, h 14) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosiladosa

giroctocogenum fitelparvovecum

giroctocogene fitelparvovec — a recombinant non-replicating adeno-associated virus type 2/6 (rAAV Rep2-Cap6) vector, encoding human B-domain-deleted blood coagulation factor VIII (hF8, FVIII) under the control of a synthetic liver-specific promoter.

giroctocogène fitelparvovec — Vecteur viral adéno-associé de type 2/6 recombinant non-répliquant (rAAV Rep2-Cap6), codant pour le facteur de coagulation sanguine VIII humain (hF8, FVIII), dont le domaine B a été supprimé, sous le contrôle d'un promoteur synthétique spécifique du foie.

giroctocogén fitelparvovec — Un vector de virus adenoasociado recombinante no replicativo del tipo 2/6 (rAAV Rep2-Cap6), que codifica para el factor de coagulación sanguíneo VIII humano (hF8, FVIII) con el dominio B delecionado, bajo el control de un promotor sintético específico del hígado.

glofitamabum

glofitamab — immunoglobulin G1-lambda/kappa with domain cross-over, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)] and anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)] monoclonal antibody, bispecific, trivalent; gamma-lambda heavy chain anti-MS4A1 and anti-CD3E (VH-CH1-V-LAMBDA-CH1-CH2-CH3) (1-674) [humanized VH anti-MS4A1 (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17 (CH1 K26>E (149), K119>E (215), K120 (216) (120-217), hinge 1-6 (218-223)) (120-223) -10-mer bis(tetraglycyl-seryl) linker (224-233) -V-LAMDDA anti-CD3E (*Mus musculus* IGLV1*01 (81.2%) -IGLJ1*01 (100%)/*Homo sapiens* IGLV7-46*01 (80.0%) -IGLJ3*01 (100%)) [9.3.9] (234-342) -2-mer biseryl linker (343-344) -*Homo sapiens* IGHG1*01, G1m17, G1m1 (CH1 K120 (441) (345-442), hinge 1-15 (443-457), CH2 L1.3>A (461), L1.2>A (462), P114>G (556) (458-567), CH3 S10>C (581), D12 (583), L14 (585), T22>W (593) (568-672), CHS (673-674)) (345-674)],

	(222-219')-disulfide with kappa light chain humanized anti-MS4A1 (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-28*01 (87.0%) -IGKJ4*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (98.1%), E12>R (128), Q13>K (129), Km3 A45.1 (158), V101 (196) (113'-219')]; (447-232''')-disulfide with VH-C-kappa light chain humanized anti-CD3E (1'''-232''') [humanized VH (*Homo sapiens* IGHV3-23*03 (87.0%) -IGKJ6*01 (90.9%)) [8.10.16] (1'''-125''') -*Homo sapiens* IGKC*01 (99.1%), T1.3>S (127), Km3 A45.1 (171), V101 (209) (126'''-232''')], gamma1 heavy chain humanized anti-MS4A1 (1''-449'') [humanized VH (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1''-119'') -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K26>E (149), K119>E (215), K120 (216) (120''-217''), hinge 1-15 (218''-232''), CH2 L1.3>A (236), L1.2>A (237), P114>G (331) (233''-342''), CH3 Y5>C (351), D12 (358), L14 (360), T22>S (368), L24>A (370), Y86>V (409) (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-219'''')-disulfide with kappa light chain humanized anti-MS4A1 (1''''-219'''') [humanized V-KAPPA (*Homo sapiens* IGKV2-28*01 (87.0%) -IGKJ4*01 (100%)) [11.3.9] (1''''-112'''') -*Homo sapiens* IGKC*01 (98.1%), E12>R (128), Q13>K (129), Km3 A45.1 (158), V101 (196) (113''''-219'''')]; dimer (453-228'':456-231'':581-351'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
glofitamab	immunoglobuline G1-lambda/kappa avec domaines échangés, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)] et anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)] anticorps monoclonal, bispécifique, trivalent; chaîne lourde gamma-lambda anti-MS4A1 et anti-CD3E (VH-CH1-V-LAMBDA-CH1-CH2-CH3) (1-674) [VH anti-MS4A1 humanisé (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17 (CH1 K26>E (149), K119>E (215), K120 (216) (120-217), charnière 1-6 (218-223)) (120-223) -10-mer bis(tétraglycyl-séryl) linker (224-233) -V-LAMDDA anti-CD3E (*Mus musculus* IGLV1*01 (81.2%) -IGLJ1*01 (100%)/*Homo sapiens* IGLV7-46*01 (80.0%) -IGLJ3*01 (100%)) [9.3.9] (234-342) -2-mer biséryl linker (343-344) -*Homo sapiens* IGHG1*01, G1m17, G1m1 (CH1 K120 (441) (345-442), charnière 1-15 (443-457), CH2 L1.3>A (461), L1.2>A (462), P114>G (556) (458-567), CH3 S10>C (581), D12 (583), L14 (585), T22>W (593) (568-672), CHS (673-674)) (345-674)], (222-219')-disulfure avec la chaîne légère kappa anti-MS4A1 humanisée (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-28*01 (87.0%) -IGKJ4*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (98.1%), E12>R (128), Q13>K (129), Km3 A45.1 (158), V101 (196) (113'-219')]; (447-232''')-disulfure avec la chaîne légère VH-C-kappa anti-CD3E humanisée (1'''-232''') [VH humanisé (*Homo sapiens* IGHV3-23*03 (87.0%) -IGKJ6*01 (90.9%)) [8.10.16] (1'''-125''') -*Homo sapiens* IGKC*01 (99.1%), T1.3>S (127), Km3 A45.1 (171), V101 (209) (126'''-232''')],

	chaîne lourde gamma1 anti-MS4A1 humanisée (1''-449'') [VH humanisé (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) - IGHJ4*01 (100%)) [8.8.12] (1''-119'') -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K26>E (149), K119>E (215), K120 (216) (120''-217''), charnière 1-15 (218''-232''), CH2 L1.3>A (236), L1.2>A (237), P114>G (331) (233''-342''), CH3 Y5>C (351), D12 (358), L14 (360), T22>S (368), L24>A (370), Y86>V (409) (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-219'''')-disulfure avec la chaîne légère kappa anti-MS4A1 humanisée (1''''-219'''') [V-KAPPA humanisé (*Homo sapiens* IGKV2-28*01 (87.0%) -IGKJ4*01 (100%)) [11.3.9] (1''''-112'''') - *Homo sapiens* IGKC*01 (98.1%), E12>R (128), Q13>K (129), Km3 A45.1 (158), V101 (196) (113''''-219'''')]; dimère (453-228'':456-231'':581-351'')-trisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
glofitamab	inmunoglobulina G1-lambda/kappa con dominios cruzados, anti-[*Homo sapiens* MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)] y anti-[*Homo sapiens* CD3E (CD3 épsilon, Leu-4)] anticuerpo monoclonal, biespecífico, trivalente; cadena pesada gamma-lambda anti-MS4A1 y anti-CD3E (VH-CH1-V-LAMBDA-CH1-CH2-CH3) (1-674) [VH anti-MS4A1 humanizado (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) - IGHJ4*01 (100%)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17 (CH1 K26>E (149), K119>E (215), K120 (216) (120-217), bisagra 1-6 (218-223)) (120-223) -conector 10-mer bis(tetraglicil-seril) (224-233) -V-LAMDDA anti-CD3E (*Mus musculus* IGLV1*01 (81.2%) -IGLJ1*01 (100%)/*Homo sapiens* IGLV7-46*01 (80.0%) -IGLJ3*01 (100%)) [9.3.9] (234-342) - conector 2-mer biseril (343-344) -*Homo sapiens* IGHG1*01, G1m17, G1m1 (CH1 K120 (441) (345-442), bisagra 1-15 (443-457), CH2 L1.3>A (461), L1.2>A (462), P114>G (556) (458-567), CH3 S10>C (581), D12 (583), L14 (585), T22>W (593) (568-672), CHS (673-674)) (345-674)], (222-219')-disulfuro con la cadena ligera kappa anti-MS4A1 humanizada (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-28*01 (87.0%) -IGKJ4*01 (100%)) [11.3.9] (1'-112') - *Homo sapiens* IGKC*01 (98.1%), E12>R (128), Q13>K (129), Km3 A45.1 (158), V101 (196) (113'-219')]; (447-232''')-disulfuro con la cadena ligera VH-C-kappa anti-CD3E humanizada (1'''-232''') [VH humanizado (*Homo sapiens* IGHV3-23*03 (87.0%) -IGKJ6*01 (90.9%)) [8.10.16] (1'''-125''') - *Homo sapiens* IGKC*01 (99.1%), T1.3>S (127), Km3 A45.1 (171), V101 (209) (126'''-232''')], cadena pesada gamma1 anti-MS4A1 humanizada (1''-449'') [VH humanizado (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) - IGHJ4*01 (100%)) [8.8.12] (1''-119'') -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K26>E (149), K119>E (215), K120 (216) (120''-217''), bisagra 1-15 (218''-232''), CH2 L1.3>A (236), L1.2>A (237), P114>G (331) (233''-342''), CH3 Y5>C (351), D12 (358), L14 (360), T22>S (368), L24>A (370), Y86>V (409) (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-219'''')-disulfuro con la cadena ligera kappa anti-MS4A1 humanizada (1''''-219'''') [V-KAPPA humanizado (*Homo sapiens* IGKV2-28*01 (87.0%) -IGKJ4*01 (100%)) [11.3.9] (1''''-112'''') - *Homo sapiens* IGKC*01 (98.1%), E12>R (128), Q13>K (129), Km3 A45.1 (158), V101 (196) (113''''-219'''')]; dímero (453-228'':456-231'':581-351'')-trisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada (1-674 anti-MS4A1, anti-CD3)

```
QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR  50
IFPGDGDTDY NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV 100
FDGYWLVYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVED 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDEKVEPK SCDGGGGSGG GGSQAVVTQE PSLTVSPGGT 250
VTLTCGSSTG AVTTSNYANW VQEKPGQAFR GLIGGTNKRA PGTPARFSGS 300
LLGGKAALTL SGAQPEDEAE YYCALWYSNL WVFGGGTKLT VLSSASTKGP 350
SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV 400
LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK KVEPKSCDKT 450
HTCPPCPAPE AAGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV 500
KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV 550
SNKALGAPIE KTISKAKGQP REPQVYTLPP CRDELTKNQV SLWCLVKGFY 600
PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF 650
SCSVMHEALH NHYTQKSLSL SPGK                              674
```

Heavy chain / Chaîne lourde / Cadena pesada (1"-449" anti-MS4A1)

```
QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR  50
IFPGDGDTDY NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV 100
FDGYWLVYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVED 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDEKVEPK SCDKTHTCPP CPAPEAAGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL GAPIEKTISK AKGQPREPQV 350
CTLPPSRDEL TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera (1'-219' and 1'"-219"" anti-MS4A1)

```
DIVMTQTPLS LPVTPGEPAS ISCRSSKSLL HSNGITYLYW YLQKPGQSPQ  50
LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCAQNLELP 100
YTFGGGTKVE IKRTVAAPSV FIFPPSDRKL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Light chain / Chaîne légère / Cadena ligera (1'"-232"" anti-CD3E)

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS TYAMNWVRQA PGKGLEWVSR  50
IRSKYNNYAT YYADSVKGRF TISRDDSKNT LYLQMNSLRA EDTAVYYCVR 100
HGNFGNSYVS WFAYWGQGTL VTVSSASVAA PSVFIFPPSD EQLKSGTASV 150
VCLLNNFYPR EAKVQWKVDN ALQSGNSQES VTEQDSKDST YSLSSTLTLS 200
KADYEKHKVY ACEVTHQGLS SPVTKSFNRG EC                    232
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 146-202 255-323 371-427 488-548 594-652
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-93' 139'-199'
22'"-98'" 152'"-212'"
23'"-93'"" 139'"-199'""
Inter-H-L (h 5-CL 126) 222-219' 447-232'" 222"-219""
Inter-H-H (h 11, h 14) 453-228" 456-231"
Inter-H-H engineered 581-351"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
524, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

gremubamabum

gremubamab immunoglobulin G1-kappa, anti-[*Pseudomonas aeruginosa* psl (polysaccharide synthesis locus, surface exopolysaccharide) and anti-[*Pseudomonas aeruginosa* type III secretion system (TTSS, T3S) PcrV protein], monoclonal antibody, bispecific;
gamma1 heavy chain VH-CH1-VH-V-KAPPA-CH2-CH3 humanized (1-720) [VH anti-PcrV (*Homo sapiens* IGHV3-23*01 (91.8%) -(IGHD) -IGHJ6*01 (94.7%)) [8.8.17] (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3 (CH1 R120 (221) (125-222) -hinge 1-5 (223-227)) -10-mer linker (228-237) -VH anti-psl (*Homo sapiens* IGHV4-59*01 (89.7%), IGHV4-4*08 (89.7%) -(IGHD) -IGHJ3*02 (93.3%)) [8.7.13] (238-356) -20-mer linker (357-376) -V-KAPPA anti-psl (*Homo sapiens* IGKV1-39*01 (94.5%) -IGKJ4*01 (90.0%)) [6.3.9] (377-483) -10-mer linker (484-493) -*Homo sapiens* IGHG1*03 (100%) nG1m1 (hinge 6-15 (494-503), CH2 (504-613), CH3 E12 (629), M14 (631) (614-718), CHS (719-720)) (494-720)], (227-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA anti-PcrV (*Homo sapiens* IGKV1-6*01 (97.9%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191)(108'-214')];
dimer (499-499':502"-502"')-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cells, glycoform alfa

grémubamab	immunoglobuline G1-kappa, anti-[*Pseudomonas aeruginosa* psl (locus de synthèse des polysaccharides, exopolysaccharide de surface)] et anti-[protéine PcrV du système de sécrétion type III (TTSS, T3S) de *Pseudomonas aeruginosa*)], anticorps monoclonal bispécifique; chaîne lourde gamma1 VH-CH1-VH-V-KAPPA-CH2-CH3 humanisée (1-720) [VH anti-PcrV (*Homo sapiens* IGHV3-23*01 (91.8%) -(IGHD) -IGHJ6*01 (94.7%)) [8.8.17] (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3 (CH1 R120 (221) (125-222) -charnière 1-5 (223-227)) -10-mer linker (228-237) -VH anti-psl (*Homo sapiens* IGHV4-59*01 (89.7%), IGHV4-4*08 (89.7%) -(IGHD) -IGHJ3*02 (93.3%)) [8.7.13] (238-356) -20-mer linker (357-376) -V-KAPPA anti-psl (*Homo sapiens* IGKV1-39*01 (94.5%) -IGKJ4*01 (90.0%)) [6.3.9] (377-483) -10-mer linker (484-493) -*Homo sapiens* IGHG1*03 (100%) nG1m1 (charnière 6-15 (494-503), CH2 (504-613), CH3 E12 (629), M14 (631) (614-718), CHS (719-720)) (494-720)], (227-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA anti-PcrV (*Homo sapiens* IGKV1-6*01 (97.9%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191)(108'-214')]; dimère (499-499':502"-502"')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
gremubamab	inmunoglobulina G1-kappa, anti-[*Pseudomonas aeruginosa* psl (lugar de síntesis de los polisacáridos, exopolisacárido de superficie)] y anti-[proteína PcrV del sistema de secreción tipo III (TTSS, T3S) de *Pseudomonas aeruginosa*)], anticuerpo monoclonal biespecífico; cadena pesada gamma1 VH-CH1-VH-V-KAPPA-CH2-CH3 humanizada (1-720) [VH anti-PcrV (*Homo sapiens* IGHV3-23*01 (91.8%) -(IGHD) -IGHJ6*01 (94.7%)) [8.8.17] (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3 (CH1 R120 (221) (125-222) -bisagra 1-5 (223-227)) -conector 10-mer (228-237) -VH anti-psl (*Homo sapiens* IGHV4-59*01 (89.7%), IGHV4-4*08 (89.7%) -(IGHD) -IGHJ3*02 (93.3%)) [8.7.13] (238-356) -conector 20-mer (357-376) -V-KAPPA anti-psl (*Homo sapiens* IGKV1-39*01 (94.5%) -IGKJ4*01 (90.0%)) [6.3.9] (377-483) -conector 10-mer (484-493) -*Homo sapiens* IGHG1*03 (100%) nG1m1 (bisagra 6-15 (494-503), CH2 (504-613), CH3 E12 (629), M14 (631) (614-718), CHS (719-720)) (494-720)], (227-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA anti-PcrV (*Homo sapiens* IGKV1-6*01 (97.9%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191)(108'-214')]; dímero (499-499':502"-502"')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMNWVRQA PGKGLEWVSA  50
ITMSGITAYY TDDVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKEE 100
FLPGTHYYYG MDVWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCGGG GSGGGGSQVQ LQESGPGLVK 250
PSETLSLTCT VSGGSISPYY WTWIRQPPGK CLELIGYIHS SGYTDYNPSL 300
KSRVTISGDT SKKQFSLKLS SVTAADTAVY YCARADWDRL RALDIWGQGT 350
MVTVSSGGGG SGGGGSGGGG SGGGGSDIQL TQSPSSLSAS VGDRVTITCR 400
ASQSIRSHLN WYQQKPGKAP KLLIYGASNL QSGVPSRFSG SGSGTDFTLT 450
ISSLQPEDFA TYYCQQSTGA WNWFGCGTKV EIKGGGGSGG GGSDKTHTCP 500
PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW 550
YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA 600
LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI 650
AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV 700
MHEALHNHYT QKSLSLSPGK                                  720
```

Light chain / Chaîne légère / Cadena ligera

```
AIQMTQSPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKLLIYS  50
ASTLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCLQ DYNYPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 151-207 259-332 281-476
22"-96" 151"-207" 259"-332" 281"-476"
399-464 534-594 640-698
399"-464" 534"-594" 640"-698"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88"' 134'"-194"'
Inter-H-L (h 5-CL 126) 227-214' 227"-214'"
Inter-H-H (h 11, h 14) 499-499" 502-502"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
570, 570"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

imifoplatinum

imifoplatin — dihydrogen (*SP*-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-κ^2*N*^{1},*N*^{2}][diphosphato(4−)-κ^2*O*^{1},*O*^{3}]platinate(2−)

imifoplatine — dihydrogène (*SP*-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-κ^2*N*^{1},κ*N*^{2}][diphosphato(4-)-κ^2*O*^{1},*O*^{3}]platinate(2-)

imifoplatino — dihidrógeno (*SP*-4-2)-[(1*R*,2*R*)-ciclohexano-1,2-diamina-κ^2*N*^{1},κ*N*^{2}][difosfato(4-)-κ^2*O*^{1},*O*^{3}]platinato(2-)

$C_6H_{16}N_2O_7P_2Pt$



imnopitantum

imnopitant — *N*-{[3,5-bis(trifluoromethyl)phenyl]methyl}-*N*-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridine-3-carboxamide

imnopitant — *N*-{[3,5-bis(trifluorométhyl)phényl]méthyl}-*N*-méthyl-4-(2-méthylphényl)-6-(4-méthylpipérazin-1-yl)pyridine-3-carboxamide

imnopitant — *N*-{[3,5-bis(trifluorometil)fenil]metil}-*N*-metil-4-(2-metilfenil)-6-(4-metilpiperazin-1-il)piridina-3-carboxamida

$C_{28}H_{28}F_6N_4O$



ivaltinostatum

ivaltinostat (2*E*)-*N*^{1}-[3-(dimethylamino)propyl]-*N*^{8}-hydroxy-2-{[(naphthalen-1-yl)oxy]methyl}oct-2-enediamide

ivaltinostat (2*E*)-*N*^{1}-[3-(diméthylamino)propyl]-*N*^{8}-hydroxy-2-{[(naphtalén-1-yl)oxy]méthyl}oct-2-ènediamide

ivaltinostat (2*E*)-*N*^{1}-[3-(dimetilamino)propil]-*N*^{8}-hidroxi-2-{[(naftalen-1-il)oxi]metil}oct-2-enodiamida

$C_{24}H_{33}N_3O_4$



ivuxolimabum #

ivuxolimab immunoglobulin G2-kappa, anti-[*Homo sapiens* TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, OX40, CD134)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain *Homo sapiens* (1-444) [VH (*Homo sapiens* IGHV3-48*02 (99.0%) -(IGHD) -IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), hinge 1-12 (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1D-16*01 (100%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide, produced in Chinese hamster ovary (CHO)-K1SV cell line, glycoform alfa

ivuxolimab immunoglobuline G2-kappa, anti-[*Homo sapiens* TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal *Homo sapiens*;
chaîne lourde gamma2 *Homo sapiens* (1-444) [VH (*Homo sapiens* IGHV3-48*02 (99.0%) -(IGHD) -IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), charnière 1-12 (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1D-16*01 (100%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (220-220":221-221":224-224":227-227")-tétrakisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire K1SV, glycoforme alfa

ivuxolimab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma2 *Homo sapiens* (1-444) [VH (*Homo sapiens* IGHV3-48*02 (99.0%) -(IGHD) -IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), bisagra 1-12 (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1D-16*01 (100%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (220-220":221-221":224-224":227-227")-tetrakisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular K1SV, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSY  50
ISSSSSTIDY ADSVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCARES 100
GWYLFDYWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPPTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 258-318 364-422
22"-96" 145"-201" 258"-318" 364"-422"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (CH1 10-CL 126) 132-214' 132"-214'"
Inter-H-H (h 4, h 5, h 8, h 11) 220-220" 221-221" 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

izencitinibum

izencitinib

3-[(1*R*,3*s*,5*S*)-3-({7-[(5-methyl-1*H*-pyrazol-3-yl)amino]-1,6-naphthyridin-5-yl}amino)-8-azabicyclo[3.2.1]octan-8-yl]propanenitrile

izencitinib

3-[(1*R*,3*s*,5*S*)-3-({7-[(5-méthyl-1*H*-pyrazol-3-yl)amino]-1,6-naphtyridin-5-yl}amino)-8-azabicyclo[3.2.1]octan-8-yl]propanenitrile

izencitinib

3-[(1*R*,3*s*,5*S*)-3-({7-[(5-metil-1*H*-pirazol-3-il)amino]-1,6-naftiridin-5-il}amino)-8-azabiciclo[3.2.1]octan-8-il]propanonitrilo

$C_{22}H_{26}N_8$



lenacapavirum

lenacapavir

N-[(1*S*)-1-{3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1*H*-indazol-7-yl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2-[(3b*S*,4a*R*)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1*H*-cyclopropa[3,4]cyclopenta[1,2-*c*]pyrazol-1-yl]acetamide

lénacapavir

N-[(1*S*)-1-{3-[4-chloro-3-(méthanesulfonamido)-1-(2,2,2-trifluoroéthyl)-1*H*-indazol-7-yl]-6-[3-(méthanesulfonyl)-3-méthylbut-1-yn-1-yl]pyridin-2-yl}-2-(3,5-difluorophényl)éthyl]-2-[(3b*S*,4a*R*)-5,5-difluoro-3-(trifluorométhyl)-3b,4,4a,5-tétrahydro-1*H*-cyclopropa[3,4]cyclopenta[1,2-*c*]pyrazol-1-yl]acetamide

lenacapavir

N-[(1*S*)-1-{3-[4-cloro-3-(metanosulfonamido)-1-(2,2,2-trifluoroetil)-1*H*-indazol-7-il]-6-[3-(metanosulfonil)-3-metilbut-1-in-1-il]piridin-2-il}-2-(3,5-difluorofenil)etil]-2-[(3b*S*,4a*R*)-5,5-difluoro-3-(trifluorometil)-3b,4,4a,5-tetrahidro-1*H*-ciclopropa[3,4]ciclopenta[1,2-*c*]pirazol-1-il]acetamida

$C_{39}H_{32}ClF_{10}N_7O_5S_2$



letetresgenum autoleucelum #

letetresgene autoleucel

Autologous CD4+ and CD8+ T cells, transduced with a non-replicating human immunodeficiency virus (HIV)-derived self-inactivating (SIN) vector that comprises a 5' LTR (RSV*-R-U5) and a 3' U3 deleted LTR (U5-R-HIV-1Delta 3'LTR), encoding an affinity enhanced NY-ESO-1 (autoimmunogenic cancer/testis antigen NY-ESO-1, CTAG1A, L antigen family member 2, LAGE-2) specific T cell receptor (TCR), under the control of elongation factor 1 alpha (EF1a) promoter. The vector is pseudotyped with vesicular stomatitis virus glycoprotein-G (VSV-G).
* RSV: Rous sarcoma virus

lététresgéne autoleucel

Lymphocytes T CD4+ et CD8+ autologues, transduits par un vecteur auto-inactivant (SIN), non-répliquant, dérivé du virus de l'immunodéficiencence humaine (VIH), contenant une séquence LTR (terminale longue répétée) en 5' (RSV*-R-U5) et une séquence LTR dont le domaine U3 est supprimé (U5-R-HIV-1Delta 3'LTR), et qui code pour un récepteur des lymphocytes T (TCR) dont l'affinité est augmentée, spécifique du NY-ESO-1 (antigène autoimmunogénique associé au cancer du testicule NY-ESO-1, CTAG1A, membre 2 de la famille de l'antigène L, LAGE-2), sous le contrôle d'un promoteur du facteur d'élongation alpha 1 (EF1a). Le vecteur est pseudotypé avec la glycoprotéine G de l'enveloppe de la stomatite vésiculaire (VSV-G).
* RSV: virus du sarcome de Rous

letetresgèn autoleucel

Linfocitos T CD4+ y CD8+ autólogos, transducidos con un vector auto-inactivante (SIN), no replicativo, derivado del virus de la inmunodeficiencia humana (VIH), que contiene una LTR en 5' (RSV*-R-U5) y una LTR con U3 delecionada en 3' (U5-R-HIV-1Delta 3'LTR), y que codifica para un receptor de linfocitos T (TCR) con afinidad aumentada, específico para NY-ESO-1 (antígeno de cáncer/testículos autoinmunogénico NY-ESO-1, CTAG1A, miembro 2 de la familia de antígenos L, LAGE-2), bajo el control del promotor del factor de elongación alfa 1 (EF1a). El vector está seudotipado con la glicoproteína G del virus de la estomatitis vesicular (VSV-G).
* RSV: virus del sarcoma de Rous

linperlisibum

linperlisib

N-{5-[6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-(morpholin-4-yl)quinazolin-4-yl]-2-methoxypyridin-3-yl}methanesulfonamide

linperlisib

N-{5-[6-fluoro-8-{[4-(2-hydroxypropan-2-yl)pipéridin-1-yl]méthyl}-2-(morpholin-4-yl)quinazolin-4-yl]-2-méthoxypyridin-3-yl}méthanesulfonamide

linperlisib

N-{5-[6-fluoro-8-{[4-(2-hidroxipropan-2-il)piperidin-1-il]metil}-2-(morfolin-4-il)quinazolin-4-il]-2-metoxipiridin-3-il}metanosulfonamida

$C_{28}H_{37}FN_6O_5S$



lodapolimabum #

lodapolimab

immunoglobulin G1-lambda, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV1-69*06 (100%) -(IGHD) -IGHJ6*01 (100%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>E (241), G1>A (243), A115>S (336), P116>S (337) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfide with lambda light chain *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV1-44*01 (91.8%) -IGLJ2*01 (90.9%)) [8.3.11] (1'-110') -*Homo sapiens* IGLC2*01 T124>A (213) (99.1%) (111'-216')]; dimer (232-232":235-235")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

lodapolimab

immunoglobuline G1-lambda, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV1-69*06 (100%) -(IGHD) - IGHJ6*01 (100%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (220) (124-221), charnière 1-15 (222-236), CH2 L1.3>A (240), L1.2>E (241), G1>A (243), A115>S (336), P116>S (337) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV1-44*01 (91.8%) -IGLJ2*01 (90.9%)) [8.3.11] (1'-110') -*Homo sapiens* IGLC2*01 T124>A (213) (99.1%) (111'-216')]; dimère (232-232":235-235")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

lodapolimab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV1-69*06 (100%) -(IGHD) - IGHJ6*01 (100%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (220) (124-221), bisagra 1-15 (222-236), CH2 L1.3>A (240), L1.2>E (241), G1>A (243), A115>S (336), P116>S (337) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfuro con la cadena ligera lambda *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV1-44*01 (91.8%) -IGLJ2*01 (90.9%)) [8.3.11] (1'-110') -*Homo sapiens* IGLC2*01 T124>A (213) (99.1%) (111'-216')]; dímero (232-232":235-235")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWVRQA PGQGLEWMGG  50
IIPIFGTANY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARSP 100
DYSPYYYYGM DVWGQGTTVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEA EGAPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPSSIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG SNTVNWYQQL PGTAPKLLIY  50
GNSNRPSGVP DRFSGSKSGT SASLAISGLQ SEDEADYYCQ SYDSSLSGSV 100
FGGGIKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APAECS                                       216
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 150-206 267-327 373-431
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L (C23-C104) 22'-89' 138'-197'
22'"-89'" 138'"-197'"
Inter-H-L (h 5-CL 126) 226-215' 226"-215'"
Inter-H-H (h 11, h 14) 232-232" 235-235"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
303, 303"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

C-terminal lysine clipping:
H CHS K2:
453, 453"

lomardexamfetaminum

lomardexamfetamine — (2*S*)-2-amino-6-(carbamimidoylamino)-*N*-[(2*S*)-1-phenylpropan-2-yl]hexanamide

lomardexamfétamine — (2*S*)-2-amino-6-(carbamimidoylamino)-*N*-[(2*S*)-1-phénylpropan-2-yl]hexanamide

lomardexamfetamina — (2*S*)-2-amino-6-(carbamimidoilamino)-*N*-[(2*S*)-1-fenilpropan-2-il]hexanamida

$C_{16}H_{27}N_5O$



lonodelestatum

lonodelestat — 1,13-anhydro[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2*S*)-2-aminodecanoyl-L-α-glutamyl-L-threonine]

lonodélestat — 1,13-anhydro[L-alanyl-L-séryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2*S*)-2-aminodécanoyl-L-α-glutamyl-L-thréonine]

lonodelestat — 1,13-anhidro[L-alanil-L-seril-L-isoleucil-L-prolil-L-prolil-L-glutaminil-L-lisil-L-tirosil-D-prolil-L-prolil-(2*S*)-2-aminodecanoil-L-α-glutamil-L-treonina]

$C_{71}H_{111}N_{15}O_{19}$



manelimabum #

manelimab — immunoglobulin G1-lambda, anti-[*Homo sapiens* CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-452) [VH (*Homo sapiens* IGHV3-20*01 (92.9%) -(IGHD) -IGHJ5*01 (100%)) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01v, G1m17>G1m3, G1m1 (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>A (239), L1.2>A (240) (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-215')-disulfide with lambda light chain (1'-216') [V-LAMBDA (*Homo sapiens* IGLV8-61*01 (85.6%) -IGLJ2*01 (90.9%)) [9.3.10] (1'-110') -*Homo sapiens* IGLC2*01 (100%) (111'-216')]; dimer (231-231":234-234")-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1-S cell line, glycoform alfa

manélimab

immunoglobuline G1-lambda, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 (1-452) [VH (*Homo sapiens* IGHV3-20*01 (92.9%) -(IGHD) -IGHJ5*01 (100%)) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01v, G1m17>G1m3,G1m1 (CH1 R120 (219) (123-220), charnière 1-15 (221-235), CH2 L1.3>A (239), L1.2>A (240) (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-215')-disulfure avec la chaîne légère lambda (1'-216') [V-LAMBDA (*Homo sapiens* IGLV8-61*01 (85.6%) -IGLJ2*01 (90.9%)) [9.3.10] (1'-110') -*Homo sapiens* IGLC2*01 (100%) (111'-216')]; dimère (231-231":234-234")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire K1-S, glycoforme alfa

manelimab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma1 (1-452) [VH (*Homo sapiens* IGHV3-20*01 (92.9%) -(IGHD) -IGHJ5*01 (100%)) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01v, G1m17>G1m3,G1m1 (CH1 R120 (219) (123-220), bisagra 1-15 (221-235), CH2 L1.3>A (239), L1.2>A (240) (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-215')-disulfuro con la cadena ligera lambda (1'-216') [V-LAMBDA (*Homo sapiens* IGLV8-61*01 (85.6%) -IGLJ2*01 (90.9%)) [9.3.10] (1'-110') -*Homo sapiens* IGLC2*01 (100%) (111'-216')]; dímero (231-231":234-234")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular K1-S, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVRPGGSLRL SCAASGFTFD DYAMSWVRQA PGKGLEWVSD  50
ISWSGSNTNY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYHCARAP 100
LLLAMTFGVG SWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPEAA GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
QTVVTQEPSL SVSPGGTVTL TCGLSSGTVT AINYPGWYQQ TPGQAPRTLI  50
YNTNTRHSGV PDRFSGSISG NKAALTITGA QAEDEADYYC ALYMGNGGHM 100
FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                       216
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	266-326	372-430
	22"-96"	149"-205"	266"-326"	372"-430"
Intra-L (C23-C104)	22'-90'	138'-197'		
	22'"-90'"	138'"-197'"		
Inter-H-L (h 5-CL 126)	225-215'	225"-215'"		
Inter-H-H (h 11, h 14)	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

mesdopetamum

mesdopetam — *N*-{2-[3-fluoro-5-(methanesulfonyl)phenoxy]ethyl}propan-1-amine

mesdopétam — *N*-{2-[3-fluoro-5-(méthanesulfonyl)phénoxy]éthyl}propan-1-amine

mesdopetam — *N*-{2-[3-fluoro-5-(metanosulfonil)fenoxi]etil}propan-1-amina

$C_{12}H_{18}FNO_3S$



mevociclibum

mevociclib — *N*-[(1*S*,3*R*)-3-{[5-chloro-4-(1*H*-indol-3-yl)pyrimidin-2-yl]amino}-1-methylcyclohexyl]-5-[(2*E*)-4-(dimethylamino)but-2-enamido]pyridine-2-carboxamide

mévociclib — *N*-[(1*S*,3*R*)-3-{[5-chloro-4-(1*H*-indol-3-yl)pyrimidin-2-yl]amino}-1-méthylcyclohexyl]-5-[(2*E*)-4-(diméthylamino)but-2-énamido]pyridine-2-carboxamide

mevociclib — *N*-[(1*S*,3*R*)-3-{[5-cloro-4-(1*H*-indol-3-il)pirimidin-2-il]amino}-1-metilciclohexil]-5-[(2*E*)-4-(dimetilamino)but-2-enamido]piridina-2-carboxamida

$C_{31}H_{35}ClN_8O_2$



mezagitamabum #

mezagitamab — immunoglobulin G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosyl cyclase 1)], monoclonal antibody; gamma1 heavy chain humanized (1-453) [VH (*Homo sapiens* IGHV3-23*01 (88.8%) -(IGHD) -IGHJ1*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (100%), G1m3, nG1m1 (CH1 R120 (220) (124-221), hinge 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfide with lambda light chain humanized (1'-216') [V-LAMBDA (*Homo sapiens* IGLV1-47*01 (91.8%) -IGLJ2*01 (100%)) [8.3.11] (1'-110') -*Homo sapiens* IGLC1*02 (100%) (111-216')]; dimer (232-232":235-235")-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1SV cell line, glycoform alfa

mézagitamab — immunoglobuline G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosyl cyclase 1)], anticorps monoclonal;

	chaîne lourde gamma1 humanisée (1-453) [VH (*Homo sapiens* IGHV3-23*01 (88.8%) -(IGHD) -IGHJ1*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (100%), G1m3, nG1m1 (CH1 R120 (220) (124-221), charnière 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfure avec la chaîne légère lambda humanisée (1'-216') [V-LAMBDA (*Homo sapiens* IGLV1-47*01 (91.8%) -IGLJ2*01 (100%)) [8.3.11] (1'-110') -*Homo sapiens* IGLC1*02 (100%) (111-216')]; dimère (232-232":235-235")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire K1SV, glycoforme alfa
mezagitamab	inmunoglobulina G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosil ciclasa 1)], anticuerpo monoclonal; cadena pesada gamma1 humanizada (1-453) [VH (*Homo sapiens* IGHV3-23*01 (88.8%) -(IGHD) -IGHJ1*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (100%), G1m3, nG1m1 (CH1 R120 (220) (124-221), bisagra 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-215')-disulfuro con la cadena ligera lambda humanizada (1'-216') [V-LAMBDA (*Homo sapiens* IGLV1-47*01 (91.8%) -IGLJ2*01 (100%)) [8.3.11] (1'-110') -*Homo sapiens* IGLC1*02 (100%) (111-216')]; dímero (232-232":235-235")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular K1SV, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFD DYGMSWVRQA PGKGLEWVSD  50
ISWNGGKTHY VDSVKGQFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGS 100
LFHDSSGFYF GHWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG DNYVSWYQQL PGTAPKLLIY  50
RDSQRPSGVP DRFSGSKSGT SASLAISGLR SEDEADYYCQ SYDSSLSGSV 100
FGGGTKLTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                       216
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 150-206 267-327 373-431
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L (C23-C104) 22'-89' 138'-197'
22'"-89'" 138'"-197'"
Inter-H-L (h 5-CL 126) 226-215' 226"-215'"
Inter-H-H (h 11, h 14) 232-232" 235-235"

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
L VL Q1:
1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
303, 303"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

milategrastum

milategrast	1-(ciclopropylmethyl)-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine

milatégrast — 1-(cyclopropylméthyl)-4-[2-(3,3,5,5-tétraméthylcyclohexyl)phényl]piperazine

milategrast — 1-(ciclopropilmetil)-4-[2-(3,3,5,5-tetrametilciclohexil)fenil]piperazine

$C_{24}H_{38}N_2$



mipetresgenum autoleucelum #

mipetresgene autoleucel — Autologous T cells, transduced with a replication incompetent Moloney murine leukemia virus (MoMLV) (a retrovirus) vector that encodes a T cell receptor (TCR) that recognizes NY-ESO-1 protein (cancer/testis antigen 1, autoimmunogenic cancer/testis antigen NY-ESO-1, CTAG1A, L antigen family member 2, LAGE-2).

mipétresgène autoleucel — Lymphocytes T autologues transduits par un vecteur du virus de la leucémie murine de Moloney (MoMLV) (un retrovirus) incompétent pour la replication et codant pour un récepteur des lymphocytes T (TCR) reconnaissant la protéine NY-ESO-1 (antigène autoimmunogénique associé au cancer du testicule NY-ESO-1, CTAG1A, membre 2 de la famille de l'antigène L, LAGE-2).

mipetresgén autoleucel — Linfocitos T autólogos transducidos con un vector del virus de la leucemia murina de Moloney (MoMLV) (un retrovirus) incompetente para replicación que codifica para un receptor de linfocitos T (TCR) que reconoce la proteína NY-ESO-1 (antígeno 1 de cáncer/testículos, antígeno autoinmunogénico de cáncer/testículos NY-ESO-1, CTAG1A, miembro 2 de la familia de antígenos L, LAGE-2).

mirzotamabum #

mirzotamab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], monoclonal antibody;
gamma1 heavy chain chimeric (1-446) [VH (*Mus musculus* IGHV3-1*02 (86.6%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens* IGHV4-38-2*01 (83.5%) -(IGHD) -IGHJ4*01 (86.7%)) [9.7.9] (1-116) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.2%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

mirzotamab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticorps monoclonal;
chaîne lourde gamma1 chimérique (1-446) [VH (*Mus musculus* IGHV3-1*02 (86.6%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens* IGHV4-38-2*01 (83.5%) -(IGHD) -IGHJ4*01 (86.7%)) [9.7.9] (1-116) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (213) (117-214), charnière 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.2%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (225-225":228-228")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

mirzotamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticuerpo monoclonal;
cadena pesada gamma1 quimérica (1-446) [VH (*Mus musculus* IGHV3-1*02 (86.6%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens* IGHV4-38-2*01 (83.5%) -(IGHD) -IGHJ4*01 (86.7%)) [9.7.9] (1-116) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (213) (117-214), bisagra 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.2%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (225-225":228-228")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQESGPG LVKPSETLSL TCAVTGYSIT SGYSWHWIRQ FPGNGLEWMG  50
YIHSSGSTNY NPSLKSRISI SRDTSKNQFF LKLSSVTAAD TAVYYCAGYD 100
DYFEYWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQNVG FNVAWYQQKP GKSPKALIYS  50
ASYRYSGVPS RFSGSGSGTD FTLTISSLQP EDFAEYFCQQ YNWYPFTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 143-199 260-320 366-424
22"-96" 143"-199" 260"-320" 366"-424"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 219-214' 219"-214'"
Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

mirzotamabum clezutoclaxum #

mirzotamab clezutoclax	immunoglobulin G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], monoclonal antibody, conjugated with clezutoclax, an inhibitor of BCL2L1 (BCL2-like 1, BCL-XL); gamma1 heavy chain chimeric (1-446) [VH (*Mus musculus* IGHV3-1*02 (86.6%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens* IGHV4-38-2*01 (83.5%) -(IGHD) -IGHJ4*01 (86.7%)) [9.7.9] (1-116) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.2%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; conjugated, on an average of 2 cysteinyl, with clezutoclax, comprising a cleavable dipeptide (valine-alanine) linker
mirzotamab clezutoclax	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticorps monoclonal; conjugué au clézutoclax, un inhibiteur de BCL2L1 (protéine 1 apparentée au BCL2, BCL-XL); chaîne lourde gamma1 chimérique (1-446) [VH (*Mus musculus* IGHV3-1*02 (86.6%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens* IGHV4-38-2*01 (83.5%) -(IGHD) -IGHJ4*01 (86.7%)) [9.7.9] (1-116) -*Homo sapiens* IGHG1*03v, G1m3>G1m17,1, nG1m1 (CH1 R120>K (213) (117-214), charnière 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.2%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa; conjugué, sur 2 cystéines en moyenne, au clézutoclax, comprenant un linker dipeptide (valine-alanine) clivable
mirzotamab clezutoclax	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticuerpo monoclonal; conjugado con clezutoclax, un inhibidor de BCL2L1 (proteína 1 vinculada con BCL2, BCL-XL); cadena pesada gamma1 quimérica (1-446) [VH (*Mus musculus* IGHV3-1*02 (86.6%) -(IGHD) -IGHJ2*01 (86.7%)/*Homo sapiens* IGHV4-38-2*01 (83.5%) -(IGHD) -IGHJ4*01 (86.7%)) [9.7.9] (1-116) -*Homo sapiens* IGHG1*03v, G1m3>G1m17,1, nG1m1 (CH1 R120>K (213) (117-214), bisagra 1-15 (215-229), CH2 L1.3>A (233), L1.2>A (234) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.2%) -IGKJ2*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa; conjugado, con 2 restos de cisteínas por término medio, con clézutoclax, que comprende un vinculador dipéptido (valina-alanina) escindible

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQESGPG LVKPSETLSL TCAVTGYSIT SGYSWHWIRQ FPGNGLEWMG  50
YIHSSGSTNY NPSLKSRISI SRDTSKNQFF LKLSSVTAAD TAVYYCAGYD 100
DYFEYWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQNVG FNVAWYQQKP GKSPKALIYS  50
ASYRYSGVPS RFSGSGSGTD FTLTISSLQP EDFAEYFCQQ YNWYPFTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 260-320 366-424
22"-96" 143"-199" 260"-320" 366"-424"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126)* 219-214' 219"-214'"
Inter-H-H (h 11, h 14) 225-225" 228-228"

*One of the inter-chain disulfide bridges is not present, an average of 2 cysteinyl being conjugated each via a thioether bond to a drug linker. *Un des ponts disulfures inter-chaînes n'est pas présent, 2 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif. *Falta uno de los puentes disulfuro inter-catenarios, una media de 2 cisteinil está conjugada a conector y principio activo.



N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
296, 296"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

mobocertinibum

mobocertinib — propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1*H*-indol-3-yl)pyrimidine-5-carboxylate

mobocertinib — 2-[4-{[2-(diméthylamino)éthyl](méthyl)amino}-2-méthoxy-5-(prop-2-énamido)anilino]-4-(1-méthyl-1*H*-indol-3-yl)pyrimidine-5-carboxylate de propan-2-yle

mobocertinib — 2-[4-{[2-(dimetilamino)etil](metil)amino}-2-metoxi-5-(prop-2-enamido)anilino]-4-(1-metil-1*H*-indol-3-il)pirimidina-5-carboxilato de propan-2-ilo

$C_{32}H_{39}N_7O_4$



monomethylis fumaras

monomethyl fumarate	(2*E*)-4-methoxy-4-oxobut-2-enoic acid
fumarate de monométhyle	acide (2*E*)-4-méthoxy-4-oxobut-2-énoïque
fumarato de monometilo	ácido (2*E*)-4-metoxi-4-oxobut-2-enoico

$C_5H_6O_4$



narsoplimabum #

narsoplimab	immunoglobulin G4-lambda, anti-[*Homo sapiens* MASP2 (mannan-binding lectin serine peptidase 2, mannan-binding lectin serine protease 2, mannan-binding lectin serine protease 1 pseudogene 1, MASP1P1)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV2-26*01 (94.0%) -(IGHD) -IGHJ4*01 (100%)) [10.7.10] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-211')-disulfide with lambda light chain *Homo sapiens* (1'-212') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (93.5%) -IGLJ2*01 (100%)) [6.3.9] (1'-106') -*Homo sapiens* IGLC2*01 (100%) (107'-212')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO)-S cell line, glycoform alfa
narsoplimab	immunoglobuline G4-lambda, anti-[*Homo sapiens* MASP2 (sérine peptidase 2 de la lectine liant le mannane, sérine protéase 2 de la lectine liant le mannane, pseudogène 1 de la protéase 1 de la lectine liant le mannane, MASP1P1)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV2-26*01 (94.0%) -(IGHD) -IGHJ4*01 (100%)) [10.7.10] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), charnière 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-211')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-212') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (93.5%) -IGLJ2*01 (100%)) [6.3.9] (1'-106') -*Homo sapiens* IGLC2*01 (100%) (107'-212')]; dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire S, glycoforme alfa
narsoplimab	inmunoglobulina G4-lambda, anti-[*Homo sapiens* MASP2 (serina peptidasa 2 de la lectina que se une al manano, serina proteasa 2 de la lectina unida al manano, pseudogen 1 de la proteasa 1 de la lectina unida al manano, MASP1P1)], anticuerpo monoclonal *Homo sapiens*;

cadena pesada gamma1 *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV2-26*01 (94.0%) -(IGHD) - IGHJ4*01 (100%)) [10.7.10] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), bisagra 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-211')-disulfuro con la cadena ligera lambda *Homo sapiens* (1'-212') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (93.5%) -IGLJ2*01 (100%)) [6.3.9] (1'-106') -*Homo sapiens* IGLC2*01 (100%) (107'-212')];
dímero (224-224":227-227")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular S, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVTLKESGPV LVKPTETLTL TCTVSGFSLS RGKMGVSWIR QPPGKALEWL  50
AHIFSSDEKS YRTSLKSRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100
RRGGIDYWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
QPVLTQPPSL SVSPGQTASI TCSGEKLGDK YAYWYQQKPG QSPVLVMYQD  50
KQRPSGIPER FSGSNSGNTA TLTISGTQAM DEADYYCQAW DSSTAVFGGG 100
TKLTVLGQPK AAPSVTLFPP SSEELQANKA TLVCLISDFY PGAVTVAWKA 150
DSSPVKAGVE TTTPSKQSNN KYAASSYLSL TPEQWKSHRS YSCQVTHEGS 200
TVEKTVAPTE CS                                          212
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 145-201 259-319 365-423
22"-97" 145"-201" 259"-319" 365"-423"
Intra-L (C23-C104) 22'-87' 134'-193'
22'"-87'" 134'"-193'"
Inter-H-L (CH1 10-CL 126) 132-211' 132"-211'"
Inter-H-H (h 8, h 11) 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
445, 445"

navafenterolum

navafenterol	*trans*-4-[{3-[5-({[(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-1*H*-1,2,3-benzotriazol-1-yl]propyl}(methyl)amino]cyclohexyl hydroxydi(thiophen-2-yl)acetate
navafentérol	hydroxydi(thiophén-2-yl)acétate de *trans*-4-[{3-[5-({[(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinoléin-5-yl)éthyl]amino}méthyl)-1*H*-1,2,3-benzotriazol-1-yl]propyl}(méthyl)amino]cyclohexyle
navafenterol	hidroxidi(tiofen-2-il)acetato de *trans*-4-[{3-[5-({[(2*R*)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolein-5-il)etil]amino}metil)-1*H*-1,2,3-benzotriazol-1-il]propil}(metil)amino]ciclohexilo

$C_{38}H_{42}N_6O_6S_2$



navocaftorum

navocaftor — (5-{3-amino-5-[4-(trifluoromethoxy)benzene-1-sulfonyl]pyridin-2-yl}-1,3,4-oxadiazol-2-yl)methanol

navocaftor — (5-{3-amino-5-[4-(trifluorométhoxy)benzène-1-sulfonyl]pyridin-2-yl}-1,3,4-oxadiazol-2-yl)methanol

navocaftor — (5-{3-amino-5-[4-(trifluorometoxi)benceno-1-sulfonil]piridin-2-il}-1,3,4-oxadiazol-2-il)methanol

$C_{15}H_{11}F_3N_4O_5S$



nelonemdazum

nelonemdaz — 2-hydroxy-5-({[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methyl}amino)benzoic acid

nélonemdaz — acide 2-hydroxy-5-({[2,3,5,6-tétrafluoro-4-(trifluorométhyl)phényl]méthyl}amino)benzoïque

nelonemdaz — ácido 2-hidroxi-5-({[2,3,5,6-tetrafluoro-4-(trifluorometil)fenil]metil}amino)benzoico

$C_{15}H_8F_7NO_3$



nerindocianinum

nerindocianine — 2-{(1*E*)-2-[3-{(2*E*)-2-[3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)-1,3-dihydro-2*H*-indol-2-ylidene]ethylidene}-2-(4-sulfophenoxy)cyclohex-1-en-1-yl]ethen-1-yl}-3,3-dimethyl-1-(4-sulfobutyl)-3*H*-indol-1-ium-5-sulfonate

nérindocianine — 2-{(1*E*)-2-[3-{(2*E*)-2-[3,3-diméthyl-5-sulfo-1-(4-sulfobutyl)-1,3-dihydro-2*H*-indol-2-ylidène]éthylidène}-2-(4-sulfophénoxy)cyclohex-1-én-1-yl]éthén-1-yl}-3,3-diméthyl-1-(4-sulfobutyl)-3*H*-indol-1-ium-5-sulfonate

nerindocianina

2-{(1*E*)-2-[3-{(2*E*)-2-[3,3-dimetil-5-sulfo-1-(4-sulfobutil)-1,3-dihidro-2*H*-indol-2-ilideno]etilideno}-2-(4-sulfofenoxi)ciclohex-1-en-1-il]eten-1-il}-3,3-dimetil-1-(4-sulfobutil)-3*H*-indol-1-ium-5-sulfonato

$C_{44}H_{52}N_2O_{16}S_5$



nogapendekinum alfa #

nogapendekin alfa

human interleukin 15 [72-aspartic acid] (human IL-15 N72>D isoform), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

nogapendékine alfa

interleukine 15 humaine [72-acide aspartique] (IL-15 humaine, isoforme N72>D), produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

nogapendekina alfa

interleukina 15 humana [72-ácido aspártico] (IL-15 humana, isoforma N72>D), producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia:

```
NWVNVISDLK KIEDLIQSMH IDATLYTESD VHPSCKVTAM KCFLLELQVI 50
SLESGDASIH DTVENLIILA NDSLSSNGNV TESGCKECEE LEEKNIKEFL 100
QSFVHIVQMF INTS                                        114
```

Disulfide bridge locations / Positions des ponts disulfure / Posiciónes de los puentes disulfuro
35-85, 42-88

Glycosylation site (N) / Site de glycosylation (N) / Posición de glicosilación (N)
Asn-79 (partially)

numidargistatum

numidargistat

(3*R*,4*S*)-3-amino-1-[(2*S*)-2-aminopropanoyl]-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid

numidargistat

acide (3*R*,4*S*)-3-amino-1-[(2*S*)-2-aminopropanoyl]-4-(3-boronopropyl)pyrrolidine-3-carboxylique

numidargistat

ácido (3*R*,4*S*)-3-amino-1-[(2*S*)-2-aminopropanoil]-4-(3-boronopropil)pirrolidina-3-carboxílico

$C_{11}H_{22}BN_3O_5$



nurulimabum #

nurulimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-446) [VH (*Homo sapiens* IGHV3-30*01 (93.9%) -(IGHD) - IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01v, G1m17>G1m3, G1m1 (CH1 K120>R (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS G1>del, K2>del) (119-446)], (221-215')-disulfide with kappa light chain *Homo sapiens* (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (97.9%) -IGKJ1*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1-S cell line, glycoform alfa
nurulimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CTLA4 (protéine 4 associée aux lymphocytes T cytotoxiques, CTLA-4, CD152)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-446) [VH (*Homo sapiens* IGHV3-30*01 (93.9%) -(IGHD) - IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01v, G1m17>G1m3, G1m1 (CH1 K120>R (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS G1>del, K2>del) (119-446)], (221-215')-disulfure avec la chaîne légère kappa *Homo sapiens* ((1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (97.9%) - IGKJ1*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire K1-S, glycoforme alfa
nurulimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CTLA4 (proteína 4 asociada con linfocitos T citotóxicas, CTLA-4, CD152)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 *Homo sapiens* (1-446) [VH (*Homo sapiens* IGHV3-30*01 (93.9%) -(IGHD) - IGHJ4*01 (100%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01v, G1m17>G1m3, G1m1 (CH1 K120>R (215) (119-216), bisagra 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS G1>del, K2>del) (119-446)], (221-215')-disulfuro con la cadena ligera kappa *Homo sapiens* ((1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (97.9%) - IGKJ1*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (227-227'':230-230'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular K1-S, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVTF  50
ISYDGNNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAIYYCARTG 100
WLGPFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSP     446
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVG SSYLAWYQQK PGQAPRLLIY  50
GAFSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-89' 135'-195'
23'"-89'" 135'"-195'"
Inter-H-L (h 5-CL 126) 221-215' 221"-215'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

obafistatum

obafistat — [8-(3-fluorobenzene-1-sulfonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl](1*H*-1,2,3-triazol-4-yl)methanone

obafistat — [8-(3-fluorobenzène-1-sulfonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl](1*H*-1,2,3-triazol-4-yl)méthanone

obafistat — [8-(3-fluorobenceno-1-sulfonil)-3,8-diazabiciclo[3.2.1]octan-3-il](1*H*-1,2,3-triazol-4-il)metanona

$C_{15}H_{16}FN_5O_3S$



odesivimabum #

odesivimab — immunoglobulin G1-kappa, anti-[*Zaire ebolavirus* (Zaire Ebola virus (EBOV)) envelope glycoprotein (GP)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV3-13*01 (100%) -(IGHD) -IGHJ4*01 (100%)) [8.7.12] (1-118) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain *Homo sapiens* (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (97.0%) -IGKJ4*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')];
dimer (227-227'":230-230")-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cells, glycoform alfa

odésivimab

immunoglobuline G1-kappa, anti-[glycoprotéine d'enveloppe (GP) de *Zaire ebolavirus* (virus Ebola Zaïre (EBOV))], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV3-13*01 (100%) -(IGHD) - IGHJ4*01 (100%)) [8.7.12] (1-118) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (97.0%) -IGKJ4*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

odesivimab

inmunoglobulina G1-kappa, anti-[glicoproteína de envoltura (GP) de *Zaire ebolavirus* (virus Ebola Zaïre (EBOV))], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV3-13*01 (100%) -(IGHD) - IGHJ4*01 (100%)) [8.7.12] (1-118) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (215) (119-216), bisagra 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (97.0%) -IGKJ4*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (227-227'':230-230'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYDMHWVRQA TGKGLEWVSA  50
IGTAGDTYYP GSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARTWF 100
GELYFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSQSVL YSSNNKNYLA WYQQKPGQPP  50
KLLIYWASTR ESGVPDRFSG SGSGTEFTLT ITSLQAEDVA VYYCQQYYSS 100
PLTFGGGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-95 145-201 262-322 368-426
22''-95'' 145''-201'' 262''-322'' 368''-426''
Intra-L (C23-C104) 23'-94' 140'-200'
23'''-94''' 140'''-200'''
Inter-H-L (h 5-CL 126) 221-220' 221''-220''
Inter-H-H (h 11, h 14) 227-227'' 230-230''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

odronextamabum #

odronextamab — immunoglobulin G4-kappa, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)] and anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Homo sapiens* monoclonal antibody, bispecific;
gamma4 heavy chain *Homo sapiens* anti-MS4A1 (1-453) [VH (*Homo sapiens* IGHV3-9*01 (94.9%) -(IGHD) -IGHJ6*01 (95.0%)) [8.8.20] (1-127) -*Homo sapiens* IGHG4*01 (CH1 (128-225), hinge 1-12 S10>P (235) (226-237), CH2 EF(1.4-1.3)>P (240), L1.2>V(241), G1.1>A (242) (238-346), CH3 (347-451), CHS (452-453)) (128-453)], (141-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (97.9%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')],
gamma4 heavy chain *Homo sapiens* anti-CD3E (1''-449'') [VH (*Homo sapiens* IGHV3-9*01 (98.0%) -(IGHD) -IGHJ6*01 (89.5%)) [8.8.16] (1''-123'') -*Homo sapiens* IGHG4*01 (CH1 (124-221), hinge 1-12 S10>P (231) (222''-233''), CH2 EF(1.4-1.3)>P (236), L1.2>V(237), G1.1>A (238) (234''-342''), CH3 H115>R (437), Y116>F(438) (343''-447''), CHS (448-449)) (124''-449'')], (137''-214''')-disulfide with kappa light chain *Homo sapiens* (1'''-214''') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (97.9%) -IGKJ4*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimer (233-229'':236-232'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cells, glycoform alfa

odronextamab — immunoglobuline G4-kappa, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)] et anti-[*Homo sapiens* CD3E (CD3 epsilon)], anticorps monoclonal *Homo sapiens* bispécifique;
chaîne lourde gamma4 *Homo sapiens* anti-MS4A1 (1-453) [VH (*Homo sapiens* IGHV3-9*01 (94.9%) -(IGHD) -IGHJ6*01 (95.0%)) [8.8.20] (1-127) -*Homo sapiens* IGHG4*01 (CH1 (128-225), charnière 1-12 S10>P (235) (226-237), CH2 EF(1.4-1.3)>P (240), L1.2>V(241), G1.1>A (242) (238-346), CH3 (347-451), CHS (452-453)) (128-453)], (141-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (97.9%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
chaîne lourde gamma4 *Homo sapiens* anti-CD3E (1''-449'') [VH (*Homo sapiens* IGHV3-9*01 (98.0%) -(IGHD) -IGHJ6*01 (89.5%)) [8.8.16] (1''-123'') -*Homo sapiens* IGHG4*01 (CH1 (124-221), charnière 1-12 S10>P (231) (222-233), CH2 EF(1.4-1.3)>P (236), L1.2>V(237), G1.1>A (238) (234-342), CH3 H115>R (437), Y116>F(438) (343-447), CHS (448-449)) (124''-449'')], (137''-214''')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'''-214''') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (97.9%) -IGKJ4*01 (100%)) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimère (233-229'':236-232'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

odronextamab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* MS4A1 (miembro 1 de la sub-familia A de 4 dominios transmembranarios, CD20)] y anti-[*Homo sapiens* CD3E (CD3 épsilon)], anticuerpo monoclonal *Homo sapiens* biespecífico;
cadena pesada gamma4 *Homo sapiens* anti-MS4A1 (1-453) [VH (*Homo sapiens* IGHV3-9*01 (94.9%) -(IGHD) -IGHJ6*01 (95.0%)) [8.8.20] (1-127) -*Homo sapiens* IGHG4*01 (CH1 (128-225), bisagra 1-12 S10>P (235) (226-237), CH2 EF(1.4-1.3)>P (240), L1.2>V(241), G1.1>A (242) (238-346), CH3 (347-451), CHS (452-453)) (128-453)], (141-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (97.9%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (154), V101 (191) (108'-214')];

cadena pesada gamma4 *Homo sapiens* anti-CD3E (1"-449") [VH (*Homo sapiens* IGHV3-9*01 (98.0%) -(IGHD) -IGHJ6*01 (89.5%)) [8.8.16] (1"-123") -*Homo sapiens* IGHG4*01 (CH1 (124-221), bisagra 1-12 S10>P (231) (222-233), CH2 EF(1.4-1.3)>P (236), L1.2>V(237), G1.1>A (238) (234-342), CH3 H115>R (437), Y116>F(438) (343-447), CHS (448-449)) (124"-449")], (137"-214"')-disulfuro con la cadena ligera kappa *Homo sapiens* (1"'-214"') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (97.9%) -IGKJ4*01 (100%)) [6.3.9] (1"'-107"') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108"'-214"')]; dímero (233-229":236-232")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD20)

```
EVQLVESGGG LVQPGRSLRL SCVASGFTFN DYAMHWVRQA PGKGLEWVSV  50
ISWNSDSIGY ADSVKGRFTI SRDNAKNSLY LQMHSLRAED TALYYCAKDN 100
HYGSGSYYYY QYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPP VAGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE 300
QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR 350
EPQVYTLPPS QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS 450
LGK                                                     453
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3)

```
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYTMHWVRQA PGKGLEWVSG  50
ISWNSGSIGY ADSVKGRFTI SRDNAKKSLY LQMNSLRAED TALYYCAKDN 100
SGYGHYYYGM DVWGQGTTVT VASASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNRFTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG  50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQH YINWPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 154-210 267-327 373-431
22"-96" 150"-206" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-88' 134'-194'
23"'-88"' 134"'-194"'
Inter-H-L (CH1 10-CL 126) 141-214' 137"-214"'
Inter-H-H (h 8, h 11) 233-229" 236-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
303, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

olafertinibum

olafertinib	*N*-[3-(2-{2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino}quinazolin-8-yl)phenyl]prop-2-enamide
olafertinib	*N*-[3-(2-{2,3-difluoro-4-[4-(2-hydroxyéthyl)pipérazin-1-yl]anilino}quinazolin-8-yl)phényl]prop-2-énamide
olafertinib	*N*-[3-(2-{2,3-difluoro-4-[4-(2-hidroxietil)piperazin-1-il]anilino}quinazolin-8-il)fenil]prop-2-enamida

$C_{29}H_{28}F_2N_6O_2$



olitresgenum autoleucelum #

olitresgene autoleucel

autologous CD4+ and CD8+ T cells, transduced with a non-replicating human immunodeficiency virus (HIV)-derived self-inactivating (SIN) vector that comprises a 5' LTR (RSV*-R-U5) and a 3' U3 deleted LTR (U5-R-HIV-1Delta 3'LTR), encoding a MAGEA10 (MAGE family member A10, MAGE-10 antigen, melanoma antigen family A10) specific T cell receptor (TCR), under the control of elongation factor 1 alpha (EF1a) promoter. The vector is pseudotyped with vesicular stomatitis virus glycoprotein-G (VSV-G).
* RSV: Rous sarcoma virus

olitresgène autoleucel

Lymphocytes T CD4+ et CD8+ autologues, transduits par un vecteur auto-inactivant (SIN), non-répliquant, dérivé du virus de l'immunodéficiencence humaine (VIH), contenant une séquence LTR (terminale longue répétée) en 5' (RSV*-R-U5) et une séquence LTR dont le domaine U3 est supprimé (U5-R-VIH-1Delta 3'LTR), et qui code pour un récepteur des lymphocytes T (TCR) spécifique du MAGEA10 (membre A10 de la famille MAGE, antigène MAGE-10, famille des antigens de mélanome A10), sous le contrôle d'un promoteur du facteur d'élongation alpha 1 (EF1a). Le vecteur est pseudotypé avec la glycoprotéine G de l'enveloppe de la stomatite vésiculaire (VSV-G).
* RSV: virus du sarcome de Rous

olitresgén autoleucel

Linfocitos T CD4+ y CD8+ autólogos, transducidos con un vector auto-inactivante (SIN), no replicativo, derivado del virus de la inmunodeficiencia humana(VIH), que contiene una LTR en 5' (RSV*-R-U5) y una LTR con U3 delecionada en 3' (U5-R-HIV-1Delta 3'LTR), y que codifica para un receptor de linfocitos T (TCR) específico para MAGEA10 (miembro A10 de la familia MAGE, antígeno MAGE-10, familia de antígenos de melanoma A10), bajo el control del promotor del factor de elongación alfa 1 (EF1a). El vector está seudotipado con la glicoproteína G del virus de la estomatitis vesicular (VSV-G).
* RSV: virus del sarcoma de Rous

olpasiranum

olpasiran

smal interfering RNA targeting apolipoprotein A (APOA) gene;

	all-P-ambo-5'-*O*-{(25*S*,30*S*)-39-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-25,30-bis[(2-{2-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]ethoxy}ethyl)carbamoyl]-1-hydroxy-23,28,33-trioxo-1-sulfanylidene-2,5,8,11,14,17,20,37-octaoxa-24,29,34-triaza-1λ^5-phosphanonatriacontan-1-yl}-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→3')-2'-deoxyadenosine duplex with *all-P-ambo*-2'-*O*-methyl-*P*-thioguanylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyl-*P*-thioguanylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(5'→3')-2'-*O*-methyluridine
olpasiran	petit ARN interférant ciblant le gène de l'apolipoprotéine A (APOA); *tout-P-ambo*-5'-*O*-{(25*S*,30*S*)-39-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-25,30-bis[(2-{2-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]éthoxy}éthyl)carbamoyl]-1-hydroxy-23,28,33-trioxo-1-sulfanylidène-2,5,8,11,14,17,20,37-octaoxa-24,29,34-triaza-1λ^5-phosphanonatriacontan-1-yl}-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→3')-2'-désoxyadénosine duplex avec *tout-P-ambo*-2'-*O*-méthyl-*P*-thioguanylyl-(5'→3')-2'-désoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-désoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-désoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-désoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyl-*P*-thioguanylyl-(5'→3')-2'-désoxy-2'-fluoro-*P*-thiocytidylyl-(5'→3')-2'-*O*-méthyluridine
olpasirán	ARN pequeño interferante con el géne de la apolipoproteína A (APOA);

todo-P-ambo-5'-*O*-{(25*S*,30*S*)-39-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-25,30-bis[(2-{2-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]etoxi}etil)carbamoil]-1-hidroxi-23,28,33-trioxo-1-sulfanilideno-2,5,8,11,14,17,20,37-octaoxa-24,29,34-triaza-1λ^5-fosfanonatriacontan-1-il}-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→3')-2'-desoxiadenosina dúplex con *todo-P-ambo*-2'-*O*-metil-*P*-tioguanilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metil-*P*-tioguanilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tiocitidilil-(5'→3')-2'-*O*-metiluridina

$C_{490}H_{652}F_{11}N_{164}O_{306}P_{41}S_7$



omidubicelum

omidubicel	allogeneic human umbilical cord blood-derived hematopoietic CD34+ progenitor cells, *ex-vivo* expanded in the presence of *nicotinamide* and cytokines.
omidubicel	cellules progénitrices hématopoïétiques CD34+ humaines, allogéniques, dérivées du sang de cordon ombilical, en culture d'expansion *ex vivo*, en présence de *nicotinamide* et de cytokines.
omidubicel	células progenitoras hematopoyéticas CD34+ alogénicas, humanas, derivadas de sangre de cordón umbilical, expandidas *ex vivo* en presencia de *nicotinamida* y citocinas.

onvansertibum

onvansertib — 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide

onvansertib — 1-(2-hydroxyéthyl)-8-[5-(4-méthylpipérazin-1-yl)-2-(trifluorométhoxy)anilino]-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide

onvansertib — 1-(2-hidroxietil)-8-[5-(4-metilpiperazin-1-il)-2-(trifluorometoxi)anilino]-4,5-dihidro-1*H*-pirazolo[4,3-*h*]quinazolina-3-carboxamida

$C_{24}H_{27}F_3N_8O_3$



orismilastum

orismilast — 3,5-dichloro-4-{2-[7-(difluoromethoxy)-1',1'-dioxo-1'λ^6-spiro[[1,3]benzodioxole-2,4'-thian]-4-yl]-2-oxoethyl}pyridine 1-oxide

orismilast — 1-oxyde de 3,5-dichloro-4-{2-[7-(difluorométhoxy)-1',1'-dioxo-1'λ^6-spiro[[1,3]benzodioxole-2,4'-thian]-4-yl]-2-oxoéthyl}pyridine

orismilast — 1-óxido de 3,5-dicloro-4-{2-[7-(difluorometoxi)-1',1'-dioxo-1'λ^6-spiro[[1,3]benzodioxol-2,4'-tian]-4-il]-2-oxoetil}piridina

$C_{19}H_{15}Cl_2F_2NO_7S$



otenaproxesulum

otenaproxesul — 4-carbamothioylphenyl (2*S*)-2-(6-methoxynaphthalen-2-yl)propanoate

oténaproxésul — (2*S*)-2-(6-méthoxynaphtalén-2-yl)propanoate de 4-carbamothioylphényle

otenaproxesul — (2*S*)-2-(6-metoxinaftalen-2-il)propanoato de 4-carbamotioilfenilo

$C_{21}H_{19}NO_3S$



pacmilimabum #

pacmilimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* CD274 (programmed cell death 1 ligand 1, B7H1, B7-H1, PDL1, PD-L1, PDCD1L1, B7 homolog 1, B7 homologue 1)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV3-23*01 (92.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 (CH1 (117-214), hinge 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS K2>del (442)) (117-442)], (130-264')-disulfide with kappa light chain *Homo sapiens* (1'-264') [N-terminal region (1'-21') -13-mer linker (22'-34') -protease cleavable region (35'-47') -3-mer linker (48'-50') -V-KAPPA (*Homo sapiens* IGKV1-39*01 (95.8%) -IGKJ4*01 (100%)) [6.3.9] (51'-157') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (203), V101 (241) (158'-264')]; dimer (222-222'':225-225'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-derived cell line, glycoform alfa

pacmilimab — immunoglobuline G4-kappa, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, B7H1, B7-H1, PDL1, PD-L1,PDCD1L1, homologue 1 de B7)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma4 *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV3-23*01 (92.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 (CH1 (117-214), charnière 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS K2>del (442)) (117-442)], (130-264')-disulfure avec la chaîne légère kappa *Homo sapiens* ((1'-264') [région N-terminale (1'-21') -13-mer linker (22'-34') -région clivable par des protéases (35'-47') -3-mer linker (48'-50') -V-KAPPA (*Homo sapiens* IGKV1-39*01 (95.8%) -IGKJ4*01 (100%)) [6.3.9] (51'-157') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (203), V101 (241) (158'-264')]; dimère (222-222'':225-225'')-bisdisulfure, produite dans une lignée cellulaire dérivée des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

pacmilimab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* CD274 (ligano 1 de muerte programada, B7H1, B7-H1, PDL1, PD-L1,PDCD1L1, homólogo 1 de B7)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma4 *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV3-23*01 (92.9%) -(IGHD) -IGHJ4*01 (100%)) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 (CH1 (117-214), bisagra 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS K2>del (442)) (117-442)], (130-264')-disulfuro con la cadena ligera kappa *Homo sapiens* ((1'-264') [región N-terminal (1'-21') -conector 13-mer (22'-34') -región escindible por las proteasas (35'-47') -conector 3-mer (48'-50') -V-KAPPA (*Homo sapiens* IGKV1-39*01 (95.8%) -IGKJ4*01 (100%)) [6.3.9] (51'-157') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (203), V101 (241) (158'-264')]; dímero (222-222'':225-225'')-bisdisulfuro, producido en una línea celular derivada de las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSS   50
IWRNGIVTVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWS  100
AAFDYWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP  150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN  200
VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS  250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS  300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS  350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF  400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG          442
```

Light chain / Chaîne légère / Cadena ligera

```
QGQSGSGIAL CPSHFCQLPQ TGGGSSGGSG GSGGISSGLL SGRSDNHGGS   50
DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA  100
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ DNGYPSTFGG  150
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  200
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  250
LSSPVTKSFN RGEC                                         264
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 257-317 363-421
22"-96" 143"-199" 257"-317" 363"-421"
Intra-L (C23-C104) 73'-138' 184'-244'
73'"-138'" 184'"-244'"
Intra-L N-terminal region 11'-16' 11'"-16'"
Inter-H-L (CH1 10-CL 126) 130-264' 130"-264'"
Inter-H-H (h 8, h 11) 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
293, 293"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

paltusotinum

paltusotine — 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile

paltusotine — 3-[4-(4-aminopipéridin-1-yl)-3-(3,5-difluorophényl)quinoléin-6-yl]-2-hydroxybenzonitrile

paltusotina — 3-[4-(4-aminopiperidin-1-il)-3-(3,5-difluorofenil)quinolein-6-il]-2-hidroxibenzonitrilo

$C_{27}H_{22}F_2N_4O$



pamufetinibum

pamufetinib — 4-(2-fluoro-4-{[(phenylacetyl)carbamothioyl]amino}phenoxy)-7-methoxy-*N*-methylquinoline-6-carboxamide

pamufétinib — 4-(2-fluoro-4-{[(phénylacétyl)carbamothioyl]amino}phénoxy)-7-méthoxy-*N*-méthylquinoléine-6-carboxamide

pamufetinib — 4-(2-fluoro-4-{[(fenilacetil)carbamotioil]amino}fenoxi)-7-metoxi-*N*-metilquinoleína-6-carboxamida

$C_{27}H_{23}FN_4O_4S$



patritumabum deruxtecanum #

patritumab deruxtecan

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], *Homo sapiens* monoclonal antibody, conjugated to deruxtecan, comprising a linker and a camptothecin derivative;
gamma1 heavy chain *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV4-34*01 (99.0%) -(IGHD) - IGHJ2*01 (100%)) [8.7.11] (1-117) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (214) (118-215), hinge 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (123-452)], (220-220')-disulfide with kappa light chain *Homo sapiens* (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (95.0%) -IGKJ1*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')];
dimer (226-226'':229-229'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cell line, glycoform alfa; conjugated, on an average of 8 cysteinyl, to deruxtecan, comprising a linker and a camptothecin derivative
For the *deruxtecan* part, please refer to the prop.INN List 116, published in *the WHO Drug Information, Vol.30, No.4, 2016*
.

patritumab déruxtecan

immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], anticorps monoclonal *Homo sapiens,* conjugué au déruxtécan, comprenant un linker et un dérivé de la camptothécine;
chaîne lourde gamma1 *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV4-34*01 (99.0%) -(IGHD) - IGHJ2*01 (100%)) [8.7.11] (1-117) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (214) (118-215), charnière 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (123-452)], (220-220')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (95.0%) -IGKJ1*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')];
dimère (226-226'':229-229'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa; conjugué, sur une moyenne de 8 cystéinyl, au déruxtécan, comprenant un linker et un dérivé de la camptothécine
Pour la partie *déruxtécan*, veuillez-vous référer à la Liste 116 des DCI prop, publiée dans le *WHO Drug Information, Vol.30, No.4, 2016.*

patritumab deruxtecán

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal *Homo sapiens,* conjugado con deruxtecán, que comprende un conector y un derivado de la camptotecina;
cadena pesada gamma1 *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV4-34*01 (99.0%) -(IGHD) -IGHJ2*01 (100%)) [8.7.11] (1-117) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (214) (118-215), bisagra 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (123-452)], (220-220')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (95.0%) -IGKJ1*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')];
dímero (226-226'':229-229'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa;conjugado, con 8 restos cisteinil por término medio, con deruxtecán, que comprende un conector y un derivado de la campotecina
Para la fracción *deruxtecán*, se puede referir a la Lista 116 de DCI prop., publicada en el *WHO Drug Information, Vol.30, No.4, 2016.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE  50
INHSGSTNYN PSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW 100
TWYFDLWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIEMTQSPDS LAVSLGERAT INCRSSQSVL YSSSNRNYLA WYQQNPGQPP  50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST 100
PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-95 144-200 261-321 367-425
22"-95" 144"-200" 261"-321" 367"-425"
Intra-L (C23-C104) 23'-94' 140'-200'
23'"-94'" 140'"-200'"
Inter-H-L (h 5-CL 126)* 220-220' 220"-220'"
Inter-H-H (h 11, h 14)* 226-226" 229-229"
*None of the four inter-chain disulfide bridges is present, an average of 8 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Aucun des quatre ponts disulfures inter-chaînes est présent, 8 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Ninguno de los cuatro puentes disulfuro inter-catenarios esta presente, una media de 8 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
447, 447"

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales



paxalisibum

paxalisib — 5-[6,6-dimethyl-4-(morpholin-4-yl)-8,9-dihydro-6*H*-[1,4]oxazino[4,3-*e*]purin-2-yl]pyrimidin-2-amine

paxalisib — 5-[6,6-diméthyl-4-(morpholin-4-yl)-8,9-dihydro-6*H*-[1,4]oxazino[4,3-*e*]purin-2-yl]pyrimidin-2-amine

paxalisib — 5-[6,6-dimetil-4-(morfolin-4-il)-8,9-dihidro-6*H*-[1,4]oxazino[4,3-*e*]purin-2-il]pirimidin-2-amina

$C_{18}H_{22}N_8O_2$



petosemtamabum #

petosemtamab — immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], and anti-[*Homo sapiens* LGR5 (leucine rich repeat containing G protein-coupled receptor 5, G protein-coupled receptor 49, GPR67, GPR49)], *Homo sapiens* monoclonal antibody, bispecific;
gamma1 heavy chain *Homo sapiens* anti-EGFR (1-449) [VH (*Homo sapiens* IGHV7-4-1*02 (91.8%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (100%), G1m3,nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 L7>D (354), E12 (359), M14 (361), L24>E (371) (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (100%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma1 heavy chain *Homo sapiens* anti-LGR5 (1-456) [VH (*Homo sapiens* IGHV7-4-1*01 (92.9%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.20] (1-127) -*Homo sapiens* IGHG1*03 (100%), G1m3,nG1m1 (CH1 R120 (224) (128-225), hinge 1-15 (226-240), CH2 (241-350), CH3 L7>K (361), E12 (366), M14 (368), T22>K (376) (351-455), CHS K2>del (456)) (128-456)], (230-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (100%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (229-236'':232-239'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

pétosemtamab — immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], et anti-[*Homo sapiens* LGR5 (récepteur 5 à répétitions riches en leucine couplé à la protéine G, récepteur 49 couplé à la protéine G, GPR67, GPR49)], anticorps monoclonal *Homo sapiens,* bispécifique;

	chaîne lourde gamma1 *Homo sapiens* anti-EGFR (1-449) [VH (*Homo sapiens* IGHV7-4-1*02 (91.8%) -(IGHD) - IGHJ4*01 (93.3%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (100%), G1m3,nG1m1 (CH1 R120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 L7>D (354), E12 (359), M14 (361), L24>E (371) (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (100%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma1 *Homo sapiens* anti-LGR5 (1-456) [VH (*Homo sapiens* IGHV7-4-1*01 (92.9%) -(IGHD) - IGHJ4*01 (93.3%)) [8.8.20] (1-127) -*Homo sapiens* IGHG1*03 (100%), G1m3,nG1m1 (CH1 R120 (224) (128-225), charnière 1-15 (226-240), CH2 (241-350), CH3 L7>K (361), E12 (366), M14 (368), T22>K (376) (351-455), CHS K2>del (456)) (128-456)], (230-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (100%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-236'':232-239'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
petosemtamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], y anti-[*Homo sapiens* LGR5 (receptor de 5 a repeticiones ricas en leucina acoplada a la proteína G; receptor 49 acoplado a la proteína G, GPR67, GPR49)], anticuerpo monoclonal *Homo sapiens*; biespecífico cadena pesada gamma1 *Homo sapiens* anti-LGR5 (1-456) [VH (*Homo sapiens* IGHV7-4-1*01 (92.9%) -(IGHD) - IGHJ4*01 (93.3%)) [8.8.20] (1-127) -*Homo sapiens* IGHG1*03 (100%), G1m3,nG1m1 (CH1 R120 (224) (128-225), bisagra 1-15 (226-240), CH2 (241-350), CH3 L7>K (361), E12 (366), M14 (368), T22>K (376) (351-455), CHS K2>del (456)) (128-456)], (230-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (100%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma1 *Homo sapiens* anti-EGFR (1-449) [VH (*Homo sapiens* IGHV7-4-1*02 (91.8%) -(IGHD) - IGHJ4*01 (93.3%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (100%), G1m3,nG1m1 (CH1 R120 (217) (121-218), bisagra1-15 (219-233), CH2 (234-343), CH3 L7>D (354), E12 (359), M14 (361), L24>E (371) (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (100%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-236'':232-239'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada (anti-EGFR)

```
QVQLVQSGSE LKKPGASVKI SCKASGYDFT NYAMNWVRQA PGHGLEWMGW  50
INANTGDPTY AQGFTGRFVF SLDTSVSTAY LQISSLKAED SAVYYCTRER 100
FLEWLHFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTDPPSREE MTKNQVSLTC EVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-LGR5)

```
EVQLVQSGSK LKKPGASVKV SCKASGYTFT SYTMNWVRQA PGQGLEWMGW  50
INTDTGDPTY AQGFTGRFVF SLDTSVSTAF LQINSLKAED TAVYYCARGD 100
CDSTSCYRYS YGYEDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT KPPSREEMTK NQVSLKCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPG                                                 456
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 154"-210" 271"-331" 377"-435"
Intra-CDR3 (C109-C111.3) 101"-106"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 223-214' 230"-214'"
Inter-H-H (h 11, h 14) 229-236" 232-239"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 307"
Defucosylated (>90%) complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes défucosylés (>90%) / glicanos de tipo CHO biantenarios complejos defucosilados (>90%)

pimitespibum

pimitespib — 3-ethyl-4-{4-[4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-imidazol-1-yl]-3-(propan-2-yl)-1*H*-pyrazolo[3,4-*b*]pyridin-1-yl}benzamide

pimitespib — 3-éthyl-4-{4-[4-(1-méthyl-1*H*-pyrazol-4-yl)-1*H*-imidazol-1-yl]-3-(propan-2-yl)-1*H*-pyrazolo[3,4-*b*]pyridin-1-yl}benzamide

pimitespib — 3-etil-4-{4-[4-(1-metil-1*H*-pirazol-4-il)-1*H*-imidazol-1-il]-3-(propan-2-il)-1*H*-pirazolo[3,4-*b*]piridin-1-il}benzamida

$C_{25}H_{26}N_8O$



praluzatamabum #

praluzatamab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CD166 (activated leucocyte cell adhesion molecule, ALCAM)], humanized monoclonal antibody;

	gamma1 heavy chain humanized (1-450) [VH (*Homo sapiens* IGHV2-5*01 (88.9%) -(IGHD) -IGHJ4*01 (92.9%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 K120 (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-270')-disulfide with kappa light chain humanized (1'-270") [N-terminal region (1'-22') -8-mer linker (23'-30') -protease cleavable region (31'-48') -3-mer linker (49'-51') -V-KAPPA (*Homo sapiens* IGKV2-28*01 (89.0%) -IGKJ2*01 (100%)) [11.3.9] (52'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (209), V101 (247) (164'-270')]; dimer (230-230":233-233")-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-derived cell line, glycoform alfa
praluzatamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD166 (molécule d'adhésion cellulaire de leucocytes activée, ALCAM)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-450) [VH (*Homo sapiens* IGHV2-5*01 (88.9%) -(IGHD) -IGHJ4*01 (92.9%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03v G1m3>G1m17,1, nG1m1 (CH1 K120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-270')-disulfure avec la chaîne légère kappa humanisée (1'-270") [région N-terminale (1'-22') -8-mer linker (23'-30') -région clivable par des protéases (31'-48') -3-mer linker (49'-51') -V-KAPPA (*Homo sapiens* IGKV2-28*01 (89.0%) -IGKJ2*01 (100%)) [11.3.9] (52'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (209), V101 (247) (164'-270')]; dimère (230-230":233-233")-bisdisulfure, produite dans une lignée cellulaire dérivée des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
praluzatamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD166 (molécula de adhesión celular de leucocitos activados, ALCAM)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-450) [VH (*Homo sapiens* IGHV2-5*01 (88.9%) -(IGHD) -IGHJ4*01 (92.9%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03v G1m3>G1m17,1, nG1m1 (CH1 K120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-270')-disulfuro con la cadena ligera kappa humanizada (1'-270") [región N-terminal (1'-22') -conector 8-mer (23'-30') -región escindible por las proteasas (31'-48') -conector 3-mer (49'-51') -V-KAPPA (*Homo sapiens* IGKV2-28*01 (89.0%) -IGKJ2*01 (100%)) [11.3.9] (52'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (209), V101 (247) (164'-270')]; dímero (230-230":233-233")-bisdisulfuro, producido en una línea celular derivada de las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QITLKESGPT LVKPTQTLTL TCTFSGFSLS TYGMGVGWIR QPPGKALEWL  50
ANIWWSEDKH YSPSLKSRLT ITKDTSKNQV VLTITNVDPV DTATYYCVQI 100
DYGNDYAFTY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
```

Light chain / Chaîne légère / Cadena ligera

```
QGQSGQGLCH PAVLSAWESC SSGGGSSGGS AVGLLAPPGG LSGRSDNHGG  50
SDIVMTQSPL SLPVTPGEPA SISCRSSKSL LHSNGITYLY WYLQKPGQSP 100
QLLIYQMSNL ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCAQNLEL 150
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 200
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 250
EVTHQGLSSP VTKSFNRGEC                                  270
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 148-204 265-325 371-429
22"-97" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 74'-144' 190'-250'
74'"-144'" 190'"-250'"
Intra-L N-terminal region 9'-20' 9'"-20'"
Inter-H-L (h 5-CL 126) 224-270' 224"-270'"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

praluzatamabum ravtansinum

praluzatamab ravtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD166 (activated leucocyte cell adhesion molecule, ALCAM)], humanized monoclonal antibody conjugated to maytansinoid DM4; gamma1 heavy chain humanized (1-450) [VH (*Homo sapiens* IGHV2-5*01 (88.9%) -(IGHD) -IGHJ4*01 (92.9%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-270')-disulfide with kappa light chain humanized (1'-270') [N-terminal region (1'-22') -8-mer linker (23'-30') -protease cleavable region (31'-48') -3-mer linker (49'-51') -V-KAPPA (*Homo sapiens* IGKV2-28*01 (89.0%) -IGKJ2*01 (100%)) [11.3.9] (52'-163') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (209), V101 (247) (164'-270')]; dimer (230-230":233-233")-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-derived cell line, glycoform alfa; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [$N^{2'}$-deacetyl-$N^{2'}$-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)butanoate]
For the *ravtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**

praluzatamab ravtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD166 (molécule d'adhésion cellulaire de leucocytes activée, ALCAM)], anticorps monoclonal humanisé conjugué au maytansinoïde DM4; chaîne lourde gamma1 humanisée (1-450) [VH (*Homo sapiens* IGHV2-5*01 (88.9%) -(IGHD) -IGHJ4*01 (92.9%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 K120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-270')-disulfure avec la chaîne légère kappa humanisée (1"-270") [région N-terminale (1'-22') -8-mer linker (23'-30') -région clivable par des protéases (31'-48') -3-mer linker (49'-51') -V-KAPPA (*Homo sapiens* IGKV2-28*01 (89.0%) -IGKJ2*01 (100%)) [11.3.9] (52'-163') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (209), V101 (247) (164'-270')]; dimère (230-230":233-233")-bisdisulfure;

produite dans une lignée cellulaire dérivée des cellules ovariennes de hamster chinois (CHO), glycoforme alfa; conjugué, sur 3 ou 4 lysyl en moyenne, au maytansinoïde DM4 [$N^{2'}$-déacétyl-$N^{2'}$-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle]
Pour la partie *ravtansine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

praluzatamab ravtansina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD166 (molécula de adhesión celular de leucocitos activados, ALCAM)], anticuerpo monoclonal humanizado conjugado con maitansinoide DM4; cadena pesada gamma1 humanizada (1-450) [VH (*Homo sapiens* IGHV2-5*01 (88.9%) -(IGHD) -IGHJ4*01 (92.9%)) [10.7.13] (1-121) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 K120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS K2>del (450)) (122-450)], (224-270')-disulfuro con la cadena ligera kappa humanizada (1''-270") [región N-terminal (1'-22') -conector 8-mer (23'-30') -región escindible por las proteasas (31'-48') -conecto 3-mer (49'-51') -V-KAPPA (*Homo sapiens* IGKV2-28*01 (89.0%) -IGKJ2*01 (100%)) [11.3.9] (52'-163') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (209), V101 (247) (164'-270')]; dímero (230-230":233-233")-bisdisulfuro;
producida en una línea celular derivada de las células ováricas de hamster chino (CHO), glicoforma alfa; conjugado, en 3 o 4 residuos lisil por término medio, con el maitansinoide DM4 [$N^{2'}$-deacetil-$N^{2'}$-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el espaciador SPDB reducible [4-(2-piridilditio)butanoato de *N*-succinimidilo]
Para la fracción *ravtansine*, se puede referirse al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QITLKESGPT LVKPTQTLTL TCTFSGFSLS TYGMGVGWIR QPPGKALEWL  50
ANIWWSEDKH YSPSLKSRLT ITKDTSKNQV VLTITNVDPV DTATYYCVQI 100
DYGNDYAFTY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
```

Light chain / Chaîne légère / Cadena ligera

```
QGQSGQGLCH PAVLSAWESC SSGGGSSGGS AVGLLAPPGG LSGRSDNHGG  50
SDIVMTQSPL SLPVTPGEPA SISCRSSKSL LHSNGITYLY WYLQKPGQSP 100
QLLIYQMSNL ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCAQNLEL 150
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 200
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 250
EVTHQGLSSP VTKSFNRGEC                                   270
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 148-204 265-325 371-429
22"-97" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 74'-144' 190'-250'
74'"-144'" 190'"-250'"
Intra-L N-terminal region 9'-20' 9'"-20'"
Inter-H-L (h 5-CL 126) 224-270' 224"-270'"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

For the *ravtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*"*
Pour la partie *ravtansine,* veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*"*.
Para la fracción *ravtansina,* se pueden dirigir al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*"*.

pregabalinum arenacarbilum

pregabalin arenacarbil — (3*S*)-5-methyl-3-{[({(1*R*)-1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl)amino]methyl}hexanoic acid

prégabaline arénacarbil — acide (3*S*)-5-méthyl-3-{[({(1*R*)-1-[(2-méthylpropanoyl)oxy]éthoxy}carbonyl)amino]méthyl}hexanoïque

pregabalina arenacarbilo — ácido (3*S*)-5-metil-3-{[({(1*R*)-1-[(2-metilpropanoil)oxi]etoxi}carbonil)amino]metil}hexanoico

$C_{15}H_{27}NO_6$



ralmitarontum

ralmitaront — 5-ethyl-4-methyl-*N*-{4-[(2*S*)-morpholin-2-yl]phenyl}-1*H*-pyrazole-3-carboxamide

ralmitaront — 5-éthyl-4-méthyl-*N*-{4-[(2*S*)-morpholin-2-yl]phényl}-1*H*-pyrazole-3-carboxamide

ralmitaront — 5-etil-4-metil-*N*-{4-[(2*S*)-morfolin-2-il]fenil}-1*H*-pirazol-3-carboxamida

$C_{17}H_{22}N_4O_2$



rebamipidum mofetilum

rebamipide mofetil — *rac*-2-(morpholin-4-yl)ethyl (2*R*)-2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoate

rébamipide mofétil — *rac*-(2*R*)-2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinoléin-4-yl)propanoate de 2-(morpholin-4-yl)éthyle

rebamipida de mofetilo — *rac*-(2*R*)-2-(4-clorobenzamido)-3-(2-oxo-1,2-dihidroquinolein-4-il)propanoato de 2-(morfolin-4-il)etilo

$C_{25}H_{26}ClN_3O_5$



and enantiomer
et énantiomère
y enantiómero

remestemcelum

remestemcel	human culture expanded allogeneic adherent mesenchymal-like stromal cells derived from bone marrow of human leukocyte antigen (HLA)-unmatched healthy adult donors. Cells express cell surface markers CD29, CD44, CD71, CD73, CD90, CD105, CD106, CD120a, CD124 and CD166, and secrete interleukin 6 (IL)-6), interleukin 8 (IL-8), vascular endothelial growth factor (VEGF), prostaglandin E2 (PGE2), stromal-derived factor-1 (SDF-1), indoleamine 2,3-dioxygenase (IDO) and keratinocyte growth factor (KGF). The cells are negative for CD14, CD34, CD45, CD80, CD86 and HLA class II histocompatibility antigen gamma chain (HLA-DR) markers.
rémestemcel	Cellules stromales semblables au mésenchyme, humaines, allogéniques, dérivées de la moelle osseuse d'un donneur adulte sain incompatible pour l'antigène leucocytaire humain (HLA), en culture d'expansion pour thérapie cellulaire. Les cellules expriment à leur surface les marqueurs CD29, CD44, CD71, CD73, CD90, CD105, CD106, CD120a, CD124 and CD166, et secrètent l'interleukine 6 (IL-6), l'interleukine 8 (IL-8), facteur de croissance de l'endothélium vasculaire (VEGF), prostaglandine E2 (PGE2), facteur 1 dérivé du parenchyme (SDF-1), indoleamine 2,3-dioxygenase (IDO) et le facteur de croissance des kératinocytes. Les cellules sont négatives pour CD14, CD34, CD45, CD80, CD86 et la chaîne gamma de l'antigène majeur d'histocompatibilité (CMH) de classe II (HLA-DR).
remestemcel	Células estromales parecidas a mesenquimales, alogénicas, humanas, adherentes y expandidas en cultivo derivadas de la médula ósea de donantes adultos sanos no compatibles para el antígeno leucocitario humano (HLA). Las células expresan los marcadores de superficie CD29, CD44, CD71, CD73, CD90, CD106, CD120a, CD124 y CD166, y secretan interleukina (IL-6), interleukina 8 (IL-8), factor de crecimiento del endotelio vascular (VEGF), prostaglandina E2 (PGE2), factor derivado del estroma 1 (SDF-1), indoleamina 2,3-dioxigenasa (IDO) y factor de crecimiento de queratinocitos (KGF). Las células son negativas para los marcadores CD14, CD34, CD45, CD80, CD86 y la cadena gamma del antígeno de histocompatibilidad de HLA clase II (HLA-DR).

remibrutinibum

remibrutinib	*N*-(3-{6-amino-5-[2-(*N*-methylprop-2-enamido)ethoxy]pyrimidin-4-yl}-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide
rémibrutinib	*N*-(3-{6-amino-5-[2-(*N*-méthylprop-2-énamido)éthoxy]pyrimidin-4-yl}-5-fluoro-2-méthylphényl)-4-cyclopropyl-2-fluorobenzamide
remibrutinib	*N*-(3-{6-amino-5-[2-(*N*-metilprop-2-enamido)etoxi]pirimidin-4-il}-5-fluoro-2-metilfenil)-4-ciclopropil-2-fluorobenzamida

$C_{27}H_{27}F_2N_5O_3$



retifanlimabum #

retifanlimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody;
gamma4 heavy chain humanized (1-445) [VH (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -*Homo sapiens* IGHG4*01 (CH1 (120-217), hinge 1-12 S10>P (227) (218-229), CH2 (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-218')-disulfide with kappa light chain chimeric (1'-218') [V-KAPPA (*Mus musculus* IGKV3-2*01 (80.8%) -IGKJ2 (91.7%)/*Homo sapiens* IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (225-225":228-228")-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cell line, glycoform alfa

rétifanlimab — immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal;
chaîne lourde gamma4 humanisée (1-445) [VH (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -*Homo sapiens* IGHG4*01 (CH1 (120-217), charnière 1-12 S10>P (227) (218-229), CH2 (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-218')-disulfure avec la chaîne légère kappa chimérique (1'-218') [V-KAPPA (*Mus musculus* IGKV3-2*01 (80.8%) -IGKJ2 (91.7%)/*Homo sapiens* IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (225-225":228-228")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

retifanlimab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal;
cadena pesada gamma4 humanizada (1-445) [VH (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -*Homo sapiens* IGHG4*01 (CH1 (120-217), bisagra 1-12 S10>P (227) (218-229), CH2 (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-218')-disulfuro con la cadena ligera kappa quimérica (1'-218') [V-KAPPA (*Mus musculus* IGKV3-2*01 (80.8%) -IGKJ2 (91.7%)/*Homo sapiens* IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (225-225":228-228")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYSFT SYWMNWVRQA PGQGLEWIGV  50
IHPSDSETWL DQKFKDRVTI TVDKSTSTAY MELSSLRSED TAVYYCAREH 100
YGTSPFAYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG      445
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL  50
LIHAASNQGS GVPSRFSGSG SGTDFTLTIS SLEPEDFAVY FCQQSKEVPY 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 146-202 260-320 366-424
22"-96" 146"-202" 260"-320" 366"-424"
Intra-L (C23-C104) 23'-92' 138'-198'
23'"-92'" 138'"-198'"
Inter-H-L (CH1 10-CL 126) 133-218' 133"-218'"
Inter-H-H (h 8, h 11) 225-225" 228-228"

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

rilzabrutinibum

rilzabrutinib — (4Ξ,7^{3}*R*)-8^{4}-amino-9^{2}-fluoro-3,3-dimethyl-6-oxo-10-oxa-8(1,3)-pyrazolo[3,4-*d*]pyrimidina-2(1,4)-piperazina-7(1,3)-piperidina-1(3)-oxetana-9(1,4),11(1)-dibenzenaundecaphan-4-ene-5-carbonitrile

rilzabrutinib — (4Ξ,7^{3}*R*)-8^{4}-amino-9^{2}-fluoro-3,3-diméthyl-6-oxo-10-oxa-8(1,3)-pyrazolo[3,4-*d*]pyrimidina-2(1,4)-pipérazina-7(1,3)-pipéridina-1(3)-oxétana-9(1,4),11(1)-dibenzénaundécaphan-4-ène-5-carbonitrile

rilzabrutinib — (4Ξ,7^{3}*R*)-8^{4}-amino-9^{2}-fluoro-3,3-dimetil-6-oxo-10-oxa-8(1,3)-pirazolo[3,4-*d*]pirimidina-2(1,4)-piperazina-7(1,3)-piperidina-1(3)-oxetana-9(1,4),11(1)-dibencenaundecafan-4-eno-5-carbonitrilo

$C_{36}H_{40}FN_9O_3$



rimtuzalcapum

rimtuzalcap — *N*-(4,4-difluorocyclohexyl)-2-(3-methyl-1*H*-pyrazol-1-yl)-6-(morpholin-4-yl)pyrimidin-4-amine

rimtuzalcap — *N*-(4,4-difluorocyclohexyl)-2-(3-méthyl-1*H*-pyrazol-1-yl)-6-(morpholin-4-yl)pyrimidin-4-amine

rimtuzalcap — *N*-(4,4-difluorociclohexil)-2-(3-metil-1*H*-pirazol-1-il)-6-(morfolin-4-il)pirimidin-4-amina

$C_{18}H_{24}F_2N_6O$



ritlecitinibum

ritlecitinib — 1-{(2*S*,5*R*)-2-methyl-5-[(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one

ritlécitinib — 1-{(2*S*,5*R*)-2-méthyl-5-[(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]pipéridin-1-yl}prop-2-én-1-one

ritlecitinib — 1-{(2*S*,5*R*)-2-metil-5-[(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)amino]piperidin-1-il}prop-2-en-1-ona

$C_{15}H_{19}N_5O$



ropocamptidum

ropocamptide — antibacterial peptide LL-37 (human): L-leucyl-L-leucylglycyl-L-α-aspartyl-L-phenylalanyl-L-phenylalanyl-L-arginyl-L-lysyl-L-seryl-L-lysyl-L-α-glutamyl-L-lysyl-L-isoleucylglycyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-lysyl-L-arginyl-L-isoleucyl-L-valyl-L-glutaminyl-L-arginyl-L-isoleucyl-L-lysyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-arginyl-L-asparaginyl-L-leucyl-L-valyl-L-prolyl-L-arginyl-L-threonyl-L-α-glutamyl-L-serine

ropocamptide — peptide antibactérien LL-37 (humain): L-leucyl-L-leucylglycyl-L-α-aspartyl-L-phénylalanyl-L-phénylalanyl-L-arginyl-L-lysyl-L-séryl-L-lysyl-L-α-glutamyl-L-lysyl-L-isoleucylglycyl-L-lysyl-L-α-glutamyl-L-phénylalanyl-L-lysyl-L-arginyl-L-isoleucyl-L-valyl-L-glutaminyl-L-arginyl-L-isoleucyl-L-lysyl-L-α-aspartyl-L-phénylalanyl-L-leucyl-L-arginyl-L-asparaginyl-L-leucyl-L-valyl-L-prolyl-L-arginyl-L-thréonyl-L-α-glutamyl-L-sérine

ropocamptida — péptido antibacterial LL-37 (humano): L-leucyl-L-leucylglycyl-L-α-aspartyl-L-phenylalanyl-L-phenylalanyl-L-arginyl-L-lysyl-L-seryl-L-lysyl-L-α-glutamyl-L-lysyl-L-isoleucylglycyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-lysyl-L-arginyl-L-isoleucyl-L-valyl-L-glutaminyl-L-arginyl-L-isoleucyl-L-lysyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-arginyl-L-asparaginyl-L-leucyl-L-valyl-L-prolyl-L-arginyl-L-threonyl-L-α-glutamyl-L-serina

$C_{205}H_{340}N_{60}O_{53}$

LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES 37

rovaleucelum

rovaleucel — human culture enriched/expanded autologous Epstein-Barr virus-specific cytotoxic T cells (EBV-CTL) derived from peripheral blood mononuclear cells (PBMCs) for cell-based therapy. Cells are generated by coculture with gamma irradiated autologous lymphoblastoid cell lines (LCL) and interleukin-2 (IL-2) stimulation.

rovaleucel — lymphocytes T cytotoxiques spécifiques du virus d'Epstein-Barr (EBV-CTL) humains, autologues, en culture d'expansion/enrichie, dérivés des cellules mononuclées du sang périphérique (PBMCs) pour thérapie cellulaire. Les cellules sont générées par coculture avec des lignées cellulaires lymphoblastoïdes (LCL) autologues irradiées par des rayons gamma et une stimulation par interleukine 2 (IL-2).

rovaleucel — linfocitos T citotóxicos específicos del virus de Epstein-Barr (EBV-CTL), autólogos, humanos, expandidos/enriquecidos en cultivo, derivados de células mononucleares de sangre periférica (PBMCs) para terapia celular. Las células se generan mediante cocultivo con líneas celulares linfoblastoides autólogas irradiadas con radiación gamma y estimulación con interleukina-2 (IL-2).

samotolisibum

samotolisib — 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2*S*)-2-methoxypropyl]-3-methyl-1,3-dihydro-2*H*-imidazo[4,5-*c*]quinolin-2-one

samotolisib — 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2*S*)-2-méthoxypropyl]-3-méthyl-1,3-dihydro-2*H*-imidazo[4,5-*c*]quinoléin-2-one

samotolisib — 8-[5-(2-hidroxipropan-2-il)piridin-3-il]-1-[(2*S*)-2-metoxipropil]-3-metil-1,3-dihidro-2*H*-imidazo[4,5-*c*]quinolein-2-ona

$C_{23}H_{26}N_4O_3$



sasanlimabum #

sasanlimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;

	gamma4 heavy chain humanized (1-444) [VH (*Homo sapiens* IGHV1-46*01 (85.7%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.10] (1-117)-*Homo sapiens* IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (87.1%) -IGKJ4*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (223-223":226-226")-bisdisulfide, produced in a glutamine synthetase knockout-Chinese hamster ovary (CHO) based expression system (CHO-K1SV GS-KO), glycoform alfa
sasanlimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-444) [VH (*Homo sapiens* IGHV1-46*01 (85.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-220')-disulfure avec la chaîne légère kappa humanisée (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (87.1%) -IGKJ4*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (223-223":226-226")-bisdisulfure, produit dans un système d'expression basé sur des cellules ovariennes de hamster chinois (CHO) glutamine-synthétase knockout (CHO-K1SV GS-KO), glycoforme alfa
sasanlimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-444) [VH (*Homo sapiens* IGHV1-46*01 (85.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), bisagraS10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-220')-disulfuro con la cadena ligera kappa humanizada (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (87.1%) -IGKJ4*01 (100%)) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (223-223":226-226")-bisdisulfuro, producido en un sistema de expresión basado en células ováricas de hamster chino (CHO) glutamina sintetasa knockout (CHO-K1SV GS-KO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWINWVRQA PGQGLEWMGN  50
IYPGSSLTNY NEKFKNRVTM TRDTSTSTVY MELSSLRSED TAVYYCARLS 100
TGTFAYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200
NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK        444
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSQSLW DSGNQKNFLT WYQQKPGQPP  50
KLLIYWTSYR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQNDYFY 100
PHTFGGGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 144-200 258-318 364-422
22"-96" 144"-200" 258"-318" 364"-422"
Intra-L (C23-C104) 23'-94' 140'-200'
23'"-94'" 140'"-200'"
Inter-H-L (CH1 10-CL 126) 131-220' 131"-220'"
Inter-H-H (h 8, h 11) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
444, 444"

sepofarsenum

sepofarsen

all-P-ambo-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyladenosine

sépofarsen

tout-P-ambo-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyladénosine

sepofarsén

todo-P-ambo-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metiladenosina

$C_{180}H_{235}N_{67}O_{101}P_{16}S_{16}$

(3'-5')(2'-*O*-methyl-*P*-thio)[G-G-U-G-G-A-U-C-A-C-G-A-G-U-U-C-A]

serplulimabum #

serplulimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain *Homo sapiens* (1-443) [VH (*Homo sapiens* IGHV3-11*01 (93.8%) -(IGHD) - IGHJ1*01 (90.9%)) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 (CH1 (117-214), hinge 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (83.2%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%),Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (222-222'':225-225'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
serplulimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 *Homo sapiens* (1-443) [VH (*Homo sapiens* IGHV3-11*01 (93.8%) -(IGHD) - IGHJ1*01 (90.9%)) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 (CH1 (117-214), charnière 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (83.2%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (222-222'':225-225'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
serplulimab	munoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; cadena pesada gamma4 *Homo sapiens* (1-443) [VH (*Homo sapiens* IGHV3-11*01 (93.8%) -(IGHD) - IGHJ1*01 (90.9%)) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 (CH1 (117-214), bisagra1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (83.2%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (222-222'':225-225'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG LVKPGGSLRL SCAASGFTFS NYGMSWIRQA PGKGLEWVST  50
ISGGGSNIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCVSYY 100
YGIDFWGQGT SVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200
VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVT TAVAWYQQKP GKAPKLLIYW  50
ASTRHTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYTIPWTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 143-199 257-317 363-421
22"-96" 143"-199" 257"-317" 363"-421"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (CH1 10-CL 126) 130-214' 130"-214'"
Inter-H-H (h 8, h 11) 222-222" 225-225"

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
293, 293"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
443, 443"

setamevetcelum

setamevetcel

Canine culture expanded adipose-derived allogeneic mesenchymal-like stromal cells for cell-based therapy. Cells express cell surface markers CD44 and CD90 (thy-1 membrane glycoprotein), and secrete interleukin-8 (IL-8), monocyte chemotactic protein 1 (MCP-1, C-C motif chemokine 2), hepatocyte growth factor (HGF, scatter factor, SF, hepatopoeitin A), metalloproteinase inhibitor 2 (TIMP-2), C-X-C motif chemokine 10 (CXCL10, 10 kDa interferon gamma-induced protein, IP-10), interleukin-1 receptor antagonist protein (IL-1RN , IL-1ra) and indoleamine 2,3-dioxygenase 1 (IDO-1, IDO). The cells are negative for CD34, CD45 and for the major histocompatibility complex (MHC) class II markers.

sétamévetcel

Cellules stromales semblables au mésenchyme, canines, allogéniques, dérivées de tissus adipeux, en culture d'expansion pour thérapie cellulaire. Les cellules expriment les marqueurs de surface CD44 et CD90 (glycoprotéine membranaire thy-1) et secrètent l'interleukine 8 (IL-8), la protéine 1 chimio-attractive du monocyte (MCP-1, chimiokine 2 de motif C-C), le facteur de croissance de l'hépatocyte (HGF, facteur dispersant, SF, hépatopoïétine A), l'inhibiteur 2 de métalloprotéinase (TIMP-2), la chimiokine 10 de motif C-X-C (CXCL10, protéine de 10 kDa induite par l'interféron gamma, IP-10), la protéine antagoniste du récepteur de l'interleukine-1 (IL-1RN, IL-1ra) et l'indoleamine 2,3-dioxygénase 1 (IDO-1, IDO). Les cellules sont négatives pour les marqueurs CD34, CD45 et l'antigène majeur d'histocompatibilité (CMH) de classe II.

setamevetcel	Células estromales parecidas a mesenquimales, alogénicas, de perro, derivadas de tejido adiposo y expandidas en cultivo para terapia celular. Las células expresan los marcadores de superficie CD44 y CD90 (glicoproteína de membrana thy-1), y secretan interleukina 8 (IL-8), proteína quimiotáctica de monocitos 1 (MCP-1, quimoquina con motivo C-C 2), factor de crecimiento de hepatocitos (HGF, factor dispersante, SF, hepatopoyetina A), inhibidor de metaloproteinasa 2 (TIMP-2), quimoquina con motivo C-X-C 10 (CXCL10, proteína de 10 kDa inductora de interferón gamma, IP-10), proteína antagonista del receptor de interleukina-1 (IL-1RN, IL-1ra) e indoleamina 2,3-dioxigenasa 1 (IDO-1, IDO). Las células son negativas para los marcadores CD34, CD45 y el antígeno principal de histocompatibilidad (MHC) de clase II.
simlukafuspum alfa #	
simlukafusp alfa	immunoglobulin G1-kappa anti-[human seprase (surface-expressed protease, fibroblast activation protein alpha, FAPα, prolyl endopeptidase FAP)], engineered human monoclonal antibody, fused to one interleukin 2 (IL2) chain, heterodimer: gamma1 heavy chain (1-447) [*Homo sapiens* VH (*Homo sapiens* IGHV3-23*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: SYAMS (31-35); CDRKabatH2: AIIGSGASTYYADSVKG (50-66); CDRKabatH3: GWFGGFNY (99-106)] (1-117) - *Homo sapiens* IGHG1*01 (CH1 (118-215), hinge (216-230), CH2 (L^{234}>A, L^{235}>A, P^{329}>G) (231-340), CH3 (Y^{349}>C, T^{366}>S, L^{368}>A, Y^{407}>V) (341-445), CHS (446-447)) (118-447)], (220-215')-disulfide with kappa light chain (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 - IGKJ1*01 [CDRKabatL1: RASQSVTSSYLA (24'-35'); CDRKabatL2[1]: VGSRRAT (51'-57'); CDRKabatL3[1]: QQGIMLPPT (90'-98')] (1'-108') - *Homo sapiens* IGKC*01 (109'-215')]; gamma1 heavy chain fused to IL2 (1''-594'') [*Homo sapiens* VH (*Homo sapiens* IGHV3-23*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: SYAMS (31''-35''); CDRKabatH2: AIIGSGASTYYADSVKG (50''-66''); CDRKabatH3: GWFGGFNY (99''-106'')] (1''-117'') - *Homo sapiens* IGHG1*01 (CH1 (118''-215''), hinge (216''-230''), CH2 (L^{234}>A, L^{235}>A, P^{329}>G) (231''-340''), CH3 (S^{354}>C, T^{366}>W,) (341''-445''), CHS (446''-446'') (K447del)) (118''-446'') -$(G_4S)_3$ linker (447''-461'') - *Homo sapiens* IL2 (Pr21-153) T^{23}>A (464''), F^{62}>A (503''), Y^{65}>A (506''), L^{92}>G (533''), C^{145}>A (586'') (462''-594'')], (220''-215''')-disulfide with kappa light chain (1'''-215''') [V-KAPPA (*Homo sapiens* IGKV3-20*01 -IGKJ1*01 [CDRKabatL1: RASQSVTSSYLA (24'''-35'''), CDRKabatL2: VGSRRAT (51'''-57'''), CDRKabatL3: QQGIMLPPT (90'''-98''')] (1'''-108''') - *Homo sapiens* IGKC*01 (109'''-215''')]; dimer (226-226'':229-229'':349-354'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

simlukafusp alfa

immunoglobuline G1-kappa, anti-[séprase humaine (protéase exprimée à la surface, protéine alpha d'activation des fibroblastes, FAPα, prolyl endopeptidase FAP)], anticorps monoclonal humain issu de l'ingénérerie) fusionnée à une chaîne de l'interleukine 2 humaine (IL2), hétérodimère:
chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (*Homo sapiens* IGHV3-23*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: SYAMS (31-35); CDRKabatH2: AIIGSGASTYYADSVKG (50-66); CDRKabatH3: GWFGGFNY (99-106)] (1-117) - *Homo sapiens* IGHG1*01 (CH1 (118-215), charnière (216-230), CH2 (L^{234}>A, L^{235}>A, P^{329}>G) (231-340), CH3 (Y^{349}>C, T^{366}>S, L^{368}>A, Y^{407}>V) (341-445), CHS (446-447)) (118-447)], (220-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 -IGKJ1*01 [CDRKabatL1: RASQSVTSSYLA (24'-35'); CDRKabatL2[1]: VGSRRAT (51'-57'); CDRKabatL3[1]: QQGIMLPPT (90'-98')] (1'-108') - *Homo sapiens* IGKC*01 (109'-215')];
chaîne lourde gamma1 fusionné à l'IL2 (1''-594'') [*Homo sapiens* VH (*Homo sapiens* IGHV3-23*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: SYAMS (31''-35''); CDRKabatH2: AIIGSGASTYYADSVKG (50''-66''); CDRKabatH3: GWFGGFNY (99''-106'')] (1''-117'') - *Homo sapiens* IGHG1*01 (CH1 (118''-215''), charnière (216''-230''), CH2 (L^{234}>A, L^{235}>A, P^{329}>G) (231''-340''), CH3 (S^{354}>C, T^{366}>W,) (341''-445''), CHS (446''-446'') (K447del)) (118''-446'') -$(G_4S)_3$ linker (447''-461'') -*Homo sapiens* IL2 (Pr21-153) T^{23}>A (464''), F^{62}>A (503''), Y^{65}>A (506''), L^{92}>G (533''), C^{145}>A (586'') (462''-594'')], (220''-215''')-disulfure avec la chaîne légère kappa (1'''-215''') [V-KAPPA (*Homo sapiens* IGKV3-20*01 -IGKJ1*01 [CDRKabatL1: RASQSVTSSYLA (24'''-35'''), CDRKabatL2: VGSRRAT (51'''-57'''), CDRKabatL3: QQGIMLPPT (90'''-98''')] (1'''-108''') - *Homo sapiens* IGKC*01 (109'''-215''')]; dimère (226-226'':229-229'':349-354'')-trisdisulfure, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

simlukafusp alfa

inmunoglobulina G1-kappa, anti-[seprasa humana (proteasa expresada en la superfice, proteína alfa de activación de los fibroblastos, FAPα, prolil endopeptidasa FAP)], anticuerpo monoclonal humano realizado a través de Ingeniera) fusionada con una cadena de la interleukina 2 humana (IL2), heterodímero:
cadena pesada gamma1 (1-447) [*Homo sapiens* VH (*Homo sapiens* IGHV3-23*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: SYAMS (31-35); CDRKabatH2: AIIGSGASTYYADSVKG (50-66); CDRKabatH3: GWFGGFNY (99-106)] (1-117) - *Homo sapiens* IGHG1*01 (CH1 (118-215), bisagra (216-230), CH2 (L^{234}>A, L^{235}>A, P^{329}>G) (231-340), CH3 (Y^{349}>C, T^{366}>S, L^{368}>A, Y^{407}>V) (341-445), CHS (446-447)) (118-447)], (220-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 -IGKJ1*01 [CDRKabatL1: RASQSVTSSYLA (24'-35'); CDRKabatL2[1]: VGSRRAT (51'-57'); CDRKabatL3[1]: QQGIMLPPT (90'-98')] (1'-108') - *Homo sapiens* IGKC*01 (109'-215')];
cadena pesada gamma1 fusionada al IL2 (1''-594'') [*Homo sapiens* VH (*Homo sapiens* IGHV3-23*01 -(IGHD)- IGHJ4*01 [CDRKabatH1: SYAMS (31''-35''); CDRKabatH2: AIIGSGASTYYADSVKG (50''-66''); CDRKabatH3: GWFGGFNY (99''-106'')] (1''-117'') - *Homo sapiens* IGHG1*01 (CH1 (118''-215''), bisagra (216''-230''), CH2 (L^{234}>A, L^{235}>A, P^{329}>G) (231''-340''), CH3 (S^{354}>C, T^{366}>W,) (341''-445''), CHS (446''-446'') (K447del)) (118''-446'') -$(G_4S)_3$ linker (447''-461'') -*Homo sapiens* IL2 (Pr21-153) T^{23}>A (464''), F^{62}>A (503''), Y^{65}>A (506''), L^{92}>G (533''), C^{145}>A (586'') (462''-594'')], (220''-215''')-disulfuro con la cadena ligera kappa (1'''-215''') [V-KAPPA (*Homo sapiens* IGKV3-20*01 -IGKJ1*01 [CDRKabatL1: RASQSVTSSYLA (24'''-35'''), CDRKabatL2: VGSRRAT (51'''-57'''), CDRKabatL3: QQGIMLPPT (90'''-98''')] (1'''-108''') - *Homo sapiens* IGKC*01 (109'''-215''')]; dímero 226-226'':229-229'':349-354'')-trisdisulfuro, producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia:
Heavy chain / Chaîne lourde / Cadena pesada (anti-FAP):

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
IIGSGASTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW 100
FGGFNYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APEAAGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALGA PIEKTISKAK GQPREPQVCT 350
LPPSRDELTK NQVSLSCAVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLVSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera:

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVT SSYLAWYQQK PGQAPRLLIN  50
VGSRRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QGIMLPPTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-FAP fused with IL2):

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
IIGSGASTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW 100
FGGFNYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APEAAGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALGA PIEKTISKAK GQPREPQVYT 350
LPPCRDELTK NQVSLWCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGGGGG 450
SGGGGSGGGG SAPASSSTKK TQLQLEHLLL DLQMILNGIN NYKNPKLTRM 500
LTAKFAMPKK ATELKHLQCL EEELKPLEEV LNGAQSKNFH LRPRDLISNI 550
NVIVLELKGS ETTFMCEYAD ETATIVEFLN RWITFAQSII STLT        694
```

Light chain / Chaîne légère / Cadena ligera:

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVT SSYLAWYQQK PGQAPRLLIN  50
VGSRRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QGIMLPPTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridge location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
intra-H: IgG1:   22-96     144-200     261-321     367-425
                 22"-96"   144"-200"   261"-321"   367"-425"
         :IL-2:  519"-566"
intra-L:         23'-89'   135'-195'   23'"-89'"   135'"-195'"
inter-H-L:       220-215'  220"-215'"
inter-H-H:       226-226"  229-229"  349-354"
```

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N297, N297"

sinbaglustatum

sinbaglustat	(2*S*,3*R*,4*R*,5*S*)-2-(hydroxymethyl)-1-pentylpiperidine-3,4,5-triol
sinbaglustat	(2*S*,3*R*,4*R*,5*S*)-2-(hydroxyméthyl)-1-pentylpipéridine-3,4,5-triol
sinbaglustat	(2*S*,3*R*,4*R*,5*S*)-2-(hidroximetil)-1-pentilpiperidina-3,4,5-triol

$C_{11}H_{23}NO_4$



sonelokimabum #

sonelokimab	immunoglobulin single chain VH-VH'-VH, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A) and *Homo sapiens* IL17F (interleukin 17F, IL-17F)] and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HAS)], humanized *Lama glama* monoclonal antibody, bispecific trivalent; scVH-VH'-VH (1-378) [humanized VH anti-IL17F (*Vicugna pacos* IGHV3-3*01 (85.6%) -(IGHD) -IGHJ5*01 (100%)/*Homo sapiens* IGHV3-23*04 (83.3%) -(IGHD) -IGHJ5*01 (100%)) [8.8.16] (1-123) -9-mer linker (tetraglycyl-seryl-triglycyl-seryl) (124-132) -humanized VH' anti-ALB (*Homo sapiens* IGHV3-23*04 (89.6%) -(IGHD) -IGHJ4*01 W118>S (237), G119 (238) (90.9%)) [8.8.8] (133-247) -9-mer linker (tetraglycyl-seryl-triglycyl-seryl) (248-256) -humanized VH anti-IL17A and anti-IL17F (*Vicugna pacos* IGHV3-3*01 (86.6%) -(IGHD) -IGHJ2*01 (92.3%)/*Homo sapiens* IGHV3-23*04 (85.6%) -(IGHD) -IGHJ5*01 (75.0%)) [6.8.17] (257-378), produced in the yeast *Pichia pastoris* (*Komagataella phaffii*), non-glycosylated
sonélokimab	immunoglobuline chaîne unique VH-VH'-VH, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A) et *Homo sapiens* IL17F (interleukine 17F, IL-17F)] et anti-[*Homo sapiens* ALB (albumine, sérum albumine humaine, SAH)], anticorps monoclonal *Lama glama* humanisé, bispécifique trivalent; scVH- VH'-VH (1-378) [VH chimérique anti-IL17F (*Vicugna pacos* IGHV3-3*01 (85.6%) -(IGHD) -IGHJ5*01 (100%)/*Homo sapiens* IGHV3-23*04 (83.3%) -(IGHD) -IGHJ5*01 (100%)) [8.8.16] (1-123) -9-mer linker (tétraglycyl-séryl-triglycyl-séryl) (124-132) -VH' humanisé anti-ALB (*Homo sapiens* IGHV3-23*04 (89.6%) -(IGHD) -IGHJ4*01 W118>S (237), G119 (238) (90.9%)) [8.8.8] (133-247) -9-mer linker (tétraglycyl-séryl-triglycyl-séryl) (248-256) -VH chimérique anti-IL17A and anti-IL17F (*Vicugna pacos* IGHV3-3*01 (86.6%) -(IGHD) -IGHJ2*01 (92.3%)/*Homo sapiens* IGHV3-23*04 (85.6%) -(IGHD) -IGHJ5*01 (75.0%)) [6.8.17] (257-378), produit dans la levure *Pichia pastoris* (*Komagataella phaffii*), non-glycosylé
sonelokimab	inmunoglobulina cadena única VH-VH'-VH, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A) y *Homo sapiens* IL17F (interleukina 17F, IL-17F)] y anti-[*Homo sapiens* ALB (albúmina, albúmina sérica humana, SAH)], anticuerpo monoclonal *Lama glama* humanizado, biespecífico trivalente; scVH- VH'-VH (1-378) [VH quimérico anti-IL17F (*Vicugna pacos* IGHV3-3*01 (85.6%) -(IGHD) -IGHJ5*01 (100%)/*Homo sapiens* IGHV3-23*04 (83.3%) -(IGHD) -IGHJ5*01 (100%)) [8.8.16] (1-123) - conector 9-mer (tetraglicil-seril-triglicil-seril) (124-132) -VH' humanizado anti-ALB (*Homo sapiens* IGHV3-23*04 (89.6%) -(IGHD) -IGHJ4*01 W118>S (237), G119 (238) (90.9%)) [8.8.8] (133-247) -conecto 9-mer (tetraglicil-seril-triglicil-seril) (248-256) -VH quimérico anti-IL17A y anti-IL17F (*Vicugna pacos* IGHV3-3*01 (86.6%) -(IGHD) -IGHJ2*01 (92.3%)/*Homo sapiens* IGHV3-23*04 (85.6%) -(IGHD) -IGHJ5*01 (75.0%)) [6.8.17] (257-378), producido en la levadura *Pichia pastoris* (*Komagataella phaffii*), no glicosilado

scVH-VH'-VH chain / Chaîne scVH-VH'-VH / Cadena scVH-VH'-VH

```
DVQLVESGGG LVQPGGSLRL SCAASGRTFS SYVVGWFRQA PGKEREFIGA  50
ISGSGESIYY AVSEKGRFTI SRDNSKNTLY LQMNSLRPED TAVYYCTADQ 100
EFGYLRFGRS EYWGQGTLVT VSSGGGGSGG GSEVQLVESG GGLVQPGNSL 150
RLSCAASGFT FSSFGMSWVR QAPGKGLEWV SSISGSGSDT LYADSVKGRF 200
TISRDNAKTT LYLQMNSLRP EDTAVYYCTI GGSLSRSSQG TLVTVSSGGG 250
GSGGGSEVQL VESGGGLVQP GGSLRLSCAA SGRTYDAMGW LRQAPGKERE 300
FVAAISGSGD DTYYADSVKG RFTISRDNSK NTLYLQMNSL RPEDTAVYYC 350
ATRRGLYYVW DANDYENWGQ GTLVTVSS                        378
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-single chain (C23-C104) 22-96 154-228 278-350

No N-glycosylation sites / pas de sites de N-glycosylation / ningún positión de N-glicosilación

sovateltidum

sovateltide	N^1-(3-carboxypropanoyl)endothelin-1 (human) (8-21)-peptide (1-14) [K2>E,C4>A,C8>A]; *N*-(3-carboxypropanoyl)-L-α-aspartyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-valyl-L-tyrosyl-L-phenylalanyl-L-alanyl-L-histidyl-L-leucyl-L-α-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan
sovateltide	N^1-(3-carboxypropanoyl)endothéline-1 (humaine) (8-21)-peptide (1-14) [K2>E,C4>A,C8>A]; *N*-(3-carboxypropanoyl)-L-α-aspartyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-valyl-L-tyrosyl-L-phénylalanyl-L-alanyl-L-histidyl-L-leucyl-L-α-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophane
sovateltida	N^1-(3-carboxipropanoil)endotelina-1 (humana) (8-21)-péptido (1-14) [K2>E,C4>A,C8>A]; *N*-(3-carboxipropanoil)-L-α-aspartil-L-α-glutamil-L-α-glutamil-L-alanil-L-valil-L-tirosil-L-fenilalanil-L-alanil-L-histidil-L-leucil-L-α-aspartil-L-isoleucil-L-isoleucil-L-triptófano

$C_{86}H_{117}N_{17}O_{27}$



stapuldencelum

stapuldencel	human autologous monocyte-derived dendritic cells (MoDCs) generated *ex-vivo* from patient's peripheral blood mononuclear cells (PBMCs) for cell-based therapy. The cells are differentiated from autologous adherent monocytes by culturing in the presence of interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF), and pulsed with a killed human prostate adenocarcinoma cell line.
stapuldencel	cellules dendritiques autologues humaines dérivées des monocytes, générées *ex vivo* à partir de cellules mononuclées du sang périphérique des patients, pour thérapie cellulaire. Les cellules se différencient à partir des monocytes adhérents autologues par culture en présence d'interleukine 4 (IL-4) et du facteur stimulant les colonies de granulocytes et de macrophages (GM-CSF), et pulsées par des cellules tuées d'une lignée cellulaire humaine d'adénocarcinome de la prostate.

estapuldencel	células dentríticas autólogas humanas derivadas de monocitos, generadas *ex vivo* a partir de células mononucleares de sangre periférica de pacientes, para terapia celular. Las células se diferencian a partir de monocitos adherentes autólogos mediante cultivo en presencia de inlerleucina-4 (IL-4) y factor estimulador de colonias de granulocitos y macrófagos (GM-CSF), y pulsadas con células matadas de una línea celular de adenocarcinoma prostático humana.
suvodirsenum	
suvodirsen	[*all*-P^S-(*S*)]-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thioguanylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thioguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridine
suvodirsen	[*tout*-P^S-(*S*)]-2'-désoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thiocytidylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thioadénylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thioadénylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thioguanylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thioadénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thiocytidylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thioadénylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-désoxy-2'-fluoro-*P*-thiocytidylyl-(3'→5')-2'-désoxy-2'-fluorouridine
suvodirsén	[*todo*-P^S-(*S*)]-2'-desoxi-2'-fluoro-*P*-tiouridilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tiocitidilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tioguanilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tioguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tiocitidilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(3'→5')-2'-desoxi-2'-fluoro-*P*-tiocitidilil-(3'→5')-2'-desoxi-2'-fluorouridina

$C_{196}H_{230}F_{15}N_{76}O_{108}P_{19}S_{15}$

(3'-5') U=C=A=A=G=G=A-A=G-A=U=G-G-C=A=
U=U=U=C=U

Legend :



A , C , G & U =
2'-deoxy-2'-fluoronucleotide

A & G =
2'-O-methylnucleotide

tafolecimabum #

tafolecimab — immunoglobulin G2-kappa, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proproteine convertase 9, PC9)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain *Homo sapiens* (1-451) [VH (*Homo sapiens* IGHV4-39*01 (96.0%) -(IGHD) -IGHJ5*02 (93.8%)) [10.7.18] (1-126) -*Homo sapiens* IGHG2*01 (CH1 (127-224), hinge 1-12 (225-236), CH2 (237-345), CH3 (346-450), CHS K2>del (451)) (127-451)], (140-213')-disulfide with kappa light chain *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (98.9%) -IGKJ4*01 (91.7%)) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (228-228":229-229":232-232":235-235")-tetrakisdisulfide, produced in Chinese Hamster Ovary (CHO)-S cell line, glycoform alfa

tafolécimab — immunoglobuline G2-kappa, anti-[*Homo sapiens* PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma2 *Homo sapiens* (1-451) [VH (*Homo sapiens* IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) [10.7.18] (1-126) -*Homo sapiens* IGHG2*01 (CH1 (127-224), charnière 1-12 (225-236), CH2 (237-345), CH3 (346-450), CHS K2>del (451)) (127-451)], (140-213')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (98.9%) -IGKJ4*01 (91.7%)) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (228-228":229-229":232-232":235-235")-tétrakisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire CHO-S, glycoforme alfa

tafolecimab — inmunoglobulina G2-kappa, anti-[*Homo sapiens* PCSK9 (proproteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosa neuronal, NARC1, NARC-1, proproteína convertasa 9, PC9)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma2 *Homo sapiens* (1-451) [VH (*Homo sapiens* IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) [10.7.18] (1-126) -*Homo sapiens* IGHG2*01 (CH1 (127-224), bisagra 1-12 (225-236), CH2 (237-345), CH3 (346-450), CHS K2>del (451)) (127-451)], (140-213')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (98.9%) -IGKJ4*01 (91.7%)) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (228-228":229-229":232-232":235-235")-tetrakisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular CHO-S, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QLQLQESGPG LVKPSETLSL TCTVSGGSIS SASYYWSWIR QPPGKGLEWI  50
GSINYRGSTY YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100
NSGVVPAAGP NWFGPWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
NFGTQTYTCN VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTFRVVSV LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PMLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RRNWFTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 153-209 266-326 372-430
22"-97" 153"-209" 266"-326" 372"-430"
Intra-L (C23-C104) 23'-88' 133'-193'
23'"-88'" 133'"-193'"
Inter-H-L (CH1 10-CL 126) 140-213' 140"-213'"
Inter-H-H (h 4, h 5, h 8, h 11) 228-228" 229-229" 232-232" 235-235"

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

taldefgrobepum alfa

taldefgrobep alfa

human immunoglobulin G1 Fc fragment (1-225) fused via a peptidyl linker (226-243) to a human fibronectin tenth type III domain variant anti-[human myostatin (MSTN, growth differentiation factor 8, GDF8)] (244-340), dimer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; gamma1 chain H-CH2-CH3 fragment [*Homo sapiens* IGHG1*01 (CH2 (11-120), CH3 (121-225))] (1-225); dimer (6-6':9-9')-bisdisulfide-linker (226-243)-human fibronectin tenth type III domain fibronectin variant anti-[human myostatin (MSTN, growth differentiation factor 8, GDF8)] (244-340), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

taldéfgrobep alfa

fragment Fc d'immunoglobuline G1 humaine (1-225) fusionné via un peptide (226-243) au variant du dixième domaine de la fibronectine humaine de type III anti-[myostatine humaine (MSTN, facteur 8 de différentiation de croissance, GDF8)] (244-340), dimère, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa; chaîne gamma1 fragment H-CH2-CH3 [*Homo sapiens* IGHG1*01 (CH2 (11-120), CH3 (121-225))] (1-225); dimère (6-6':9-9')-bisdisulfure-linker (226-243)-variant du dixième domaine de la fibronectine humaine de type III anti-[myostatine humaine (MSTN, facteur 8 de différentiation de croissance, GDF8)] (244-340), produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

taldefgrobep alfa

fragmento Fc de inmunoglobulina G1 humana (1-225) fusionada mediante un péptido (226-243) a la variante del décimo dominio de la fibronectina humana del tipo III anti-[miostatina humana (MSTN, factor 8 de diferenciación de crecimiento, GDF8)] (244-340), dímero, producido en las células ováricas de hamster chino (CHO), glicoforma alfa;
cadena gamma1 fragmento H-CH2-CH3 [*Homo sapiens* IGHG1*01 (CH2 (11-120), CH3 (121-225))] (1-225); dímero (6-6':9-9')-bisdisulfuro-conector (226-243)-variante del décimo dominio de la fibronectina humana del tipo III anti-[miostatina humana (MSTN, factor 8 de diferenciación de crecimiento, GDF8)] (244-340), producido en las célulass ováricas de hamster chino (CHO), glicoforma alfa

Monomer / monomère / monómero

```
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 50
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 100
CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK 150
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 200
NVFSCSVMHE ALHNHYTQKS LSLSPELQLE ESAAEAQEGE LEGVSDVPRD 250
LEVVAATPTS LLISWSLPHQ GKANYYRITY GETGGNSPVQ EFTVPGRGVT 300
ATISGLKPGV DYTITVYAVT VTDTGYLKYK PISINYRTEI            340
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H: 41-101 147-205
41'-101' 147'-205'
Inter-H-H: 6-6' 9-9'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
Asn-77 Asn-77''

talquetamabum #

talquetamab

immunoglobulin G4-kappa/G4-lambda, anti-[*Homo sapiens* GPRC5D (G protein-coupled receptor class C group 5 member D)], and anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], humanized and chimeric monoclonal antibody, bispecific;
gamma4 heavy chain humanized anti-GPRC5D (1-445) [VH (*Homo sapiens* IGHV1-18*01 (89.8%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.11] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 F1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-214')-disulfide with kappa light chain humanized anti-GPRC5D (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-17*02 (85.3%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma4 heavy chain chimeric anti-CD3E (1-452) [VH (*Mus musculus* IGHV10-1*02 (89.8%)/*Homo sapiens* IGHV3-72*01 (88.0%) -(IGHD) -IGHJ6*01 (90.9%)) [8.10.16] (1-125) -*Homo sapiens* IGHG4*01 (CH1 (126-223), hinge 1-12 S10>P (233) (224-235), CH2 F1.3>A (239), L1.2>A (240) (236-345), CH3 F85.1>L (410), R88>K (414) (346-450), CHS (451-452)) (126-452)], (139-214')-disulfide with lambda light chain humanized anti-CD3E (1'-215') [V-LAMBDA (*Homo sapiens* IGLV7-43*01 (81.9%) -IGLJ3*02 (100%)) [9.3.9] (1'-109') -*Homo sapiens* IGLC2*01 (100%) (110'-215')];
dimer (224-231'':227-234'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa

talquétamab

immunoglobuline G4-kappa/G4-lambda, anti-[*Homo sapiens* GPRC5D (membre D du groupe 5 de la classe C du récepteur couplé aux protéines G)], et anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], anticorps monoclonal humanisé et chimérique, bispécifique;

	chaîne lourde gamma4 anti-GPRC5D humanisée (1-445) [VH (*Homo sapiens* IGHV1-18*01 (89.8%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.11] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), charnière 1-12 S10>P (226) (217-228), CH2 F1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-214')-disulfure avec la chaîne légère kappa anti-GPRC5D humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-17*02 (85.3%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma4 anti-CD3 chimérique (1-452) [VH (*Mus musculus* IGHV10-1*02 (89.8%)/*Homo sapiens* IGHV3-72*01 (88.0%) -(IGHD) -IGHJ6*01 (90.9%)) [8.10.16] (1-125) -*Homo sapiens* IGHG4*01 (CH1 (126-223), charnière 1-12 S10>P (233) (224-235), CH2 F1.3>A (239), L1.2>A (240) (236-345), CH3 F85.1>L (410), R88>K (414) (346-450), CHS (451-452)) (126-452)], (139-214')-disulfure avec la chaîne légère lambda anti-CD3E humanisée (1'-215') [V-LAMBDA (*Homo sapiens* IGLV7-43*01 (81.9%) -IGLJ3*02 (100%)) [9.3.9] (1'-109') -*Homo sapiens* IGLC2*01 (100%) (110'-215')]; dimère (224-231'':227-234'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire K1, glycoforme alfa
talquetamab	inmunoglobulina G4-kappa/G4-lambda, anti-[*Homo sapiens* GPRC5D (miembro D del grupo 5 de la clase C del receptor acoplado con proteínas G)], y anti-[*Homo sapiens* CD3E (CD3 épsilon, Leu-4)], anticuerpo monoclonal humanizado y quimérico, biespecífico; cadena pesada gamma4 anti-GPRC5D humanizada (1-445) [VH (*Homo sapiens* IGHV1-18*01 (89.8%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.11] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), bisagra 1-12 S10>P (226) (217-228), CH2 F1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-214')-disulfuro con la cadena ligera kappa anti-GPRC5D humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-17*02 (85.3%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma4 anti-CD3 quimérica (1-452) [VH (*Mus musculus* IGHV10-1*02 (89.8%)/*Homo sapiens* IGHV3-72*01 (88.0%) -(IGHD) -IGHJ6*01 (90.9%)) [8.10.16] (1-125) -*Homo sapiens* IGHG4*01 (CH1 (126-223), bisagra 1-12 S10>P (233) (224-235), CH2 F1.3>A (239), L1.2>A (240) (236-345), CH3 F85.1>L (410), R88>K (414) (346-450), CHS (451-452)) (126-452)], (139-214')-disulfuro con la cadena ligera lambda anti-CD3E humanizada (1'-215') [V-LAMBDA (*Homo sapiens* IGLV7-43*01 (81.9%) -IGLJ3*02 (100%)) [9.3.9] (1'-109') -*Homo sapiens* IGLC2*01 (100%) (110'-215')]; dímero (224-231'':227-234'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular K1, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada (anti-GPRC5D)

```
QVQLVQSGAE VKKPGASVKV SCKASGYSFT GYTMNWVRQA PGQGLEWMGL  50
INPYNSDTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARVA 100
LRVALDYWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EAAGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK      445
```

Light chain / Chaîne légère / Cadena ligera (anti-GPRC5D)

```
DIQMTQSPSS LSASVGDRVT ITCKASQNVA THVGWYQQKP GKAPKRLIYS  50
ASYRYSGVPS RFSGSGSGTE FTLTISNLQP EDFATYYCQQ YNRYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3E)

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR  50
IRSKYNNYAT YYAASVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR 100
HGNFGNSYVS WFAYWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFL LYSKLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450
GK                                                     452
```

Light chain / Chaîne légère / Cadena ligera (anti-CD3E)

```
QTVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWVQQ KPGQAPRGLI  50
GGTNKRAPGT PARFSGSLLG GKAALTLSGV QPEDEAEYYC ALWYSNLWVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS                                       215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfur
Intra-H (C23-C104) 22-96 145-201 259-319 365-423
22"-98" 152"-208" 266"-326" 372"-430"
Intra-L (C23-C104) 23'-88' 134'-194'
22'"-90'" 137'"-196'"
Inter-H-L (CH1 10-CL 126) 132-214' 139"-214'"
Inter-H-H (h 8, h 11) 224-231" 227-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennair
complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tanimilastum

tanimilast	3,5-dichloro-4-[(2*S*)-2-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-{[3-(cyclopropylmethoxy)-4-(methanesulfonamido)benzoyl]oxy}ethyl]pyridine 1-oxide
tanimilast	1-oxyde de 3,5-dichloro-4-[(2*S*)-2-[3-(cyclopropylméthoxy)-4-(difluorométhoxy)phényl]-2-{[3-(cyclopropylméthoxy)-4-(méthanesulfonamido)benzoyl]oxy}éthyl]pyridine
tanimilast	1-óxido de 3,5-dicloro-4-[(2*S*)-2-[3-(ciclopropilmetoxi)-4-(difluorometoxi)fenil]-2-{[3-(ciclopropilmetoxi)-4-(metanosulfonamido)benzoil]oxi}etil]piridina

$C_{30}H_{30}Cl_2F_2N_2O_8S$



tapotoclaxum

tapotoclax	(1^3*S*,3^1*R*,3^2*R*,4*S*,5*E*,8*S*,9*R*)-6'-chloro-4-methoxy-8,9-dimethyl-3',4'-dihydro-1^2*H*,1^4*H*,2'*H*-10λ^6-thia-11-azaspiro[1(5,7)-[1,5]benzoxazepina-3(1,2)-cyclobutanacyclododecaphan-5-ene-1^3,1'-naphthalene]-10,10,12-trione
tapotoclax	(1^3*S*,3^1*R*,3^2*R*,4*S*,5*E*,8*S*,9*R*)-6'-chloro-4-méthoxy-8,9-diméthyl-3',4'-dihydro-1^2*H*,1^4*H*,2'*H*-10λ^6-thia-11-azaspiro[1(5,7)-[1,5]benzoxazépina-3(1,2)-cyclobutanacyclododécaphan-5-ène-1^3,1'-naphtalène]-10,10,12-trione
tapotoclax	(1^3*S*,3^1*R*,3^2*R*,4*S*,5*E*,8*S*,9*R*)-6'-cloro-4-metoxi-8,9-dimetil-3',4'-dihidro-1^2*H*,1^4*H*,2'*H*-10λ^6-tia-11-azaspiro[1(5,7)-[1,5]benzoxazepina-3(1,2)-ciclobutanaciclododecafan-5-eno-1^3,1'-naftaleno]-10,10,12-triona

$C_{33}H_{41}ClN_2O_5S$



tebrocabtagenum autoleucelum #

tebrocabtagene autoleucel	Autologous T cells, transduced with a replication incompetent Moloney murine leukemia virus (MoMLV) (a retrovirus) vector that encodes a chimeric antigen receptor (CAR) targeting human B-lymphocyte antigen CD19 (CD19 molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3).
tébrocabtagène autoleucel	Lymphocytes T autologues transduits par un vecteur du virus de la leucémie murine de Moloney (MoMLV) (un retrovirus) incompétent pour la replication et codant pour un récepteur antigénique chimérique (CAR) dirigé contre l'antigène CD19 des lymphocytes B humains (molecule CD19, antigène de surface B4 des lymphocytes B, antigène de surface Leu-12 des lymphocytes T, CVID3).

tebrocabtagén autoleucel	Linfocitos T autólogos transducidos con un vector del virus de la leucemia murina de Moloney (MoMLV) (un retrovirus) incompetente para replicación que codifica para un receptor de antígenos quimérico (CAR) dirigido al antígeno de linfocitos B humanos CD19 (molécula CD19, antígeno B4 de superficie de linfocitos B, antígeno de superficie de linfocitos T Leu-12, CVID3).

tilvestamabum #

tilvestamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* AXL (AXL receptor tyrosine kinase, tyrosine-protein kinase receptor UFO)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (*Homo sapiens* IGHV3-66*01 (76.5%) -(IGHD) -IGHJ4*01 (100%)) [8.7.12] (1-118) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-210')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
tilvestamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* AXL (récepteur tyrosine kinase AXL, récepteur tyrosine-protéine kinase UFO)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-448) [VH (*Homo sapiens* IGHV3-66*01 (76.5%) -(IGHD) -IGHJ4*01 (100%)) [8.7.12] (1-118) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-210')-disulfure avec la chaîne légère kappa humanisée (1'-219') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112) -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
tilvestamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* AXL (receptor tirosina kinasa AXL, receptor tirosina-proteína kinasa UFO)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-448) [VH (*Homo sapiens* IGHV3-66*01 (76.5%) -(IGHD) -IGHJ4*01 (100%)) [8.7.12] (1-118) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (215) (119-216), bisagra 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-210')-disulfuro con la cadena ligera kappa humanizada (1'-219') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (227-227":230-230")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYSFT DFYINWVRQA PGKGLEWVAR  50
IFPGGDNTYY NEKFKGRFTL SADTSKSTAY LQMNSLRAED TAVYYCARRG 100
LYYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRSSQSLV HSNGIPYLHW YQQKPGKAPK  50
LLIYRVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCSQGTHVP 100
PTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L (h 5-CL 126) 221-219' 221"-219'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

C-terminal lysine clipping:
H CHS K2:
448, 448"

tinlarebantum

tinlarebant — 1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridin-6-yl)ethan-1-one

tinlarébant — 1-(3-{4-[3,4-difluoro-2-(trifluorométhyl)phényl]pipéridine-1-carbonyl}-1,4,5,7-tétrahydro-6*H*-pyrazolo[3,4-*c*]pyridin-6-yl)éthan-1-one

tinlarebant — 1-(3-{4-[3,4-difluoro-2-(trifluorometil)fenil]piperidina-1-carbonil}-1,4,5,7-tetrahidro-6*H*-pirazolo[3,4-*c*]piridin-6-il)etan-1-ona

$C_{21}H_{21}F_5N_4O_2$



tinurilimabum

tinurilimab — immunoglobulin G2-kappa, anti-[*Homo sapiens* CEACAM6 (carcinoembryonic antigen related cell adhesion molecule 6, CD66c)], humanized monoclonal antibody;
gamma2 heavy chain *Homo sapiens* (1-443) [VH (*Homo sapiens* IGHV2-70*01 (92.0%) -(IGHD) -IGHJ4*01(86.7%)) [10.7.10] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), hinge 1-12 (217-228), CH2 (229-337), CH3 (338-442), CHS K2>del (443)) (119-443)], (132-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-9*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

tinurilimab

immunoglobuline G2-kappa, anti-[*Homo sapiens* CEACAM6 (molécule d'adhésion cellulaire 6 apparentée à l'antigène carcinoembryonnaire, CD66c)], anticorps monoclonal humanisé; chaîne lourde gamma2 *Homo sapiens* (1-443) [VH (*Homo sapiens* IGHV2-70*01 (92.0%) -(IGHD) -IGHJ4*01(86.7%)) [10.7.10] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), charnière 1-12 (217-228), CH2 (229-337), CH3 (338-442), CHS K2>del (443)) (119-443)], (132-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-9*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (220-220":221-221":224-224":227-227")-tétrakisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

tinurilimab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* CEACAM6 (molécula de adhesión celular 6 relacionada con el antígeno carcinoembrionario, CD66c)], anticuerpo monoclonal humanizado; cadena pesada gamma2 *Homo sapiens* (1-443) [VH (*Homo sapiens* IGHV2-70*01 (92.0%) -(IGHD) -IGHJ4*01(86.7%)) [10.7.10] (1-118) -*Homo sapiens* IGHG2*01 (CH1 (119-216), bisagra 1-12 (217-228), CH2 (229-337), CH3 (338-442), CHS K2>del (443)) (119-443)], (132-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-9*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (220-220":221-221":224-224":227-227")-tetrakisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVTLRESGPA LVKPTQTLTL TCTFSGFSLS TYGIGVGWIR QPPGKALEWL  50
AHIWWNDNKY YSTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100
SLPYFDYWGQ GTTLTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPG        443
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSF LSASVGDRVT ITCKASQNVG TAVAWYQQKP GKAPKLLIYS  50
ASNRYTGVPS RFSGSGSGTE FTLTISSLQP EDFATYYCQQ YSSYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 145-201 258-318 364-422
22"-97" 145"-201" 258"-318" 364"-422"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (CH1 10-CL 126) 132-214' 132"-214'"
Inter-H-H (h 4, h 5, h 8, h 11) 220-220" 221-221" 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

toludesvenlafaxinum

toludesvenlafaxine

rac-4-[(1*R*)-2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate

toludesvenlafaxine — 4-méthylbenzoate de *rac*-4-[(1*R*)-2-(diméthylamino)-1-(1-hydroxycyclohexyl)éthyl]phényle

toludesvenlafaxina — 4-metilbenzoato de *rac*-4-[(1*R*)-2-(dimetilamino)-1-(1-hidroxiciclohexil)etil]fenilo

$C_{24}H_{31}NO_3$



and enantiomer
et énantiomère
y enantiómero

tominersenum

tominersen — *all-P-ambo*-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)adenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)adenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidine

tominersen — *tout-P-ambo*-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)adénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)adénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidine

tominersén — *todo-P-ambo*-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-*O*-(2-metoxietil)adenilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)adenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidina

$C_{230}H_{319}N_{74}O_{122}P_{19}S_{13}$

(3'-5') mC=mU-mC-A-G=d(T=A=A=mC=A=T=T=G=A=mC)=A-mC-mC-A=mC

Legend : A & G = 2'-O-(2-methoxyethyl)nucleotide

mC & mU = 2'-O-(2-methoxyethyl)-5-methylnucleotide

d(A , G & T) = 2'-deoxynucleotide

d(mC) = 2'-deoxy-5-methylcytidine



trazpirobenum

trazpiroben — 3-{[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl}benzoic acid

trazpirobène — acide 3-{[1-cyclohexyl-4-oxo-8-(4-oxo-4-phénylbutyl)-1,3,8-triazaspiro[4.5]décan-3-yl]méthyl}benzoïque

trazpirobén — ácido 3-{[1-ciclohexil-4-oxo-8-(4-oxo-4-fenilbutil)-1,3,8-triazaspiro[4.5]decan-3-il]metil}benzoico

$C_{31}H_{39}N_3O_4$



treprostinilum palmitilum

treprostinil palmitil — hexadecyl ({(1*R*,2*R*,3a*S*,9a*S*)-2-hydroxy-1-[(3*S*)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]naphthalen-5-yl}oxy)acetate

tréprostinil palmitil — ({(1*R*,2*R*,3a*S*,9a*S*)-2-hydroxy-1-[(3*S*)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]naphtalén-5-yl}oxy)acétate de hexadécyle

treprostinil palmitilo — ({(1*R*,2*R*,3a*S*,9a*S*)-2-hidroxi-1-[(3*S*)-3-hidroxioctil]-2,3,3a,4,9,9a-hexahidro-1*H*-ciclopenta[*b*]naftalen-5-il}oxi)acetato de hexadecilo

$C_{39}H_{66}O_5$



velsecoratum

velsecorat — 3-{5-[(1*R*,2*S*)-2-(2,2-difluoropropanamido)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)propoxy]-1*H*-indazol-1-yl}-*N*-[(3*R*)-oxolan-3-yl]benzamide

velsécorat

3-{5-[(1*R*,2*S*)-2-(2,2-difluoropropanamido)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)propoxy]-1*H*-indazol-1-yl}-*N*-[(3*R*)-oxolan-3-yl]benzamide

velsecorat

3-{5-[(1*R*,2*S*)-2-(2,2-difluoropropanamido)-1-(2,3-dihydro-1,4-benzodioxin-6-il)propoxi]-1*H*-indazol-1-il}-*N*-[(3*R*)-oxolan-3-il]benzamida

$C_{32}H_{32}F_2N_4O_6$



veverimerum

veverimer

poly[N^1,N^2-di(prop-2-en-1-yl)ethane-1,2-diamine-*co*-N^1,N^3-di(prop-2-en-1-yl)propane-1,3-diamine-*co*-prop-2-en-1-amine (≈ 2:2:5)], produced by crosslinking of poly[N^1,N^3-di(prop-2-en-1-yl)propane-1,3-diamine)-*co*-prop-2-en-1-amine (≈ 2:9)] with 1,2-dichloroethane (2 mol) and neutralization

vévérimère

poly[N^1,N^2-di(prop-2-én-1-yl)éthane-1,2-diamine-*co*-N^1,N^3-di(prop-2-én-1-yl)propane-1,3-diamine-*co*-prop-2-én-1-amine (≈ 2:2:5)], produit par réticulation de poly[N^1,N^3-di(prop-2-én-1-yl)propane-1,3-diamine)-*co*-prop-2-én-1-amine (≈ 2:9)] avec le 1,2-dichloroéthane (2 mol) et neutralisation

veverímero

poli[N^1,N^2-di(prop-2-en-1-il)etano-1,2-diamina-*co*-N^1,N^3-di(prop-2-en-1-il)propano-1,3-diamina-*co*-prop-2-en-1-amina (≈ 2:2:5)], producido por entrecruzamiento de poli[N^1,N^3-di(prop-2-en-1-il)propano-1,3-diamina)-*co*-prop-2-en-1-amina (≈ 2:9)] con 1,2-dicloroetano (2 mol) y neutralización

$[(C_3H_7N)_{\sim 5}(C_9H_{18}N_2)_{\sim 2}(C_8H_{16}N_2)_{\sim 2}]_n$, n = ∞



vibostolimabum

vibostolimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized monoclonal antibody;

gamma1 heavy chain humanized (1-449) [VH (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) -IGHJ3*01 (92.9%)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (100%), G1m17,1 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-27*01 (85.3%) -IGKJ5*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-231":228-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

vibostolimab immunoglobuline G1-kappa, anti-[*Homo sapiens* TIGIT (immunorécepteur des lymphocytes T avec domaine Ig et ITIM, membre 9 de l'Ig V-set, VSIG9, membre 3 de l'Ig V-set et région transmembrane, VSTM3)], anticorps monoclonal humanisé;
chaîne lourde gamma1 humanisée (1-449) [VH (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) -IGHJ3*01 (92.9%)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (100%), G1m17,1 (CH1 K120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-27*01 (85.3%) -IGKJ5*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-231":228-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

vibostolimab inmunoglobulina G1-kappa, anti-[*Homo sapiens* TIGIT (inmunoreceptor de los linfocitos T con dominio Ig e ITIM, miembro 9 de la Ig V-set, VSIG9, miembro 3 de la Ig V-set y región transmembrana, VSTM3)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-449) [VH (*Homo sapiens* IGHV1-69*02 (84.7%) -(IGHD) -IGHJ3*01 (92.9%)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (100%), G1m17,1 (CH1 K120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-27*01 (85.3%) -IGKJ5*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-231":228-231")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGSSVKV SCKASGYTFS SYVMHWVRQA PGQGLEWIGY  50
IDPYNDGAKY AQKFQGRVTL TSDKSTSTAY MELSSLRSED TAVYYCARGG 100
PYGWYFDVWG QGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASEHIY SYLSWYQQKP GKVPKLLIYN  50
AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDVATYYCQH HFGSPLTFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 222-214' 222"-214'"
Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

C-terminal lysine clipping:
H CHS K2:
449, 449"

vupanorsenum

vupanorsen

all-P-ambo-5'-*O*-(28-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]methyl}-1-hydroxy-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-phosphaoctacosan-1-yl)-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)guanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)adenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)adenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)adenosine

vupanorsen

tout-P-ambo-5'-*O*-(28-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]méthyl}-1-hydroxy-1,10,14,21-tétraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-phosphaoctacosan-1-yl)-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)adénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)adénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)adenosine

vupanorsén

todo-P-ambo-5'-*O*-(28-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis{[3-({6-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]hexil}amino)-3-oxopropoxi]metil}-1-hidroxi-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-fosfaoctacosan-1-il)-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)guanilil-(3'→5')-2'-*O*-(2-metoxietil)adenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-*O*-(2-metoxietil)adenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)adenosine

$C_{296}H_{434}N_{86}O_{152}P_{20}S_{13}$

(3'-5') R1-G=G-A-C-A-d(T=T=G=C=C=A=G=T=A=A=)U-C-G=C=A

Legend:

A & G: 2'-*O*-(2-methoxyethyl)nucleotide

C & U : 2'-*O*-(2-methoxyethyl)-5-methylnucleotide

d(A , G & T) : 2'-deoxynucleotide

d(C) : 2'-deoxy-5-methylcytidine



xiliertinibum

xiliertinib — (3a*R*,6a*R*)-*N*-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]-1-methylhexahydropyrrolo[3,4-*b*]pyrrole-5(1*H*)-carboxamide

xiliertinib — (3a*R*,6a*R*)-*N*-[4-(3-éthynylanilino)-7-méthoxyquinazolin-6-yl]-1-méthylhexahydropyrrolo[3,4-*b*]pyrrole-5(1*H*)-carboxamide

xiliertinib — (3a*R*,6a*R*)-*N*-[4-(3-etinilanilino)-7-metoxiquinazolin-6-il]-1-metilhexahidropirrolo[3,4-*b*]pirrol-5(1*H*)-carboxamida

$C_{25}H_{26}N_6O_2$



zagotenemabum #

zagotenemab — immunoglobulin G4-kappa, anti-[*Homo sapiens* MAPT (microtubule-associated protein tau, tau)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-442) [VH (*Homo sapiens* IGHV5-51*01 (84.7%) -(IGHD) -IGHJ4*01 (86.7%)) [8.8.9] (1-116)-*Homo sapiens* IGHG4*01 (CH1 (117-214), hinge 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS K2>del (442)) (117-442)], (130-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (79.0%) -IGKJ4*01 (100%)) [9.4.11] (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (222-222":225-225")-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-GS cell line, glycoform alfa

zagoténémab — immunoglobuline G4-kappa, anti-[*Homo sapiens* MAPT (protéine tau associée aux microtubules, tau)], anticorps monoclonal humanisé;

chaîne lourde gamma4 humanisée (1-442) [VH (*Homo sapiens* IGHV5-51*01 (84.7%) -(IGHD) -IGHJ4*01 (86.7%)) [8.8.9] (1-116)-*Homo sapiens* IGHG4*01 (CH1 (117-214), charnière 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS K2>del (442)) (117-442)], (130-219')-disulfure avec la chaîne légère kappa humanisée (1'-219') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (79.0%) -IGKJ4*01 (100%)) [9.4.11] (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (222-222":225-225")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire GS, glycoforme alfa

zagotenemab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* MAPT (proteína tau asociada a los microtúbulos, tau)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 humanizada (1-442) [VH (*Homo sapiens* IGHV5-51*01 (84.7%) -(IGHD) -IGHJ4*01 (86.7%)) [8.8.9] (1-116)-*Homo sapiens* IGHG4*01 (CH1 (117-214), bisagra 1-12 S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS K2>del (442)) (117-442)], (130-219')-disulfuro con la cadena ligera kappa humanizada (1'-219') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (79.0%) -IGKJ4*01 (100%)) [9.4.11] (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (222-222":225-225")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular GS, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada
```
EVQLVQSGAE VKKPGESLKI SCKGSGYTFS NYWIEWVRQM PGKGLEWMGE  50
ILPGSDSIKY EKNFKGQVTI SADKSISTAY LQWSSLKASD TAMYYCARRG 100
NYVDDWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200
VDHKPSNTKV DKRVESKYGP PCPPCPAPEA AGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG         442
```

Light chain / Chaîne légère / Cadena ligera
```
EIVLTQSPGT LSLSPGERAT LSCRSSQSLV HSNQNTYLHW YQQKPGQAPR  50
LLIYKVDNRF SGIPDRFSGS GSGTDFTLTI SRLEPEDFAV YYCSQSTLVP 100
LTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 143-199 257-317 363-421
22"-96" 143"-199" 257"-317" 363"-421"
Intra-L (C23-C104) 23'-93' 139'-194'
23'"-93'" 139'"-199'"
Inter-H-L (CH1 10-CL 126) 130-219' 130"-219'"
Inter-H-H (h 8, h 11) 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
293, 293"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

zanidatamabum #
zanidatamab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB2 (epidermal growth factor receptor 2, receptor tyrosine protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, biparatopic (targeting two different non-overlapping epitopes on ERBB2);

gamma1 heavy chain humanized (1-449) [VH (*Homo sapiens* IGHV3-66*01 (78.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-120) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 T6>V (353), L7>Y (354), D12 (359), L14 (361), F85.1>A (408), Y86>V (410) (344-448), CHS K2>del (449)) (121-449)], (223-215')-disulfide with kappa light chain humanized (1'-215') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (84.2%) -IGKJ1*01 (100%)) [6.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-215')];
gamma1 heavy chain V-KAPPA-VH-CH2-CH3 humanized (1"-481") [V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.3%) -IGKJ1*01 (100%)) [6.3.9] (1"-108") -20-mer linker (109"-128") -VH (*Homo sapiens* IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (129"-248") -dialanyl (249"-250") -*Homo sapiens* IGHG1*01 (hinge 1-15, C5>S (255) (251-265), CH2 (266-375), CH3 T6>V (385), D12 (391), L14 (393), T22>L (401), K79>L (427), T81>W (429) (376-480), CHS K2>del (481)) (251"-481")];
dimer (229-261":232-264")-bisdisulfide, produced in Chinese hamster ovary (CHO), glycoform alfa

zanidatamab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB2 (récepteur 2 du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticorps monoclonal humanisé, biparatopique (ciblant deux épitopes différents non chevauchants sur ERBB2);
chaîne lourde gamma1 humanisée (1-449) [VH (*Homo sapiens* IGHV3-66*01 (78.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-120) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 T6>V (353), L7>Y (354), D12 (359), L14 (361), F85.1>A (408), Y86>V (410) (344-448), CHS K2>del (449)) (121-449)], (223-215')-disulfure avec la chaîne légère kappa humanisée (1'-215') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (84.2%) -IGKJ1*01 (100%)) [6.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-215')];
chaîne lourde gamma1 V-KAPPA-VH-CH2-CH3 humanisée (1"-481") [V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.3%) -IGKJ1*01 (100%)) [6.3.9] (1"-108") -20-mer linker (109"-128") -VH (*Homo sapiens* IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (129"-248") -dialanyl (249"-250") -*Homo sapiens* IGHG1*01 (charnière 1-15 C5>S (255) (251-265), CH2 (266-375), CH3 T6>V (385), D12 (391), L14 (393), T22>L (401), K79>L (427), T81>W (429) (376-480), CHS K2>del (481)) (251"-481")];
dimère (229-261":232-264")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

zanidatamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB2 (receptor 2 del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticuerpo monoclonal humanizado, biparatópico (cuya diana son dos epítopos diferentes no solapables en ERBB2);
cadena pesada gamma1 humanizada (1-449) [VH (*Homo sapiens* IGHV3-66*01 (78.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.12] (1-120) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 T6>V (353), L7>Y (354), D12 (359), L14 (361), F85.1>A (408), Y86>V (410) (344-448), CHS K2>del (449)) (121-449)], (223-215')-disulfuro con la cadena ligera kappa humanizada (1'-215') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (84.2%) -IGKJ1*01 (100%)) [6.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-215')];
cadena pesada gamma1 V-KAPPA-VH-CH2-CH3 humanizada (1"-481") [V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.3%) -IGKJ1*01 (100%)) [6.3.9] (1"-108") -conector 20-mer (109"-128") -VH (*Homo sapiens* IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (129"-248") -dialanil (249"-250") -*Homo sapiens* IGHG1*01 (bisagra 1-15 C5>S (255) (251-265), CH2 (266-375), CH3 T6>V (385), D12 (391), L14 (393), T22>L (401), K79>L (427), T81>W (429) (376-480), CHS K2>del (481)) (251"-481")];
dímero (229-261":232-264")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
GEVQLVESGG GLVQPGGSLR LSCAASGFTF ADYTMDWVRQ APGKGLEWVG  50
DVNPNSGGSI YNQRFKGRFT FSVDRSKNTL YLQMNSLRAE DTAVYYCARN 100
LGPSFYFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYVYPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFALV SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Heavy chain / Chaîne lourde / Cadena pesada

```
GDIQMTQSPS SLSASVGDRV TITCRASQDV NTAVAWYQQK PGKAPKLLIY  50
SASFLYSGVP SRFSGSRSGT DFTLTISSLQ PEDFATYYCQ QHYTTPPTFG 100
QGTKVEIKGG SGGGSGGGSG GGSGGGSGEV QLVESGGGLV QPGGSLRLSC 150
AASGFNIKDT YIHWVRQAPG KGLEWVARIY PTNGYTRYAD SVKGRFTISA 200
DTSKNTAYLQ MNSLRAEDTA VYYCSRWGGD GFYAMDYWGQ GTLVTVSSAA 250
EPKSSDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD 300
VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN 350
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYVLPPSR DELTKNQVSL 400
LCLVKGFYPS DIAVEWESNG QPENNYLTWP PVLDSDGSFF LYSKLTVDKS 450
RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G                     481
```

Light chain / Chaîne légère / Cadena ligera

```
GDIQMTQSPS SLSASVGDRV TITCKASQDV SIGVAWYQQK PGKAPKLLIY  50
SASYRYTGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QYYIYPATFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 23-97 147-203 264-324 370-428
24"-89" 150"-224" 296"-356" 402"-460"
Intra-L (C23-C104) 24'-89' 135'-195'
Inter-H-L (h 5-CL 126) 223-215'
Inter-H-H (h 11, h 14) 229-261" 232-264"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 332"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

zelminemabum #

zelminemab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ADCYAP1R1 (adenylate cyclase-activating polypeptide (ADCYAP) type I receptor, pituitary adenylate cyclase-activating polypeptide (PACAP) type I receptor, PAC1, PAC1R)], monoclonal antibody;
gamma1 heavy chain humanized (1-450) [VH (*Homo sapiens* IGHV1-46*01 (80.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-5*01 (85.6%) -IGKJ3*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (229-229":232-232")-bisdisulfide, produced in Chinese Hamster Ovary (CHO) cell line, non-glycosylated

zelminémab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ADCYAP1R1 (récepteur de type I du polypeptide activant l'adénylate cyclase (ADCYAP), récepteur de type I du polypeptide activant l'adénylate cyclase pituitaire (PACAP), PAC1, PAC1R)], anticorps monoclonal;

chaîne lourde gamma1 humanisée (1-450) [VH (*Homo sapiens* IGHV1-46*01 (80.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 K120 (217) (121-218), charnière 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-5*01 (85.6%) -IGKJ3*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), non glycosylé

zelminemab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ADCYAP1R1 (receptor de tipo I de polipéptido activador de la adenilato ciclasa (ADCYAP), receptor de tipo I de polipéptido activador de la adenilato ciclasa pituitaria (PACAP), PAC1, PAC1R)], anticuerpo monoclonal;
cadena pesada gamma1 humanizada (1-450) [VH (*Homo sapiens* IGHV1-46*01 (80.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 K120 (217) (121-218), bisagra 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-5*01 (85.6%) -IGKJ3*02 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (229-229":232-232")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), no glicosilado

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGAE VVKPGASVKV SCKASGFTFS RFAMHWVRQA PGQGLEWMGV  50
ISYDGGNKYY AESVKGRVTM TRDTSTSTLY MELSSLRSED TAVYYCARGY 100
DVLTGYPDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYG 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSF LSASVGDRVT ITCRASQSIG RSLHWYQQKP GKAPKLLIKY  50
ASQSLSGVPS RFSGSGSGTE FTLTISSLQP EDFATYYCHQ SSRLPFTFGP 100
GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126)* 223-214' 223"-214'"
Inter-H-H (h 11, h 14)* 229-229" 232-232"
N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"

No N-glycosylation sites / pas de sites de N-glycosylation / ningún positión de N-glicosilación:
H CH2 N84.4>G:
300, 300"

C-terminal lysine clipping:
H CHS K2:
450, 450"

zelquistinelum

zelquistinel — *tert*-butyl (4*S*)-2-[(2*S*,3*R*)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate

zelquistinel — (4*S*)-2-[(2*S*,3*R*)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate de *tert*-butyle

zelquistinel — (4*S*)-2-[(2*S*,3*R*)-1-amino-3-hidroxi-1-oxobutan-2-il]-1-oxo-2,5-diazaspiro[3.4]octano-5-carboxilato de *terc*-butilo

$C_{15}H_{25}N_3O_5$



zildistrogenum varoparvovecum #

zildistrogene varoparvovec — A recombinant non-replicating adeno-associated virus type 2/9 (rAAV Rep2-Cap9) vector, encoding human microdystrophin 5 (h-μD5) under control of CK8 muscle creatine kinase promoter and enhancer elements

zildistrogène varoparvovec — vecteur viral adéno-associé de type 2/9 recombinant non-répliquant (rAAV Rep2-Cap9) codant pour la microdystrophine 5 humaine (h-mD5) sous le contrôle de l'activateur/promoteur de la créatine kinase musculaire CK8

zildistrogén varoparvovec — Un vector de virus adenoasociado recombinante no replicativo del tipo 2/9 (rAAV Rep2-Cap9), que codifica para la microdistrofina 5 humana (h-mD5) bajo el control del promotor y elementos potenciadores (enhancer) de la creatina quinasa CK8 de músculo.

ziltivekimabum #

ziltivekimab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IL6 (interleukin 6, IL-6)], monoclonal antibody; gamma1 heavy chain humanized (1-450) [VH (*Homo sapiens* IGHV3-66*01 (88.8%) -(IGHD) -IGHJ1*01 (90.9%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 M15.1>Y (255), S16>T (257), T18>E (259) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-213')-disulfide with kappa light chain *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-5*03 (96.7%) -IGKJ2*03 (100%)) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-GS cell line, glycoform alfa

ziltivékimab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL6 (interleukine 6, IL-6)], anticorps monoclonal;
chaîne lourde gamma1 humanisée (1-450) [VH (*Homo sapiens* IGHV3-66*01 (88.8%) -(IGHD) -IGHJ1*01 (90.9%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (217) (121-218), charnière 1-15 (219-233), CH2 M15.1>Y (255), S16>T (257), T18>E (259) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-213')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-5*03 (96.7%) -IGKJ2*03 (100%)) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO) lignée cellulaire GS, glycoforme alfa

ziltivekimab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL6 (interleukina 6, IL-6)], anticuerpo monoclonal;
cadena pesada gamma1 humanizada (1-450) [VH (*Homo sapiens* IGHV3-66*01 (88.8%) -(IGHD) -IGHJ1*01 (90.9%)) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 G1m3, nG1m1 (CH1 R120 (217) (121-218), bisagra 1-15 (219-233), CH2 M15.1>Y (255), S16>T (257), T18>E (259) (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-213')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-5*03 (96.7%) -IGKJ2*03 (100%)) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (229-229":232-232")-bisdisulfuro, producido en las células ováricas de hamster chino (CHO) línea celular GS, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTIS SNYMIWVRQA PGKGLEWVSD  50
LYYYAGDTYY ADSVKGRFTM SRDISKNTVY LQMNSLRAED TAVYYCARWA 100
DDHPPWIDLW GRGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLYITREP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPST LSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKVLIYK  50
ASTLESGVPS RFSGSGSGTE FTLTISSLQP DDFATYYCQQ SWLGGSFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 23'-88' 133'-193'
23'"-88'" 133'"-193'"
Inter-H-L (h 5-CL 126) 223-213' 223"-213'"
Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300'
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

zorifertinibum

zorifertinib

4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl (2*R*)-2,4-dimethylpiperazine-1-carboxylate

zorifertinib	(2*R*)-2,4-diméthylpipérazine-1-carboxylate de 4-(3-chloro-2-fluoroanilino)-7-méthoxyquinazolin-6-yle
zorifertinib	(2*R*)-2,4-dimetilpiperazina-1-carboxilato de 4-(3-cloro-2-fluoroanilino)-7-metoxiquinazolin-6-ilo

$C_{22}H_{23}ClFN_5O_3$



Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/
* http://www.who.int/medicines/services/inn/publication/en/

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): Lists 24 and 27
Dénominations communes internationales recommandées (DCI Rec.): Listes 24 et 27
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Listas 24 y 27
(***WHO Chronicle, Vol. 38, No. 6, Suppl., 1984; WHO Drug Information, Vol. 1, No. 4, 1987***)

ademetioninum

ademetionine	*replace the chemical name and the structure by the following ones*
adémétionine	*remplacer le nom chimique et la structure par les suivants*
ademetionina	*sustitúyase el nombre químico y la estructura por los siguientes*

(2*S*)-2-amino-4-[(*S*/*R*)-(5'-deoxyadenosin-5'-yl)(methyl)sulfaniumyl]butanoate

(2*S*)-2-amino-4-[(*S*/*R*)-(5'-désoxyadénosin-5'-yl)(méthyl)sulfaniumyl]butanoate

(2*S*)-2-amino-4-[(*S*/*R*)-(5'-desoxiadenosin-5'-il)(metil)sulfaniumil]butanoato



and less than 40% of epimer at S*
et moins de 40% d'épimère en S*
y menos de 40% del epímero al S*

Recommended International Nonproprietary Names (Rec. INN): List 40
Dénominations communes internationales recommandées (DCI Rec.): Liste 40
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 40
(WHO Drug Information, Vol. 12, No. 2, 1998)

p.175 **denileukinum diftitoxum**

denileukin diftitox	*replace the molecular formula by the following one*
dénileukine diftitox	*remplacer la formule moléculaire brute par la suivante*
denileukina diftitox	*sustitúyase la fórmula molecular por la siguiente*

$C_{2560}H_{4038}N_{678}O_{799}S_{17}$

Recommended International Nonproprietary Names (Rec. INN): List 69
Dénominations communes internationales recommandées (DCI Rec.): Liste 69
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69
(WHO Drug Information, Vol. 27, No. 1, 2013)

p. 76 **rabusertibum**

rabusertib	replace the chemical name by the following one
rabusertib	remplacer le nom chimique par le suivant
rabusertib	sustitúyase el nombre químico por el siguiente

N-(5-bromo-4-methyl-2-{[(2*S*)-morpholin-2-yl]methoxy}phenyl)-*N*′-(5-methylpyrazin-2-yl)urea

N-(5-bromo-4-méthyl-2-{[(2S)-morpholin-2-yl]méthoxy}phényl)-*N'*-(5-méthylpyrazin-2-yl)urée

N-(5-bromo-4-metil-2-{[(2*S*)-morfolin-2-il]metoxi}fenil)-*N'*-(5-metilpirazin-2-il)urea

Recommended International Nonproprietary Names (Rec. INN): List 76
Dénominations communes internationales recommandées (DCI Rec.): Liste 76
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 76
(WHO Drug Information, Vol. 30, No. 3, 2016)

p.495 **edasalonexentum**

edasalonexent	*replace the molecular formula by the following one*
édasalonexent	*remplacer la formule moléculaire brute par la suivante*
edasalonexento	*sustitúyase la fórmula molecular por la siguiente*

$C_{31}H_{42}N_2O_3$

Recommended International Nonproprietary Names (Rec. INN): List 77
Dénominations communes internationales recommandées (DCI Rec.): Liste 77
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 77
(WHO Drug Information, Vol. 31, No. 1, 2017)

p.117 **pegvorhyaluronidasum alfa #**

pegvorhyaluronidase alfa	*replace the description and the structure by the following ones*
pègvorhyaluronidase alfa	*remplacer la description et la structure par les suivantes*
pegvorhialuronidasa alfa	*sustitúyase la descripción y la estructura por las siguientes*

human hyaluronidase PH-20 (hyaluronoglucosaminidase PH-20, sperm adhesion molecule 1, EC 3.2.1.35) precursor-(36-482)-peptide (mature (1-447)-peptide), produced in Chinese hamster ovary (CHO) cells, glycoform alfa, substituted on an average of 4 to 5 sites among N^2 of Leu1 and N^6 of lysyl residues with 4-[ω-methoxypoly(oxyethylene)-α-yl]butanoyl groups (~30 kDa each)

hyaluronidase PH-20 humaine (hyaluronoglucosaminidase PH-20, molécule adhésive 1 du sperme, EC 3.2.1.35) précurseur-(36-482)-peptide (à maturité-(1-447)-peptide), produite par des cellules ovariennes de hamster chinois (CHO), forme glycosylée alfa, substituée sur une moyenne de 4 à 5 sites parmi le N^2 du résidu Leu1 et N^6 des résidus lysyl par des groupes 4-[ω-méthoxypoly(oxyéthylène)-α-yl]butanoyle (~30 kDa chacun)

hialuronidasa PH-20 humana (hialuronoglucosaminidasa PH-20, molécula de adhesión 1 de esperma, EC 3.2.1.35) precursor-(36-482)-péptido (maduro-(1-447)-péptido), producida por células ováricas de hamster chino (CHO), forma glicosilada alfa, sustituída pro termino medio de 4 a 5 sitios entre el N^2 del residuo Leu1 y el N^6 de los residuos lisil por grupos 4-[ω-metoxipoli(oxietileno)-α-il]butanoilo (~ 30 kDa cada uno)

C-terminal number / numéro C-terminal / número C-terminal:
... EEPQIFY 447 instead of 457

```
LNFRAPPVIP NVPFLWAWNA PSEFCLGKFD EPLDMSLFSF IGSPRINATG 50
QGVTIFYVDR LGYYPYIDSI TGVTVNGGIP QKISLQDHLD KAKKDITFYM 100
PVDNLGMAVI DWEEWRPTWA RNWKPKDVYK NRSIELVQQQ NVQLSLTEAT 150
EKAKQEFEKA GKDFLVETIK LGKLLRPNHL WGYYLFPDCY NHHYKKPGYN 200
GSCFNVEIKR NDDLSWLWNE STALYPSIYL NTQQSPVAAT LYVRNRVREA 250
IRVSKIPDAK SPLPVFAYTR IVFTDQVLKF LSQDELVYTF GETVALGASG 300
IVIWGTLSIM RSMKSCLLLD NYMETILNPY IINVTLAAKM CSQVLCQEQG 350
VCIRKNWNSS DYLHLNPDNF AIQLEKGGKF TVRGKPTLED LEQFSEKFYC 400
SCYSTLSCKE KADVKDTDAV DVCIADGVCI DAFLKPPMET EEPQIFY   447
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
25-316 189-203 341-352 346-400 402-408 423-429

Pegylated residues / Résidus pégylés / Restos pegilados



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-47 Asn-131 Asn-200 Asn-219 Asn-333 Asn-358

Recommended International Nonproprietary Names (Rec. INN): List 79
Dénominations communes internationales recommandées (DCI Rec.): Liste 79
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 79
(WHO Drug Information, Vol. 32, No. 1, 2018)

p.123 **ianalumabum #**
-124 ianalumab *replace the description and the structure by the following ones*
ianalumab *remplacer la description et la structure par les suivantes*
ianalumab *sustitúyase la descripción y la estructura por las siguientes*

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BAFF-R, BR3, B cell activating factor receptor, CD268)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (233-233":236-236")-bisdisulfide; produced in Chinese hamster ovary (CHO-FUT8$^{-/-}$) cells, glycoform alfa

immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF13C (membre 13C de la super famille du récepteur du facteur de nécrose tumorale (TNFR), BAFFR, BAFF-R, BR3, récepteur du facteur d'activation des lymphocytes B, CD268], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (233-233":236-236")-bisdisulfure, produit dans des cellules de hamster chinois (CHO-FUT8$^{-/-}$), glycoforme alfa

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF13C (miembro 13C de la super familia del receptor del factor de necrosis tumoral (TNFR), BAFFR, BAFF-R, BR3, receptor del factor de activación de los linfocitos B, CD268], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfuro con la cadena ligera (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (233-233'':236-236'')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO-FUT8$^{-/-}$), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPG LVKPSQTLSL TCAISGDSVS SNSAAWGWIR QSPGRGLEWL  50
GRIYYRSKWY NSYAVSVKSR ITINPDTSKN QFSLQLNSVT PEDTAVYYCA 100
RYDWVPKIGV FDSWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAT LSLSPGERAT LSCRASQFIS SSYLSWYQQK PGQAPRLLIY  50
GSSSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QLYSSPMTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                        215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-99	151-207	268-328	374-432
	22''-99''	151''-207''	268''-328''	374''-432''
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'''-89'''	135'''-195'''		
Inter-H-L (h 5-CL 126)	227-215'	227''-215'''		
Inter-H-H (h 11, h 14)	233-233''	236-236''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304''
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados
N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1: 1, 1''

C-terminal lysine clipping
H CHS K2:
454, 454''

Recommended International Nonproprietary Names (Rec. INN): List 82
Dénominations communes internationales recommandées (DCI Rec.): Liste 82
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 82
(WHO Drug Information, Vol. 33, No. 3, 2019)

p.612 **balstilimabum #**

balstilimab *replace the structure by the following one*
balstilimab *remplacer la structure par la suivante*
balstilimab *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV  50
IWYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCASNG 100
DHWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH 200
KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP KDTLMISRTP 250
EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT 300
VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE 350
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY 400
SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK            440
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG  50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	140-196	254-314	360-418
	22"-96"	140"-196"	254"-314"	360"-418"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	127-214'	127"-214'"		
Inter-H-H (h 8, h 11)	219-219"	222-222"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
290, 290"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"
C-terminal lysine clipping / Coupure de la lysine C-terminale / Recorte de lisina C-terminal
H CHS K2:
440, 440"

p.644 **ieramilimabum #**

ieramilimab *replace the structure by the following one*
iéramilimab *remplacer la structure par la suivante*
ieramilimab *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGFTLT NYGMNWVRQA RGQRLEWIGW  50
INTDTGEPTY ADDFKGRFVF SLDTSVSTAY LQISSLKAED TAVYYCARNP 100
PYYYGTNNAE AMDYWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCSSSQDIS NYLNWYLQKP GQSPQLLIYY  50
TSTLHLGVPS RFSGSGSGTE FTLTISSLQP DDFATYYCQQ YYNLPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	152-208	266-326	372-430	
	22"-96"	152"-208"	266"-326"	372"-430"	
Intra-L (C23-C104)	23'-88'	134'-194'			
	23'"-88'"	134'"-194'"			
Inter-H-L (CH1 10-CL 126)	139-214'	139"-214'"			
Inter-H-H (h 8, h 11)	231-231"	234-234"			

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

p.653 **maftivimabum #**

maftivimab *replace the structure by the following one*
maftivimab *remplacer la structure par la suivante*
maftivimab *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTSS SYAMNWVRQA PGKGLEWVST  50
ISGMGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRG 100
YPHSFDIWGQ GTMVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQSIS SFLNWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTLTFGQG 100
TRLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 133'-193'
23'"-88'" 133'"-193'".
Inter-H-L (h 5-CL 126) 221-213' 221"-213'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

p.701 **zalifrelimabum #**

zalifrelimab *replace the structure by the following one*
zalifrélimab *remplacer la structure par la suivante*
zalifrelimab *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVKPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSS  50
ISSSSSYIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARVG 100
LMGPFDIWGQ GTMVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS RYLGWYQQKP GQAPRLLIYG  50
ASTRATGIPD RFSGSGSGTD FTLTITRLEP EDFAVYYCQQ YGSSPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 221-214' 221"-214'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
448, 448"

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.